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Therapies to limit or reverse fibrosis have thus far proved unsuccessful, highlighting the need for a 
greater understanding of the basic mechanisms driving fibrosis and in particular the link between fibrosis 
and inflammation. Obliterative Bronchiolitis (OB) is the pathological correlate of Bronchiolitis Obliterans 
Syndrome (BOS) a progressive disease that results in the fibrotic obliteration and blockage of the airways. 
Development of OB is strongly associated with elevated fibrotic, transforming growth factor beta 1 (TGF-
β1), and inflammatory, tumour necrosis factor alpha (TNFα) and interleukin 1 beta, mediators; and the 
process of epithelial to mesenchymal transition (EMT) has been proposed as a mechanism of OB 
initiation and progression. 
Previous work in our group has demonstrated that a physiologically relevant dose of TGF-β1 is capable 
of driving EMT in primary human bronchial epithelial cells (PBEC) isolated from lung-transplant recipients, 
an effect that was accentuated by TNFα. It was hypothesized that an unknown synergistic signalling 
cascade may mediate this accentuation, and identifying candidates for this role is the main aim of this 
thesis. 
TGF-β1 and TNFα were used to induce EMT in PBEC cultures; the relative roles of several signalling 
proteins (SMAD3, IKKβ, TAK1, p38, ERK-1/2 and JNK-1/2) in the development of EMT were assessed by 
chemical inhibition and siRNA knockdown along with phosphorylation response, to describe a signalling 
cascade. 
The results describe a mechanism whereby TGF-β1 drives EMT through SMAD3 with a requirement for 
TAK1 and JNK-2. TNFα signals through TAK1, IKKβ and JNK-2 but is not capable of driving EMT alone. 
Upon co-stimulation, TAK1 and JNK-2 display an enhanced activation that leads to an accentuation of 
EMT, possibly through c-Jun activation. JNK-2 sits downstream of TAK1 therefore the results indicate that 
TAK1 activity plays a key role both modulating TGF-β1 SMAD3 driven EMT, and its accentuation by TNFα. 
TAK1 was also shown to be more strongly activated in fibrotic human airway sections compared to 
control, suggesting that the findings have direct disease relevance. 
Much further work into how TAK1 modulates SMAD3 activity after TGF-β1 stimulation and how its 
enhanced activation leads to accentuated EMT is required. Greater understanding of these mechanisms 
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1.1 The Lung 
The primary function of the lung is to facilitate gaseous exchange between the circulatory network and 
the outside environment. This is achieved by a branching network of airways; lined with a continuous 
epithelial sheet of varying function, which at the lower levels are intimately associated with the circulatory 
system to facilitate a rapid and efficient uptake of O2 into the blood and expulsion of CO2. This network 
exists within a mechanically, metabolically and immunologically supportive matrix that acts to facilitate 
healthy lung function. 
The airways branch approximately 23 times in a normal healthy lung, transitioning from conducting 
airways into those where gaseous exchange can occur. The conducting zone begins with the trachea 
that divides into the left and right bronchi, which in turn divide into lobar, segmental and sub-segmental 
bronchi before concluding at the terminal bronchioles. This point onwards is known as the respiratory 
zone, with respiratory bronchioles with a few alveoli budding from their walls, passing into the alveolar 
ducts and finally terminating at the alveolar sacs. The distance between the respiratory bronchioles and 
alveolar sacs is small but due to the high number of branching events occurring within this zone, they 
make up the majority of the airway volume. 
 
1.1 .1 Large Airways 
The term large airways is usually used to describe divisions of the bronchial tree from 20 through 25. The 
epithelium of the large airways is pseudo-stratified in nature and consists of three main types of cells, 
basal, goblet and ciliated, which are attached to a basal lamina composed of epithelial derived collagen 
IV and laminin, by hemi-desmosomes. This basal lamina in turn sits on a mature supportive ECM, 
produced by resident mesenchymal cells, composed predominately of collagen 1 fibres, surrounded by a 
protective network of smooth muscle and cartilage. 
Basal cells are usually not exposed to the airway itself due to their more squat morphology, although due 
to the pseudo-stratified nature of the epithelium they are technically on the same plane as the other cells. 
Basal cells are thought to act as the progenitor cell in the upper airway (Rock et al., 2009), a fact which is 
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1.1 .2 Small Airways 
Small airways are defined as those between divisions 26 and 222, and as such mark the transition from the 
conductive to the respiratory zone of the lungs. Proximally there is little to distinguish them from the 
larger airways apart from the decreasing calibre of the airway. Progressing distally down the airway the 
cartilage support present in the airway wall decreases until it is no longer present in the smaller airways 
and is replaced instead by more elastic smooth muscle fibres. The respective thickness of the underlying 
ECM also decreases, until at the most distal regions the cells sit directly on the basal lamina closely 
associated with the vascular system with no cartilaginous and very little smooth muscle support. The 
occurrence of goblet cells decreases more distal regions of the lung, and they are replaced by the multi-
functional Clara cell, there is also a transition from the cuboidal pseudo-stratified morphology to a more 
squat regular morphology.  
Due to the small calibre of the airways at this point the surface tension of the fluid coating would be 
sufficient to collapse the airway under exhalation. As such Clara cells secrete a surfactant protein known 
as Clara cell secretory protein (CCSP) which, due to its amphiphilic nature, migrates to the surface of the 
fluid layer, and dramatically reduces the surface tension present (Hawgood and Clements, 1990). These 
Clara cells are although thought to act as the resident progenitor cell in the small airways (Stripp and 
Reynolds, 2008), able to divide into replacement ciliated and non-ciliated cells as required. Towards the 
most distal ends of the airways a squamous epithelium is found with few if any ciliated cells, it is at this 
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proteins which, while distinct in structure, perform the same action as described for CCSP (Hawgood and 
Clements, 1990). In diseases affecting Type II pneumocytes the loss of this surfactant production can 
cause alveolar collapse, with the subsequent reduction in gas exchange. Alveoli also lack any mechanistic 
clearance mechanisms and so are dependent on the activity of alveolar macrophages in association with 
other immune cells to maintain their function.  
Alveolar Type I pneumocytes make up the majority of the surface of the septa, approximately 95%, 
although due to their large flattened shape they only make up approximately 40% of total cell number. 
Type I cells are joined into a continuous sheet by tight junction proteins such as E-cadherin, preventing 
both the transmission of proteins into the alveolar space, and invasion of pathogens into the lung 
interstitium, although macrophages can still pass freely between through these junctions. The flattened 
shape of the Type I pneumocytes is designed to facilitate efficient gas exchange across the basement 
lamina into the associated pulmonary capillaries. 
Type II epithelial cells, are typically found in the junctions between septa and are smaller and rounder 
than the Type I cell, although found in higher numbers. As well as producing surfactant proteins Type II 
cells are thought to act as the progenitor cell population within the alveoli replenishing the frequently 
damaged Type I cells (Evans et al., 1973, 1975), similar to the role of Clara cells found in the small airways. 
Type II cells have also been shown to release inflammatory cytokines in response to injury, thus 
contributing to the immune response (Koyama et al., 1998). Type I pneumocytes were traditionally 
thought to be terminally differentiated and incapable of expansion in culture, however recent advances 
in isolation and culture protocols have demonstrated expansion and de-differentiation capabilities (Wang 
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Fibroblasts are generally spindle shaped, and unlike the epithelial cells they underlie are not associated 
into ordered sheets, display no apical-basal polarity and are free to migrate throughout the ECM. 
Damage to the ECM results in the recruitment of surrounding resident fibroblasts in response to stimuli 
such as TGF-β1 (Degryse et al., 2011) which can also induce fibroblasts to proliferate more rapidly 
(Hetzel et al., 2005). These resident fibroblasts may also be supplemented by fibrocytes derived from the 
bone-marrow and recruited from the vasculature by a chemotactic gradient, originating at the damage 
foci (Bucala et al., 1994). Once resident these fibrocytes are hypothesized to transition into an active 
fibroblast state and contribute to ECM repair and renewal (Abe et al., 2001; Lapar et al., 2011). 
Myofibroblasts are typically not seen within the stable ECM, but rather are associated with the wound 
healing process with aggregate myofibroblast foci often associated with fibrotic disorders (Kis et al., 
2011). The primary role of the myofibroblast is to contract an exposed wound site reducing the chances 
of infection. This is achieved by secretion of several ECM proteins including α smooth muscle actin 
(αSMA) in a network with other myofibroblasts around the wound site (Hinz and Gabbiani, 2003). 
Myofibroblasts are thought to differentiate from fibroblasts under conditions of mechanical stress within 
the ECM, and also in response to factors such as TGF-β1 (Ramirez et al., 2006). 
Increased numbers of fibroblasts and myofibroblasts are often implicated in the development of fibrotic 
disorders. Whilst required in normal wound resolution their persistence can lead to excessive deposition 
of disorganized ECM components, often in association with an up-regulation of proteinase inhibitors 
such as the TIMP family. This leads to the gradual loss of structure and function within the organ 
affecting regions that had often suffered no direct injury themselves. Understanding the mechanisms that 
initiate this dysregulated production and persistence of fibroblasts and myofibroblasts is a key area of 
on-going research in many fibrotic disorders. 
 
1.1 .5 Pulmonary Capillaries 
Pulmonary capillaries interweave throughout the majority of the alveolar walls, taking up approximately 
90% of the alveolar wall volume. This high density exists to maximise the occurrence of gas exchange by 
maximising the surface area to volume ratio of the blood present in the lungs. The capillaries themselves 
have a diameter only slightly greater than that of a red blood cell, and the majority of their surface is 
tightly associated with the flattened portions of Type I pneumocytes, forming a fused basement 
membrane over which gas exchange occurs. Exchange of O2 and CO2 is a passive process based on the 
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differences in partial pressures of the two gasses, however diffusion efficiency is also affected by the 
thickness of the fused basement membrane. A thickening of the alveolar wall and hence reduced efficacy 
of gas exchange is often associated with the development of pulmonary fibrosis. 
 
1.1 .6 Resident Immune Cells 
Large numbers of dendritic cells are interspersed throughout the lung, whilst often located underneath 
the basal lamina they are able to sample the airway space by deploying sensory protrusions between 
epithelial cells. Dendritic cells, in association with neighbouring epithelial cells (Upham and Stick, 2006), 
continually probe the airway space and are able to recognize inhaled antigens and present them to 
relevant immune cells, they are also capable of responding to danger signals generated by damage to 
resident cells (Upham and Stick, 2006). 
As previously discussed, the upper airways utilise mechanistic clearance to dispose of particulate matter 
and inactivate prospective pathogens. However, the alveoli have no such measures and instead rely on 
the activity of resident alveolar macrophages as a first line of defence to ingest and clear the 
continuously deposited foreign materials. In homeostasis alveolar macrophages are held close to the 
alveolar wall in a quiescent state, with little phagocytic activity (Holt et al., 1993), consequently supressing 
the response of other immune cells such as the aforementioned dendritic cells (Upham and Stick, 2006). 
The macrophages are held in this state to prevent collateral damage to the delicate Type I pneumocytes 
and associated capillary networks, which may occur in response to continuous low-grade immune 
response. However, upon detection of potentially dangerous antigens or damage, either by themselves 
or through associated epithelial or dendritic cells the macrophages are released from quiescence and 
phagocytic and pro-inflammatory responses are initiated. Macrophages also contribute towards the 
initiation of correct wound resolution (Porcheray et al., 2005), however their presence is deleterious to 
end-stage resolution and so a decrease in macrophage number and activity is required (Martin et al., 
2003). 
Both macrophages and dendritic cells play key roles in the innate and adaptive immune responses of the 
lung. A dysregulation of their response is associated with several diseases such as asthma, where a 
hyper-activated response is associated with over-recruitment of other mediators of the immune system 
and tissue remodelling. Understanding the modulation of recruitment, activity and subsequent dispersal 
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1.2 Fibrotic & Inflammatory Lung Disease 
The lung is exposed to numerous mechanical and biological insults, and these insults can often lead to 
the onset and exacerbation of inflammation and fibrosis in the lung. Correspondingly, there is a wide 
range of lung diseases caused by these insults. The location, cause, progression and outcome of lung 
disease varies greatly however they are broadly characterized into two classes. 
Obstructive airway diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma and 
Bronchiolitis Obliterans Syndrome (BOS) result in increased resistance to airflow caused by some form of 
obstruction, resulting in a decrease in the amount of air that can reach the respiratory zone, decreasing 
the efficiency of gas exchange. Three main mechanisms can cause this obstruction; a build-up of 
material in the airway, as in the chronic bronchitis strand of COPD or BOS, a thickening of the airway wall 
as in asthma or a degradation of the supportive matrix that helps keep the airways open and taut as in 
the emphysematous strand of COPD. Restrictive lung diseases such as Idiopathic Pulmonary Fibrosis (IPF) 
inhibit the ability of the lung to expand and contract during respiration. Restrictive diseases are often the 
result of a change, usually an increase in or thickening of, the supportive ECM. In the case of IPF this can 
be seen by the thickening of the alveolar walls, which is followed by the loss of epithelial covering within 
the alveoli. This increase in ECM makes it difficult to breathe, hence the restrictive terminology, whilst also 
reducing the surface area available for gas exchange. 
The lung relies on structural and mechanical means as a first line of defence, however when a harmful 
object is detected by resident immune cells or the epithelium itself a classic inflammatory response 
ensues. Resident cells produce a cocktail of inflammatory mediators such as TNFα, IFN-γ and IL-1β/8/17, 
which act to recruit other immune cells, and modulate the response of cells already present. If the 
vasculature is breached by injury then factors such as thrombin are also released which are designed to 
facilitate clotting and quick re-constitution of a barrier between the vasculature and outside world. In 
more severe cases, non-resident immune cells are recruited to help with clearance and re-constitution of 
the epithelium. 
Under normal circumstances where the stimulus is removed the inflammatory response is short lived due 
in part to the short lifespan of the released immune mediators and attracted cells , and the release of 
anti-inflammatory mediators such as IL-10, TGF-β1 (Sanjabi et al., 2009) and proteases capable of 
cleaving immune mediators (Gueders et al., 2006). In the development of chronic inflammation this 
clearance does not occur, either as a result of an un-clearable antigen as in allergic responses, a 
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repeating injurious process as with the majority of diseases relating to particulate mediated damage or 
some other factor such as a chronic infection or genetic susceptibility. 
The inflammatory response can often lead to damage of the lung epithelium; under normal conditions 
where this may only affect a small region the damage is usually repaired correctly restoring an intact and 
functional epithelium. However, where inflammation persists one of the common outcomes is the 
development of fibrotic tissue. The immune mediators released by immune cells recruit fibroblasts 
resident in the tissue which repair any damage to the ECM caused by the inflammatory response. If the 
inflammatory response continues then progressively more fibroblasts are activated and encouraged to 
proliferate (Hetzel et al., 2005), circulating fibrocytes may be recruited from the vasculature (Abe et al., 
2001) and induction and survival of myofibroblasts may be increased (Kis et al., 2011). The end result is 
an excess of mesenchymal cells producing a disorganized matrix of ECM proteins such as collagen III 
and fibronectin which can quickly over-run the immediate area, destroying the epithelial structure. Not 
all fibrosis is induced by inflammation as in some instances the causes is unknown, excessive fibroblast 
recruitment and proliferation can also be induced by factors such as TGF-β1 and FGF, all of which may 
be linked to genetic pre-dispositions to fibrosis (Riha et al., 2004). 
 
1.2.1 Wound Repair & Chronic Wounding 
In a healthy individual epithelial injury should repair effectively in a physiological manner returning it to 
functional homeostasis. This repair requires a spatially and temporally orchestrated response from the 
cells of the lung epithelial sheet, the underlying progenitor and supportive cells and resident immune 
cells, as well as those drawn from the circulatory system. This process can be thought of as occurring in 
three overlapping phases: an initial response, a recovery of integrity and a final resolution phase. The 
severity of injury, existing environment and occurrence of prior injury all have a marked effect on the 
efficacy of recovery and can help explain poor recovery and resolution. It is this poor recovery and 
resolution that are the pre-cursors to the development of fibrosis, and there are numerous points at 
which dysregulation can occur. 
Upon wounding numerous factors are released into the airway or alveolar space from the epithelial cells 
themselves, the ECM and the vasculature if breached. These factors recruit non resident immune cells 
such as neutrophils, eosinophils and basophils migrate to the wound area through chemotaxis (Hudson 
et al., 1977), and degrade any cellular debris by phagocytosis and/or neutralizing invading pathogens 
 12 
 
through an oxidative burst response. The granulocyte count in the wound area peaks rapidly, but is 
followed by an equally rapid decrease in number due to apoptosis and non-inflammatory phagocytosis 
by resident macrophages and responding monocytes. Fibroblasts create a temporary ECM composed of 
factors such as fibronectin and collagen III (Santos et al., 2006) which is more flexible due to a lack of 
cross linking. Larger wounds are contracted through the activity of myofibroblasts (Hinz, 2007) and 
nearby epithelial cells loosen their adherence to each other and the basal lamina and creep across the 
provisional ECM (Farooqui and Fenteany, 2005). This provisional ECM and motile epithelial cells are more 
susceptible to colonisation from opportunistic pathogens such as Pseudomonas aeruginosa (De 
Bentzmann et al., 1996), an effect which may be exacerbated by immuno-suppression in transplant 
recipients, or existing physiological conditions. 
The few remaining macrophages in the wound are thought to transition from a pro-inflammatory form, 
often termed the classically activated macrophage, into one with a pro-resolution character often termed 
the alternatively activated macrophage. These macrophages and monocytes gradually lose their 
inflammatory nature, and take on a more recovery orientated role before eventually leaving the site 
(Bellingan et al., 1996; Porcheray et al., 2005). This allows the epithelium to proliferate and re-mature in 
the best cases regaining full functionality. Alongside this the underlying ECM matures under the control 
of residing fibroblasts which degrade collagen III and fibronectin replacing it with collagen I which can 
then be cross linked. A more in-depth coverage of this event process can be found in my review article 






































































































































































































































































































































































































































































































































































































































































































































































































Table 1 - Potential anti wound resolution mechanisms  
Anti-resolution factors Mechanism 
Dysregulation at the Response Stage 
Non-clearance of immune cells, counteracted by overactive anti-inflammatory/pro-fibrotic response. 
Repeated initiation of 
immune response: 
Repeated initiation of the wound healing response which prevents resolution and may lead 
to the development of fibrosis: 
 - Allergy Repeated targeting of non-harmful allergens leads to repeated activation of the immune 
response. (Holgate et al., 2010) 
 - Pathogen colonisation A non-clearable pathogenic colonisation symptomatic of several diseases such as Cystic 
Fibrosis, or in immuno-compromised individuals, leads to repeated or constant activation of 
the immune response. (Hafkin and Blumberg, 2009) 
 - Particulate Matter Particulate matter that triggers an immune response directly or damages epithelium thus 




Granulocytes are usually only present in the wound site for a short period; longevity in the 
wound can initiate fibrosis. (Riise et al., 1999) 
Dysregulation at the Recovery Stage 
Hyperactive fibrotic response, may. be stimulated by inflammatory mediators 
Fibroblast activity: Over-recruitment or dysregulation of repair mechanisms leading to the development of 
fibrosis. 
 - Overactive resident 
fibroblasts 
Resident fibroblasts proliferate and deposit and re-model ECM in a wound environment. 
Over activation or over proliferation leads to the development of fibrosis. (Hetzel et al., 2005)
 - Excessive fibrocyte 
recruitment 
Circulating fibrocytes can be recruited to assist in wound repair, over-recruitment leads to 
the development of fibrosis. (Lapar et al., 2011) 
 - Too many myofibroblasts Over activation, over recruitment/differentiation or resistance to apoptosis lead to the 
development of fibrosis. (Kis et al., 2011) 
Too 'mesenchymal' 
epithelium 
The transient gain of mesenchymal characteristics by the motile epithelial sheet can become 
dysregulated, with epithelial cells contributing directly to fibrosis. (Willis and Borok, 2007) 
Dysregulation at the Resolution Stage 
Opportunistic colonisation The motile epithelium and provisional ECM are susceptible to colonisation, which can re-
initialize the immune response, leading to further damage in the wound. (De Bentzmann et 
al., 1996) 
Non maturing epithelium The motile epithelium may not mature correctly, making colonisation more likely, or 
contributing to fibrosis directly as above. 
Non stabilising ECM The ECM is remodelled to contain cross-linked collagen I, by fibroblasts and factor release, a 
continuation of this process leads to the development of fibrosis. (Ehrlich and Krummel, 
1996) 
Other Forms of Dysregulation  
Genetic mutations: All of the above occurrences may be purely environmental in origin however; there are 
several fibrotic diseases with a genetic association. This may manifest itself as the over 
expression, or activity of a pro-inflammatory factor or receptor, the under expression or 
activity of a repressor of inflammation or fibrosis; or the activation of differential signalling 
networks in response to 'normal' stimuli. (Riha et al., 2004; Charpidou et al., 2008; Sharma et 
al., 2008; Rogers et al., 2009)  
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The table above outlines several of the mechanisms that can dysregulate a normal wound healing 
response and lead to a chronic wound with the subsequent development of fibrosis. Whilst correct 
resolution and progression through all stages of the wound repair process is vital, it is the origin and 
maintenance of excess or dysregulated fibrogenic cells that is perhaps the most important area to 
investigate in relation to the development of fibrotic disorders. There are several hypotheses as to the 
origins of these cells, and the relationship within a chronic wound environment can play a key role in this 
process. 
 
1.2.2 Origin of Fibrogenic Cells 
There are three prominent hypotheses as to the origin of fibrogenic cells in fibrotic disorders, firstly that 
resident fibroblasts proliferate rapidly and potentially differentiate into myofibroblasts, secondly that 
circulating fibrocytes are recruited from the vasculature and differentiate into fibroblasts and thirdly that 
epithelial cells present in the lung trans-differentiate into fibroblasts. None of these processes are 
innately pathologic, as they all serve important roles in the normal wound healing process so it is likely 
that hyper-activation of or prolongation of the response is key. 
There are many fibroblasts distributed throughout the supportive matrix of the lung and whilst they are 
required in normal wound resolution their persistence and hyper-activation is a key contributor to 
fibrosis. The release of several growth factors such as TGF-β1 and FGF as well as other factors such as 
mechanical stress within the ECM can lead to fibroblast activation. This activation leads to an increase in 
proliferation and the secretion of less mature ECM products such as fibronectin and collagen III (Hetzel 
et al., 2005). In more severe wound events these fibroblasts are often induced into the contractile 
myofibroblast phenotype which associate into foci to facilitate wound closure (Hinz, 2007). These foci 
contain large amounts of fibrotic material required to facilitate the mechanistic closure of the wound, 
and dysregulation of this process, or increased proliferation and resistance to apoptosis of 
myofibroblasts is a hallmark of fibrosis (Kis et al., 2011). 
The theory of circulating fibrocytes contributing to repair of lung epithelial wounds is a relatively new 
concept (Bucala et al., 1994), suggesting that bone marrow-derived fibrocytes can be recruited from the 
vasculature in response to a chemotactic gradient emanating from the wound. These cells differ from 
resident fibroblasts in that they express hematopoietic markers such as CD34, CD45 and CD54 (Quan et 
al., 2004). CD34 was the first marker described for fibrocytes and has therefore been the focus of most 
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research. Expression of these markers has been shown to decrease in vitro, however, it is thought that 
fibrocytes in the wound environment retain this expression profile (Bucala et al., 1994).  
The factors responsible for the chemotactic recruitment of these fibrocytes are not completely 
understood; however, expression of the CCR3, CCR5, CCR7 and CXCR4 receptors have been shown to 
play a role (Abe et al., 2001). Once resident in the wound site, the fibrocytes are capable of producing 
collagen and αSMA, a process that is increased in the presence of TGF-β1 (Abe et al., 2001). While these 
fibrocytes may play a role in physiological wound repair, over-recruitment is associated with numerous 
pulmonary disorders. An increased number of fibrocytes is associated with IPF, with an even greater 
abundance in acute exacerbations (Moeller et al., 2009), although which, if any, of the aforementioned 
factors is responsible for their recruitment is unknown. In asthma, an increased number of fibrocytes are 
present in the hyperplasic airway smooth muscle, although it has not yet been determined if they 
contribute significantly to disease progression or severity, or are attracted by the already hyperplasic 
tissue (Saunders et al., 2009). In obliterative bronchiolitis (OB) elevated levels of fibrocytes are present in 
the lung tissue and in the pulmonary vessels running through this tissue, with both displaying evidence of 
remodelling, although the authors present no evidence about a contribution to obliteration of airways 
themselves (Andersson-Sjöland et al., 2009).  
The third mechanism, trans-differentiation of resident epithelial cells into fibroblasts, termed epithelial to 
mesenchymal transition is the focus of my project and is discussed below.  
 
1.2.3 Plasticity & Epithelial to Mesenchymal Transition 
Epithelial to mesenchymal transition (EMT) describes the loss of epithelial character of a cell, namely tight 
junction adherence to adjacent cells and a basal lamina forming a continuous epithelial sheet with apical-
basal polarity, into a mesenchymal form characterized by increased motility of individual cells and an 
increase in the ability to secrete ECM proteins. EMT has been demonstrated to play an important role at 
numerous stages, firstly in early development when mesodermal cells are formed and internalized at the 
primitive streak. EMT also plays a key role in the wound healing response of the epithelium, in areas 
where the epithelium has been denuded surrounding basal cells move over the wound site secreting a 
new basal lamina as they go, displaying several of the characteristics used to define EMT.  
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EMT is also thought to play a key role in tumorigenesis, with a decrease in E-cadherin expression 
strongly associated with several cancers, which is thought to facilitate metastasis (Chao et al., 2010; Hou 
et al., 2011). The role of TGF-β in the development of cancer is poorly understood; initially described as a 
pro-metastatic factor it has now been shown to display both pro (Dalal et al., 1993) and anti-cancer (Zhu 
et al., 1998) properties in various different models, and even within models (Siegel et al., 2003). This 
multifunctional response is likely due to the ubiquitous expression of both TGF-β and its receptors and 
the pleiotropic nature of TGF-β; so whilst TGF-β is important, it is the modulation of upstream activation 
and downstream effect that is likely to be important as opposed to direct targeting.  
The role of dysregulated inflammatory activity in tumorigenesis is much more widely accepted (Lin and 
Karin, 2007), with factors such as alcoholism and particulate exposure (smoking, asbestos etc.) strongly 
associated with the development of inflammatory mediated liver and lung cancers respectively. However, 
the mechanics of this association is again poorly understood; with the multifaceted response of nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) the main cause of this lack of clarity. NF-
κB was long thought to have purely a tumorigenic role, mediating the expression of anti-apoptotic 
genes (Barkett and Gilmore, 1999), induction of the cell cycle and cell invasiveness (Pahl, 1999). However 
a new role as a tumour suppressor is emerging whereby apoptosis of tumour cells is induced by p53 in 
an NF-κB dependant manner (Rocha et al., 2003). As with TGF-β the multifaceted role of NF-κB means 
that modulation of function rather than direct targeting may produce better therapeutic targets for EMT. 
Since starting my project the consensus view on EMT in fibrosis has shifted considerably. Perhaps due to 
the over-exuberant claims that were initially made, things now seem to have swung the other way 
towards general scepticism of the process, at least in vivo. Early experiments in the kidney (Iwano et al., 
2002), liver (Omenetti et al., 2008) and pancreas (Gershengorn et al., 2004) suggested that EMT may be 
a key conserved role in the development of fibrosis. However later, more robust lineage tracing 
experiments in the same systems failed to re-produce these findings; kidney (Humphreys et al., 2010), 
liver (Scholten et al., 2010) and pancreas (Morton et al., 2007). 
Luckily, the one exception to this to date is the lung, as far as I am currently aware no negative lineage 
tracing studies investigating EMT have been published, although I admit that this alone would not be 
sufficient evidence. A potential end stage of EMT in the human lung was demonstrated Willis et al 
whereby tissue segments isolated from patients with advanced IPF showed co-expression of both Type II 
alveolar epithelial (pro-surfactant protein-B) and myofibroblast (αSMA) markers (Willis et al., 2006). One 
of the potential driving mechanisms for the induction of this transition is the excessive or continuous 
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release of cytokines in the lung, with numerous groups showing that treatment with TGF-β1 can induce 
this change both in vivo (Kim et al., 2006; Tanjore et al., 2009) and ex vivo in rat cells (Willis et al., 2006) 
along with human cell lines (Kasai et al., 2005; Borthwick et al., 2011) and primary cultures (Borthwick et 
al., 2009, 2010; Câmara and Jarai, 2010). The studies by Kim et al (Kim et al., 2006) and Tanjore et al 
(Tanjore et al., 2009) are especially powerful as by utilising transgenic mice with labelled epithelial cells 
they were able to show in vivo that these epithelial cells, or their descendants, began expressing 
mesenchymal markers such as αSMA and vimentin, and a loss of epithelial character in response to 
stimulation with TGF-β1. Tanjore et al went one step further and were able to demonstrate that 
approximately 30% of resident fibroblasts were derived from the labelled epithelium 2 weeks post 
bleomycin injury. 
Perhaps some of the hostility against EMT arises from the lack of clear definition, does it refer to a 
complete switch in character or a more gradual transition across a spectrum with the most highly 
specified cell types at either end, where cells can share display both mesenchymal and epithelial 
character? By using the second definition, it does not seem too difficult to see how EMT could have a 
role to play in fibrotic development. 
Whilst I am focusing on the process of EMT in this thesis, it is likely that all three described mechanisms 
play an important role in the development of fibrosis. 
 
1.2.4 Obliterative Bronchiolitis 
OB, the pathological correlate of BOS is a progressive scarring disease of the small airways, which, along 
with a destruction of the epithelium in the local airway often blocks the airway itself with a plug of fibrotic 
material, mesenchymal and immune cells. There is a strong association of OB in lung transplant 
recipients with approximately 40% of patients displaying evidence of disease 5 years post-transplant 
(Christie et al., 2010). Diagnosis is made based upon the decline in FEV1, a measure of expiratory ability 
within 1 second as a percentage of the total lung capacity, and is often associated with the development 
of dyspnoea and a productive cough (Cooper et al., 1993).  
There are numerous mechanisms which have been proposed as initiators of disease, prime among them 
being the occurrence of tissue rejection with the corresponding development of an inflammatory 
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1.3 Signalling Mechanisms 
As described in 1.2 an excessive or prolonged release of inflammatory or pro-fibrotic mediators is often 
a key driver in the development of fibrosis. These factors initiate signalling cascades within receptive 
epithelial, mesenchymal and immune cells. An understanding the mechanisms at play in these cells may 
shed light on the development of fibrosis. 
In order to respond quickly to stimuli cells need a ready supply of signalling capable proteins, however 
they also need to exert control over these pathways. Two mechanisms which can regulate these 
signalling proteins, and that I discuss throughout this thesis are, phosphorylation and ubiquitination. 
Phosphorylation involves the addition of a phosphate group PO43- onto a specific residue within a 
protein, which can induce a conformational change of the protein structure, usually resulting in the gain 
or loss of function. This process usually involves a kinase targeting a specific residue, typically serine, 
threonine or tyrosine and transferring a phosphate group from another molecule such as Adenosine-5'-
triphosphate (ATP). Phosphorylation is a reversible procedure, with phosphatases removing phosphate 
groups from the target protein, which can then either cycle through another phosphorylation de-
phosphorylation cycle or be degraded. 
Ubiquitination is the process whereby a small ubiquitin protein or proteins are conjugated to a protein in 
a three step process. The ubiquitin molecule is first activated by an E1 ubiquitin-activating enzyme which, 
as above, is dependent upon ATP mediated activity. This activated ubiquitin molecule is then conjugated 
to the lysine residue of the target protein by an E2 ubiquitin-conjugating enzyme, which is then ligated in 
place by an E3 ubiquitin-ligase enzyme. Again, as above the process is fully reversible under the activity 
of de-ubiquitinating enzymes. It was traditionally thought that ubiquitination was purely a means for a 
cell to target unwanted proteins for degradation in the proteasome mediated by the formation of Lys481 
linked chains of ubiquitin molecules on proteins. However more recently the ability of ubiquitin to form 
Lys63 linked chains has demonstrated a remarkable capacity to affect numerous cell processes. It is now 
thought that these chains can play a key role in maintaining protein stability, assisting in protein-protein 
binding and facilitating conformational changes within target proteins (Adhikari and Chen, 2009). 
Throughout this project I have used phosphorylation as a marker of protein activation in response to 
stimulation. I do not analyze ubiquitination within this system, although its relevance at several key points 
is discussed. By analyzing the phosphorylation response to stimulation, and by measuring the impact of 
                                                 
1 As well as Lys6, 11, 27, 29 and 33. 
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signalling protein inhibition I hope to be able to construct a signalling cascade relevant to fibrosis in the 
lung. 
 
1.3.1 Transforming Growth Factor Beta 1 
The cytokine TGF-β1 was first described in 1983, when it was isolated from platelets in its active form 
(Assoian et al., 1983), and it is now thought that the majority of cells are capable of its expression, 
including in the lung; epithelial (Xu et al., 2003), mesenchymal and immune cells (Zhang et al., 1995). 
Encoded by the TGFB1 gene an initial 75 kDa pro-TGF-β1 protein is created which forms a homodimer. 
This homodimer is then cleaved into an active 48 kDa TGF-β1 dimer, and a 100 kDa latency associated 
protein (LAP) which immediately binds with and inhibits the function of TGF-β1. This LAP protein then 
associates with a latent-TGF-β1 binding protein which localizes the LAP and bound TGF-β1 to the cell 
membrane. The majority of TGF-β1 exists in this form and cleavage from LAP is required before 
signalling can be induced (Annes, 2003; Shi et al., 2011) 
Factors such as MMP-2 and 9 are able to cleave LAP and liberate free TGF-β1 which can then induce the 
canonical mothers against decapentaplegic (SMAD2) signalling response. TGF-β1 binds to a TGF-β 
Receptor 2 (TGF-R2) dimer inducing a conformational change, which allows for the recruitment of two 
TGF-β Receptor 1 (TGF-R1) molecules. The binding of TGF-R1 with TGF-R2 activates the innate kinase 
activity of TGF-R1, and also recruits a chaperone protein such as SMAD anchor for receptor activation 
(SARA) although others have also been described, which holds SMAD3 inactive in the cytoplasm (Xu et 
al., 2000). SARA facilitates the phosphorylation of SMAD3 by TGF-R1, the phosphorylated SMAD3 is then 
released from SARA and is able to form a heterodimer with SMAD4; or a heterotrimer with either 
SMAD2 or another SMAD3 protein, and SMAD4 (Chacko et al., 2001; Wu et al., 2001). This molecule is 
transcriptionally active and is able to translocate to the nucleus (Derynck and Zhang, 2003). 
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A similar role for TGF-β1 has been demonstrated in OB as well, with elevated levels of TGF-β detected in 
the airway and lung tissue associated with, and shown to precede the development of OB (El-Gamel et 
al., 1999), as well as increased levels detected in the BAL of patients (Elssner et al., 2000). A similar role 
for SMAD3 has also been described. Using primary fibroblasts isolated from the trachea of either wild-
type or SMAD3 deficient mice, SMAD3 deficient fibroblasts did not up-regulate expression of 
mesenchymal markers in response to TGF-β1 (Ramirez et al., 2006). Previous work performed in our 
laboratory has also described a similar SMAD3 dependant effect on EMT in primary human bronchial 
epithelial cells (Borthwick et al., 2009, 2010). 
 
1.3.2 Tumour Necrosis Factor Alpha 
The inflammatory cytokine TNFα was first described in 1975 and named for its ability to selectively 
induce necrosis in transplanted sarcomas in mice (Carswell et al., 1975). The same paper also postulated 
that the release of TNFα was attributable to macrophages, which was later confirmed in a different paper 
(Matthews, 1978). Although primarily produced in alveolar macrophages in the lung (Nii et al., 1993) 
TNFα is also produced by numerous other cells, including resident fibroblasts (Bashir et al., 2009) (only 
demonstrated in skin fibroblasts) and epithelial cells (Miyazaki et al., 1995). 
Encoded by the gene TNFA TNFα is produced as a 26 kDa membrane bound protein which associates 
into homotrimers. This membrane-associated homotrimer can be cleaved by the activity of TNFα 
converting enzyme (TACE) into a soluble homotrimer composed of 17 kDa molecules. TNFα signals 
through two distinct trans-membrane receptors, TNF Receptor 1 (TNFR1) and TNF Receptor 2 (TNFR2) 
(Locksley et al., 2001). TNFR1 is ubiquitously expressed and can respond to both membrane-bound and 
soluble forms of TNFα whereas TNFR2 is highly regulated in its expression, mainly on immune cells and 
responds, efficiently, only to membrane bound TNFα (Grell et al., 1995). 
The canonical signalling pathway driven by TNFα has been extensively investigated in response to TNF-
R1 activation which induces a signalling cascade through NF-κB. TNF-R1 recruits TNF-receptor-
associated factor 2 (TRAF2) (Rothe et al., 1994) along with E3 ubiquitin-ligases forming a complex which 
polyubiquitinates the receptor interacting protein kinase 1 (RIP1) (Ea et al., 2006) as well as TRAF2 itself in 
a Lys63 dependant manner. This complex then aids phosphorylation of transforming growth factor beta 
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activated kinase 1 (TAK13), again through poly-ubiquitination of TAK1 and associated TAK1 associated 
binding protein (TAB) proteins (Shim et al., 2005; Yang et al., 2011). Activated TAK1 then phosphorylates 
the kinase components of the IκB kinase (IKK) complex which is composed of three subunits, the 
regulatory IKK and the catalytic IKKα and IKKβ (Wang et al., 2001). The IKK complex binds with Iκ-Bα, a 
protein which holds NF-κB in the cytoplasm (Jacobs and Harrison, 1998), phosphorylates it and targets it 
for degradation in the proteasome. The NF-κB dimer, composed from five possible monomers p1054, 
p1005, p656, RelB and c-Rel, is then free to translocate to the nucleus and influence transcription. There 
are numerous levels of processing, activation and regulation that occur throughout this signalling 
cascade which are covered more elegantly in the following review by Perkins (Perkins, 2007). 
  
                                                 
3 MAP3K7 
4 NF-κB1, p105 can be cleaved to p50, but mainly transcribed independently 
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seeming to refer to the chronic, early onset neutrophilic response, nor provide direct evidence of 
elevated TNFα in the lungs of patients with OB. An inflammatory response is still associated with the later 
onset disease but it is less severe. 
The contribution of inflammation to the development of IPF is still under debate. On the one hand an 
increased number of macrophages are often found in the alveoli of IPF patients and from this it was 
hypothesized that these macrophages were contributing to a non-resolving pro-inflammatory milieu 
(ATS, 2000). As such the current treatment practice is to deliver anti-inflammatory drugs, such as 
corticosteroids, cyclophosphamide, cyclosporine or pirfenidone, to the lung (ATS, 2000). This hypothesis 
was challenged by the lack of strong clinical trials showing a benefit from treatment with any of these 
drugs, although some slight positive trends were observed (Gharaee-Kermani et al., 2007). As well an 
inability to detect inflammatory markers themselves in situ throughout disease progression. It however is 
worth noting that the lack of strong clinical trials may be due to the ethical constraints of offering a 
placebo treatment to patients with a rapidly progressing disease. As such, some people now think of 
inflammation as an effect of IPF and not a driver as such. Conversely, the TNFA-308G>A polymorphism, 
which has previously been reported to produce elevated free TNFα levels in sarcoidosis patients (Sharma 
et al., 2008), was also found to be associated with IPF patients (Riha et al., 2004), suggesting that our 




1.3.3 Interleukin-1 Beta 
The inflammatory cytokine IL-1β was first described in 1972 (Gery et al., 1972) for its ability to activate 
lymphocytes , but it was not until later that it was differentiated from IL-1α as a protein secreted from 
macrophages (March et al., 1985). 
Encoded by the gene IL1B IL-1β is produced as an inactive 31 kDa protein which is converted into an 
active 17 kDa molecule by numerous proteinases. Mast cell chymase and tryptase (Black et al., 1989) 
being the first described although it was later shown IL-1β converting enzyme (ICE) as the primary 
proteinase (Thornberry et al., 1992). Interestingly whilst many cells, such as fibroblasts, are able to 
produce the pre-cursor form of IL-1β they lack the ability to produce the proteinases which activates it 
(Kostura et al., 1989). It is possible for the airway macrophages to secrete proteinases that have been 
shown to cleave inactive IL-1β extracellularly, albeit in a skin and not lung model. IL-1β binds to IL-1 
receptor type 1 (IL-1R1) which recruits IL-1R accessory protein, which is required for transmission of the 
signal (Wang et al., 2010). 
This activation triggers the recruitment of myeloid differentiation primary-response protein 88 (MyD88) 
to the intracellular portion of the receptor complex, which in turn recruits IL-1R-associated kinase 4 
(IRAK4). IRAK4 is then able to recruit and activate ,through phosphorylation, IRAK1; this phosphorylation 
allows for the recruitment of TRAF6, a homolog of the previously described TRAF2, which interacts with 
TAK1 in a similar fashion (Akira and Takeda, 2004). At which point the remaining signalling mechanism is 
conserved with that of TNFα, although evidently there is some form of modulation allowing for the 
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variation in receptor expression between IPF and control patients, and there is the aforementioned poor 
response of IPF to existing anti-inflammatory treatments. More recently, studies have associated 
polymorphisms within IL1RN the gene encoding for IL-1R1A that result in a reduction in mRNA 
expression with IPF. The authors suggesting that drugs such as anakinra that mimics IL-1R1As activity, 
and has previously been used in other inflammatory disorders may be of use in IPF (Korthagen et al., 
2012). 
In OB a significant increase in the levels of IL-1β in the BAL of patients has been described in one study 
(Vanaudenaerde, De Vleeschauwer, et al., 2008), yet confusingly in another study not only was this effect 
not replicated, but an increase in the inhibitory IL-1R1A was described instead (Belperio et al., 2002). 
Although in both cases the authors link their findings with development of disease, in the first instance by 
hypothesising that the increased inflammation would lead to excessive fibrosis, and in the second by 
suggesting the anti-fibrotic effects of the inflammatory response were being blocked. Neither of these 
papers refer to the current debate about the dual forms of OB disease characterisation that may account 
for their differing findings. One study which investigated this effect, albeit with a small sample size, 
described an increase in IL-1β detected in the BAL in the early onset neutrophilic form of OB, with no 
change detected in the late onset form of the disease (Verleden et al., 2011). 
 
1.3.4 Mitogen Activated Protein Kinase Cascade 
The previous sections have described the canonical signalling responses of TGF-β1, TNFα and IL-1β, 
however these molecules also induce other non-canonical signalling responses. One common alternative 
signalling pathway, which can be activated by all three stimuli, is the mitogen activated protein kinase 
(MAPK) cascade. Although describing this cascade as common is perhaps a misnomer due both to the 
breadth of components contained within, and the variety of interactions possible. 
There are several families of MAPKs, and of these there are three that are well described. The 
extracellular signal related kinases (ERK)-1/2 were described first, followed quickly by the c-Jun N-
terminal kinases (JNK)-1/2 and p38 families. Each MAPK is activated by dual phosphorylation of a 
threonine and tyrosine residue separated by a single amino acid. For ERK-1/2 this is glutamate, for JNK-
1/2 a proline and p38 gylcine. Once activated these MAPKs can, through the activity of transcription 




The traditional view of MAPK activation is that a signal induces activation of an upstream MAP3K (MAP 
kinase kinase kinase), which in turn activates a MAP2K and in turn the requisite MAPK. Each MAPK can be 
activated by several MAP2Ks that can in turn be activated by several MAP3Ks that creates a system with 
redundancy built in, whilst also facilitating a wide array of outcomes based on the exact signalling input. 
For example at least four MAP3Ks have been implicated in the activation of JNK-1/2 in response to 
stimulation by TNFα or IL-1β, with some of these same MAP3Ks being involved in the non-canonical 
TGF-β1 response. Adding another layer of complexity is that signalling responses are often not 
conserved between different cell types, for example the MAP3K MEKK1 was required for activation of 
JNK-1/2 by TNFα in embryonic stem cells (Xia, 2000), but not in fibroblasts (Yujiri, 1998). I cover the 
specific activities of each MAPK in more detail in the results chapters dealing with each protein, but the 
review by Rubinfeld et al covers the activation and response of each in more detail (Rubinfeld and Seger, 
2005). 
 
1.3.5 Synergistic Response 
Recently our group and others have shown that TGF-β1 can drive EMT in primary bronchial epithelial 
cells (PBEC)s (Ward et al., 2005; Hackett et al., 2009), and that inflammatory stimuli such as TNFα and IL-
1β can accentuate this effect (Borthwick et al., 2009, 2010; Câmara and Jarai, 2010). However, the 
signalling mechanisms that underpin this synergistic effect are unknown; and a greater understanding of 
their interactions is required. TGF-β1, TNFα and IL-1β are all pleiotropic in nature and they often display 
apparently conflicting effects. 
TGF-β1 has strong pro-fibrotic effects and it can also act as a potent suppressor of the immune response, 
conversely TNFα displays strong inflammatory abilities alongside anti-fibrotic abilities, and yet the 
presence of both is seen as key in OB and implicated in IPF. Evidently, there is some mechanism that is 
overriding the conflicting effects of TGF-β1 and TNFα, and by referring back to the chronic wound 
theory outlined in 1.2.1 it is possible to see how such a mechanism could arise. The immune response 
usually tails off post clearance of the initiating factor, however if this factor is un-clearable for example in 
allergic responses, in response to chronic infection or a repeated injury from industrial particulates then 
this response may be maintained. 
Studies have demonstrated that TNFα is capable of increasing the transcription of TGF-β1, as well as 
stabilising TGF-β1 mRNA in vitro, these findings were confirmed in vivo in a study whereby transient 
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over-expression of TNFα induced an increase in detected TGF-β1 and a subsequent development of 
fibrosis (Sime et al., 1998). However in an alternative study, mice over expressing TNFα in the lung were 
shown to develop less severe pulmonary fibrosis in response to bleomycin, or when TGF-β1 was also 
over-expressed (Fujita et al., 2003). It was then postulated that it may be the type of TNFα present that 
determines whether a fibrotic response is initiated.  
Using transgenic mice it was demonstrated that the membrane bound un-processed form of TNFα could 
generate an inflammatory response in vivo but that a subsequent fibrotic response did not occur, 
whereas the soluble cleaved form of TNFα induced both an in inflammatory and fibrotic response. The 
same study also demonstrated that the source of this soluble TNFα that drove TGF-β1 and fibrosis was 
the airway epithelium itself (Oikonomou et al., 2006). It is not known what type of TNFα was 
predominantly produced in the study which demonstrated TNFα induced bleomycin resistance, as TNFα 
production was not assessed, however previous studies using the same model measured TNFα in the 
BAL by ELISA suggesting that at least some soluble TNFα was produced.  
Other differences between the models include the uses of a transient TNFα expression with a positive 
effect on fibrosis, whereas permanent expression inhibited the development of fibrosis. This may indicate 
that continuous inflammation can inhibit the initiation of fibrosis, whereas pulsed occurrences of TNFα 
accentuate rather than inhibit the already occurring fibrotic response. The detected levels of TNFα also 
differed slightly between the two models with the transient model peaking at approximately 150ng/mL, 
and the permanent model at 90ng/mL of TNFα, although it seems unlikely that such a small variation 
would produce such a difference in response. 
A mechanism whereby TGF-β1 induces the production of TNFα has not been described however, with 
several studies describing the inhibition of TNFα by TGF-β1 (Vaday et al., 2001; Yu et al., 2009). Together 
all these studies demonstrate how poorly understood the interplay between TGF-β1 and TNFα is, and 




1.4 Hypothesis, Aims & Objectives 
I propose that the development of fibrosis in OB is at least partially facilitated by a dysregulated wound 
healing response initiated by a non-resolving, but not continuous, pro-inflammatory milieu within the 
airway or alveoli which induces a pro-fibrotic response. That this dysregulated wound response manifests 
itself as EMT, with the airway lining losing its epithelial character and gaining a motile, pro-fibrotic 
mesenchymal character; an effect which is driven by TGF-β1 and accentuated by inflammatory mediators 
such as TNFα. That the accentuative effect of TNFα on TGF-β1 driven EMT in the airway epithelium is 
mediated by a protein (or proteins) which hyper-activates existing signalling pathways or activates a 
novel signalling cascade.  
 
1.4.1 Aims 
 To isolate PBECs from stable lung transplant recipients by bronchial brushing. 
 To culture these cells in a submerged system and use this system to model the fibrotic and 
inflammatory milieu present in OB. 
 To observe and quantify the onset and development of EMT within this system. 
 To unpick the signalling events involved in the onset and development of EMT. 
 
1.4.2 Objectives 
 Utilise previously described PBEC isolation and culture methods to establish sufficient cell stocks. 
 Induce EMT within these cultures by the addition of recombinant human TGF-β1 or TNFα; 
observe the morphological changes and measure the changes in protein expression associated 
with EMT. 
 Disrupt the function of key proteins within the TGF-β1 and TNFα signalling cascades by chemical 
inhibition and siRNA mediated knockdown, and measure the impact of this disruption on EMT. 
 Assess the phosphorylation of proteins within the TGF-β1 and TNFα signalling cascades to 




2 Materials & Methods 
All experimental procedures were conducted in compliance with Newcastle University and Institute of 
Cellular Medicine Safety Policy according to the Control of Substances Hazardous to Health (COSHH) 




All reagents were sourced directly through the relevant suppliers and COSHH regulations were followed 
throughout their usage. 
 
2.1.1 Cell Lines 
Throughout this project wherever possible I have tried to use primary human cells as due to their un-
transformed nature I feel that they are a more relevant model in which to investigate physiological 
effects. However in some instances due to the requirement for either large cell numbers or a high 
protein yield it has been necessary to use an alternative cell line population. 
 
2.1 .1 . 1 A549 
A549 cells were derived from an explanted lung tumour isolated from a 58 year old male in 1972. They 
were described as having characteristic multilamellar bodies in the cytoplasm and a high level surfactant 
protein synthesis from which it was concluded that they are a good model for type II pneumocyte cells. 
The cell line is predominately hypotriploid with a modal chromosome number of 66 although other 
frequencies do occur (Giard et al., 1973; Lieber et al., 1976).  
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2.1.2 Media  
Reagent Supplier Cat. # Volume (mL)
Dulbeco’s Modified Eagle Medium (DMEM) for A549 Cells 
Dulbeco’s Modified Eagle Medium (DMEM)/F-12 Ham Sigma D6421 500
Foetal Calf Serum Sigma 12133C 50
Penicillin (100 units/mL)/Streptomycin (1mg/mL) Sigma P4333 5
L-Glutamine Sigma G7513 5
Roswell Park Memorial Institute-1640 (RPMI) 
Roswell Park Memorial Institute-1640 Sigma R0883 500
Foetal Calf Serum Sigma 12133C 50
Penicillin (100 units/mL)/Streptomycin (1mg/mL) Sigma P4333 5
L-glutamine Sigma G7513 5
Roswell Park Memorial Institute-1640 (SAGM) 
Small Airway Growth Medium Lonza CC-3119 500
Bovine Pituitary Extract 
Lonza CC-3118 Kit form
Hydrocortisone 







Bovine Serum Albumin 
Penicillin (100 units/mL)/Streptomycin (1mg/mL) Sigma P4333 5





Reagent Supplier Cat. # Concentration (M)
TBS-Tween (pH 7.6) 
Trizma Base Sigma T1503 0.05
NaCl Sigma S3014 0.15
Polysorbate-20 (Tween-20) Sigma 44112 0.005
-In dH20 
Table 3 - General Solutions 
 
Reagent Supplier Cat. # Concentration (M)
Denaturing Lysis Buffer 
Sodium Dodecyl Sulphate Sigma L3771 0.0034
Ethylenediaminetetraacetic acid Sigma EDS 0.005
β-mercaptoethanol (added just prior to use) Sigma M3148 0.1
- In dH20 
Non-denaturing Lysis Buffer 
Trizma HCL Sigma T3253 0.02
NaCl Sigma S3014 0.140
Glycerol Sigma G5516 0.1
Triton X-100 Sigma T9284 0.01
Ethylenediaminetetraacetic acid Sigma EDS 0.002
- In dH20 
Table 4 - Immuno-precipitation Solutions 
 
Reagent Supplier Cat. # Concentration (M)
Zymography Buffer 1 
Triton-X 100 Sigma T9284 0.025
Zymography Buffer 2 (ph 7.5) 
Trizma Base Sigma T1503 0.05
CaCl2 Sigma C1016 0.005




Reagent Supplier Cat. # Concentration (M)
Resolving Buffer (pH 8.8) 
Trizma Base Sigma T1503 1.5
- In dH20 
1x Stacking Buffer (ph 6.8) 
Trizma Base Sigma T1503 0.5
- In dH20 
10x Running Buffer (pH 8.3) 
Trizma Base Sigma T1503 0.25
Glycine Sigma G8898 1.92
Sodium Dodecyl Sulphate Sigma L3771 0.034
- In dH20 
Sample Loading Buffer 
Trizma HCL Sigma T3253 0.0625
Glycerol Sigma G5516 2
Sodium Dodecyl Sulphate Sigma L3771 0.034
Bromophenol Blue Sigma 114391 0.0005
β-mercaptoethanol (added just prior to use) Sigma M3148 0.01
- In dH20 
Table 6 - SDS-PAGE Solutions 
 
Reagent Supplier Cat. # Concentration (M)
Transfer Buffer 
Trizma Base Sigma T1503 0.25
Glycine Sigma G8898 1.92
- In dH20 
Stripping Buffer 
Trizma HCl Sigma T3253 0.0625
Sodium Dodecyl Sulphate Sigma G8898 0.07
β-mercaptoethanol (added just prior to use) Sigma M3148 0.1






Target Supplier Cat. # Technique Dilution 
TAK1 Cell-Signalling 4505 
Western Blot 1:1000 
ICC/IHC 1:100 
Immuno-Precipitation 1:87 
pTAK1 (Thr184) Cell-Signalling 4537 
Western Blot 1:1000 
ICC/IHC 1:100 
Indirect ELISA 1:5000 
pTAK1 (Thr187) Cell-Signalling 4536 
Western Blot 1:1000 
ICC/IHC 1:100 
Indirect ELISA 1:5000 
TAB1 Cell-Signalling 3226 Western Blot 1:1000 
TAB2 Cell-Signalling 3745 Western Blot 1:1000 
TAB3 Abcam ab85655 Western Blot 1:1000 
SMAD3 Abcam ab29379 
Western Blot 1:3000 
ICC/IHC 1:100 
Immuno-Precipitation 1:128 
pSMAD3 (Ser423/425) Abcam ab52903 
Western Blot 1:1000 
ICC/IHC 1:100 
Indirect ELISA 1:10000 
JNK-1/2 Cell-Signalling 9252 
Western Blot 1:1000 
ICC/IHC 1:100 
Immuno-Precipitation 1:69 
pJNK-1/2 (Both Thr183/Tyr185) Cell-Signalling 4668 
Western Blot 1:1000 
ICC/IHC 1:100 
Indirect ELISA 1:4000 
c-Jun Cell-Signalling 9165 Western Blot 1:500 
pc-Jun (Ser63) Cell-Signalling 2361 Western Blot 1:250 
p38 Santa-Cruz sc-7149 Western Blot 1:1000 
pp38 (Thr180/Tyr182) Santa-Cruz sc-17852 Western Blot 1:500 
ERK-1/2 Cell-Signalling 4695 Western Blot 1:1000 
pERK-1/2 (Thr202/Tyr204 & Thr185 & 
Tyr187) 
Cell-Signalling 4370 Western Blot 1:500 
IKKα/β Santa-Cruz sc-7607 Western Blot 1:2000 
Immuno-Precipitation 1:178 
pIKKα/β (Ser176/180 & Ser177/181)  Cell-signalling 2697 Western Blot 1:1000 
Indirect ELISA 1:5000 
Iκ-Bα Santa-Cruz sc-1643 Western Blot 1:1000 
pIκ-Bα (Ser32 & Ser36) Cell-Signalling 9246 Western Blot 1:500 
Table 8 - Antibodies  
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Target Supplier Cat. # Technique Dilution 
E-cadherin BD Bioscience 610181 
Western Blot 1:3000 
ICC/IHC 1:100 
ZO-1 Santa-Cruz sc-10804 
Western Blot 1:1000 
ICC/IHC 1:100 
Cytokeratin-14 Santa-Cruz sc-6278 
Western Blot 1:2000 
ICC/IHC 1:100 
Cytokeratin-17 Santa-Cruz sc-6278 
Western Blot 1:2000 
ICC/IHC 1:100 
Cytokeratin-19 Santa-Cruz sc-6278 
Western Blot 1:2000 
ICC/IHC 1:100 
CCSP Abcam ab40873 
Western Blot 1:500 
ICC/IHC 1:100 
AQP-4 Abcam ab11026 
Western Blot 1:1000 
ICC/IHC 1:100 




αSMA Abcam ab32575 Western Blot 1:2000 
ICC/IHC 1:100 
Fibronectin Sigma F3648 
Western Blot 1:4000 
ICC/IHC 1:100 
Vimentin Santa-Cruz sc-6260 
Western Blot 1:500 
ICC/IHC 1:100 
β-actin Sigma A2228 Western Blot 1:4000 
ICC/IHC 1:100 
Ran Cell-signalling 4462 Western Blot 1:1000 
Pan-IgG Abcam  Immuno-Precipitation 1:84 




2.1.5 Cytokines & Growth Factors 
Recombinant human cytokines were delivered to cells directly in serum containing media. Effect on EMT 
was assayed by western blot for endpoint markers at 72 hours post stimulation with phosphorylation 
response assayed 30 minutes post stimulation. A dose response curve of for each cytokine and pro-
fibrotic pro-inflammatory combination was performed in A549 cells assaying for cell viability, growth and 
morphology and efficacy of inhibition on EMT. 
Cytokine Source Supplier Cat. # 
Final Concentration (µg/ml of 
media)
TGF-β1 Chinese Hamster Ovary cells Peprotech 100-21C 10ng/mL
TNFα Escherichia coli Invitrogen PHC3011 20ng/mL
IL-1β Escherichia coli Invitrogen PHC0814 20ng/mL
Table 9 - Recombinant Cytokines 
 
2.1.6 Chemical Inhibitors 
Chemical inhibitors were delivered to cells 1 hour prior to stimulation. Efficacy of effect was assayed by 
western blot for EMT endpoint markers at 72 hours post stimulation with phosphorylation response 
assayed 30 minutes post stimulation. A dose response curve of for each chemical inhibitor was 
performed in A549 cells assaying for cell viability, growth and morphology and efficacy of inhibition on 
EMT. 
Target Inhibitor Supplier Cat. # Final Concentration (μM)
SMAD3 Specific Inhibitor of SMAD3 Calbiochem 566405 10
IKKβ IKK-2 Inhibitor IV Calbiochem 401481 5
p38 SB 203580 Calbiochem 559389 10
ERK-1/2 FR180204 Calbiochem 328007 5
JNK-1/2 SAPK Inhibitor II Calbiochem 420119 5
TAK1 (5Z)-7-Oxozeaenol, Curvularia sp. Calbiochem 499610 1




2.1.7 Small Interfering RNA 
siRNA was delivered to PBECs with HiPerfect lipid transfection reagent (Qiagen: #301705) 24 hours prior 
to stimulation. Efficacy of siRNA knockdown was assessed by probing for the total form of the protein 24, 
48, 72 and 96 hours after transfection, and the impact on detected phosphorylation was also assessed at 
an appropriate time point after stimulation with TGF-β1 and TNFα. 
A scrambled siRNA was used as a negative control in all experiments, the same concentration and dose 
of transfection reagent of the respective siRNA was used in each instance. A dose response curve of 
scramble siRNA only, lipid only and scramble siRNA with lipid was performed when first optimising 
transfection of PBECs assaying for cell viability, growth and morphology.  
Target Sequence Supplier Cat. # Concentration (nM)
SMAD3 ATCAAGGGATTTCCTATGGAA Qiagen SI00082481 5
IKKβ CTGGAGAAGTACAGCGAGCAA Qiagen SI02777376 0.1
JNK-1 GTGGAAAGAATTGATATATAA Qiagen SI02757209 5
JNK-2 GCCGUCCUUUUCAGAACCAT Qiagen SI00300797 10
TAK1 AAGATGGTATATACCAAGTTA Qiagen SI02758763 3
Scramble Proprietary Qiagen SI03650318 As per experiment




2.2 Cell Isolation, Culture & Treatment 
2.2.1 A549 Cell Line Culture 
A549 cells were cultured on un-coated plastic tissue culture vessels or un-coated glass coverslips for 
immunocytochemistry, in DMEM media. Cells were passaged upon reaching approximately 90% 
confluence. To passage, cells were washed once with sterile 1x PBS before trypsin (Sigma: #T3924), pre-
warmed to 37°C, was added to the culture vessel. Cells were incubated for approximately 5 minutes until 
the majority had lifted off from the surface, the trypsin was then neutralized with an equal volume of FCS 
containing DMEM media. Cells were pelleted by centrifugation at 250 x g for 4 minutes and the 
supernatant was discarded. The cell pellet re-suspended in fresh DMEM and plated according to 
experimental parameters 
 
2.2.2 Primary Sample Isolation & Culture 
All Human Tissue Act regulations and European Union Tissue and Cells Directives were adhered to. I 
would like to thank Drs Malcolm Brodlie, Laura MacKay, Elizabeth Moisey, Danai Karamanou and Nicola 
Green, as well as Gail Johnson, Kasim Jiwa and Dr Chris Ward and all the transplant staff at the Freeman 
Hospital for taking the time out of their already busy days to consent patients, isolate and prepare 
samples prior to me receiving them. 
2.2.2.1 Clinical Definit ion of BOS 
BOS was diagnosed as per International Society of Heart and Lung Transplantation guidelines (Estenne 
et al., 2002). Briefly, a decrease in FEV1 to between 81 and 90% (averaged over two separate visits) of 
baseline would highlight the potential development of BOS. Further decreases are classified onto a 3-
stage scale with diagnosis confirmed by histological analysis. 
2.2.2.2 Primary Sample Isolation Ethics 
This study was performed in accordance with approval from the Newcastle and North 
Tyneside Local Regional Ethics Committee and informed written consent was obtained from all study 
patients (REC 2001/179). 
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2.2.2.3 PBEC Isolation 
Patient metrics are included in Appendix 8.1. PBECs were isolated by bronchial brushing of the sub-
segmental bronchi in previously consented lung transplant patients, using a protected specimen single-
sheath nylon cytology brush (Olympus: #BC-202D). Cells were dispersed into 5mL of sterile PBS with a 
further addition of 5mL of RPMI media (Forrest et al., 2005).  
 
2.2.2.4 PBEC Culture 
PBECs were cultured on 0.5% collagen I (Nutacon: #5005-B) coated plastic tissue vessels or collagen 
coated glass coverslips for immunocytochemistry, in SAGM. Cells were passaged upon reaching 
approximately 90% confluence, and were not taken beyond five passages to ensure epithelial 
morphology. Very early cultures displayed a morphologically heterogeneous population, however this 
was lost before first passage with all cells displaying a rounded cobblestone like appearance, at high 
(>10) passage PBECs became senescent A confluent T25 flask contained approximately 3-400,000 cells 
and yielded between 100-150µg of total protein. To passage, cells were washed once with sterile 1x PBS 
before trypsin (Lonza: #CC-5012), pre-warmed to 37°C, was added to the culture vessel. Cells were the 
incubated for approximately 5 minutes until the majority of cells had lifted off from the surface, the 
trypsin was then neutralized with an equal volume of trypsin neutralizing solution (Lonza: #CC-5002). 
Cells were pelleted by centrifugation at 250 x g for 4 minutes and the supernatant was discarded. The 
cell pellet re-suspended in fresh SAGM and re-plated at a 1:2-1:3 ratio according to experimental 
parameters. Therefore, from an initial isolation of two T25 flasks it would be possible to generate 8-18 
T25 flasks, or equivalent surface area, by P2. 
 
2.2.2.5 Bronchoalveolar Lavage  
Bronchoalveolar Lavage was collected as part of the normal screening protocol in post-transplant 
patients. Where research permission had been previously provided excess BAL samples after clinical 
diagnostic procedures were carried out were provided for use. Briefly, 60mL aliquots of sterile saline 
solution are introduced into the lung at the level of the sub-segmental bronchi by a bronchoscope, the 
aliquot is aspirated then withdrawn under low pressure to minimise airway collapse. This procedure is 
repeated three times in each patient with the lavage collected as a single sample. 
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2.2.3 Cell Treatments & Stimulations 
All cell treatments were performed using aseptic technique and treatments were made up en masse 
before being aliquoted onto appropriate cells to ensure consistency of treatment.  
 
2.2.3.1 Chemical Inhibit ion 
Experiment appropriate amounts of chemical inhibitors were added to cells in culture 1 hour before 
stimulation with TGF-β1, TNFα or IL-1β, alongside untreated controls. 
 
2.2.3.2 Small Interfering RNA 
siRNA in experiment appropriate amounts was mixed with HiPerfect lipid transfection reagent diluted in 
sterile 1xPBS for 30 minutes at room temperature. Complexes were added to cell culture 24 hours before 
stimulation with TGF-β1, TNFα or IL-1β, alongside untreated and sequence scrambled controls. 
 
2.2.3.3 Cytokines 
Experiment appropriate doses of TGF-β1, TNFα or IL-1β were added to cells after chemical inhibition or 
siRNA knockdown. For the assessment of EMT endpoint markers cells were harvested 72 hours post- 





2.2.4 Cell Preparation 
2.2.4.1 For Immuno-Cytochemistry 
Cells cultured on glass coverslips were washed 1 time with 1x PBS before fixation in situ with 4% PFA for 
1 hour at room temperature or overnight at 4°C. Cells were then washed with 1mM glycine in dH2O to 
quench the crosslinking action of PFA for 30 minutes at room temperature. Cells were then stored under 
1x PBS at 4°C prior to immuno-staining. 
 
2.2.4.2 For SDS-PAGE & Immuno-Precipitation 
Media was harvested and stored at -80°C for gelatin zymography and Sircol assay. Cells were washed 1 
time with 1x PBS before being harvested by cell scraping into ice cold 1x PBS. Cells were pelleted by 
centrifugation at 1000 x g for 5 minutes at 4°C and stored in PhosphoSafe Extraction Reagent (EMD: 
#71296-3) at -80°C to prevent protease and phosphatase activity. 
 
2.3 Protein Expression & Analysis 
2.3.1 Lysate Fractionation 
Lysates isolated as per 2.2.4.2 were fractionated by reagent based lysis into nuclear and non-nuclear 
fractions (Pierce: #78833) as per manufacturer’s instructions. Briefly proteins are isolated in a two-step 
process; firstly the cell membrane is chemically disrupted and the cytoplasm released, the intact nuclei 
are then pelleted out by centrifugation before being themselves lysed. The cell adhesion protein E-
cadherin and Ras-related Nuclear Protein (Ran), a nuclear specific Ras GTPase (Wennerberg et al., 2005), 
were used as markers to confirm the purity of the respective fractions. 
2.3.2 Bicinchoninic Acid Protein Assay 
Protein concentration was determined by the Bicinchoninic Acid Protein Assay (BCA – Pierce: #23225). 
Prior to assay lysates isolated as in 2.2.4.2 were sonicated in a standard fashion, and centrifuged at 500 x 
g for 1 minute to pellet any remaining cell debris. A standard curve derived from serially diluted 2mg/mL 
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BSA was also prepared. Samples were loaded onto a 96 well plate as per manufacturer’s instruction and 
incubated at 37°C to improve assay sensitivity (Olson and Markwell, 2007). The plate was read at 570nm. 
 
2.3.3 Immuno-Precipitation 
Cells were cultured on 6 well tissue culture plates coated with collagen I, cells were prepared as 
described in 2.2.4.2 prior to Immuno-precipitation. Samples were well mixed and 10μL was removed for 
BCA protein assay as described above. The maximum constant protein concentration available was used 
for all assays, which approximated 20µg. 
The harvested cell suspension was centrifuged at 250 x g for 5 minutes at 4°C to pellet the cells. 250μL of 
ice cold non-denaturing or denaturing lysate buffer mixed with a protease inhibitor cocktail in a 10:1 
ratio was added to the cells. When using non-denaturing lysis buffer the cells were agitated for 30 
minutes at 4°C before being centrifuged at 1200 x g for 20 minutes, the supernatant was kept and the 
pellet discarded. For cells lysates which were denatured the samples were boiled for 5 minutes before 
being quenched with an equal volume of non-denaturing lysis buffer and mechanically agitated through 
a 20G needle. Samples were spun at 12,000 x g for 10 minutes and re-suspended in 250μL of 1x PBST. 
To remove any non-specific IgG binding proteins from the sample 25μL of control IgG antibody was 
incubated with the sample for 1 hour on ice, 25μL of protein G coated magnetic beads were then added 
and incubated for 30 minutes under agitation. Beads were isolated through application of a magnetic 
field and the supernatant collected, beads were re-suspended in 250μL of 1x PBST before being isolated 
again, this supernatant was added to that previously collected, the beads coated with non-specific IgG 
binding proteins were discarded. 
1μg of antibody was added per 100μg of protein in each sample and incubated overnight at 4°C under 
agitation. 25μL of protein G coated magnetic beads were added to each sample and incubated for 30 
minutes at room temperature under agitation. Beads were isolated through application of a magnetic 
field and the supernatant collected. Beads were re-suspended in 250μL of 1x PBST before being isolated 
again, and this supernatant was added to that previously collected. 50μL of sample loading buffer 
(without bromophenol blue for indirect ELISA experiments) was added to the beads and heated at 80°C 





A standard concentration of protein as used for all samples on a gel, and each sample was mixed with an 
equal volume of 4x sample loading buffer before being boiled for 5 minutes. This solution was loaded 
onto either a 4-12% Bis-Tris gradient gel (Invitrogen: #NP0322) and run at 100V in 1x Running Buffer; 
with a SeeBlue Plus 2 pre-stained ladder (Invitrogen: #LC5925), for 2 hours on ice.  
 
2.3.5 Zymography 
An 8% resolving gel was made up as described below and loaded into the casting apparatus; the gel was 
covered with an appropriate volume of saturated butanol. A stacking gel made up as described below 
and was layered on top of the resolving gel and left to set at room temperature with an appropriately 
sized comb in place. 
Reagent Supplier Cat. # 8% Resolving (mL) 4% Stacking (mL)
Acrylamide Sigma A3699 4 1.3
1.5M 
Tris(hydroxymethyl)aminomethane 
Sigma 93349 3.75 2.5
1mg/ml Gelatin in dH20 Sigma G2500 6.95 -
dH20 - - - 5.8
10% Sodium Dodecyl Sulfate Sigma L4390 0.15 0.1
10% Ammonium Persulfate Sigma A5508 0.3 0.1
Tetramethylethylenediamine Sigma T9281 0.02 0.02
Table 12 - SDS-PAGE Gel Recipe 
 
The required loading volume of media harvested as per 2.2.4.2 & 2.3.2 is mixed with neat 4x sample 
loading buffer, without β-mercaptoethanol, in a 3:1 ratio. This solution was loaded into the wells and ran 
at 100V for approximately 2 hours in 1x Running Buffer. Gels were washed 2 times for 15 minutes in 
Zymography Buffer 1 prior to 6 quick washes in dH20; gels were then incubated overnight at 37°C in 
Zymography Buffer 2. Gels were stained with Coomassie Blue Stain for around 2 hours before being 
washed in Coomassie destain until distinct bands are visible against the background. Gels were 
photographed on a SynGene G:Box iChemi XL. 
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2.3.6 Western Blotting 
Proteins separated by SDS-PAGE were transferred onto Polyvinylidene Fluoride (PVDF - GE Healthcare: 
#RPN303F) membranes at 50mA per membrane overnight on ice. The membranes were then blocked 
with, either 5% dried milk in 1x TBST; or with 3% BSA for phospho-signalling molecules. Membranes 
were then incubated overnight at 4°C with a primary antibody diluted in blocking solution. Membranes 
were washed 3 times for 10 minutes in 1x TBST before being incubated with isotype and species 
appropriate Horseradish Peroxidase (HRP) conjugated secondary antibodies diluted in blocking solution 
for 2 hours at room temperature. Membranes were then washed 3 times for 10 minutes in 1x TBST 
before being covered with Enhanced Chemiluminescence (ECL – Pierce: #32106) substrate for 2 minutes. 
Membranes were photographed on a SynGene G:Box iChemi XL. For 
 
2.3.7 Band Density Analysis 
Band density of western blots and zymograms was analyzed by Image J software (Abramoff et al., 2004). 
Epithelial marker band intensity was measured relative to controls, with mesenchymal marker expression 
measured relative to TGF-β1 alone stimulations. All EMT endpoint bands were standardized against β-
actin loading controls either co-probed on the same membrane or generated by strip and re-probe of 
the same membrane. Bands for phospho-signalling protein were standardized against the total form of 
the protein, which unless otherwise stated was achieved by re-probing the original membrane. Where 
applicable the mean and Standard Error of the Mean (SEM) were generated and plotted. 
 
2.3.8 Indirect Enzyme Linked Immuno-Sorbent Assay 
To perform and indirect Enzyme Linked Immuno-Sorbent Assay (ELISA) 20μL of immuno-precipitated 
lysate was diluted up to 310μL in 1x PBS, and 100μL of this solution was used to coat 3 wells of a 96 well 
ELISA plate. The plate was sealed and then incubated overnight at 4°C. The plate was washed 3 times 
with 1x PBST before being blocked with 100μL of 1% BSA in 1x PBST for 1 hour at room temperature. 
This was replaced with 100μL of primary antibody diluted in blocking solution and the plate incubated at 
4°C overnight. The plate was washed 3 times with 1x PBST before being incubated with 100μL of isotype 
and species appropriate HRP conjugated secondary antibody diluted in blocking solution for 2 hours at 
room temperature. The plate was washed 3 times with 1x PBST before 100μL of Tetramethylbenzidine 
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(TMB) substrate solution was added and the plate stored in the dark for approximately 20 minutes. 50μL 
of 0.25M sulphuric acid was added to stop the reaction and the plate was read using at 450nm. Patient 
samples were averaged after samples were standardized with un-stimulated 0 minute samples set at 0.1 
relative units. 
 
2.3.9 Bronchoalveolar Lavage Cytokine Assay 
Levels of TNFα and IL-1β in the bronchoalveolar lavage (BAL) sampled from a longitudinal population of 
lung transplant patients were assessed by a Meso Scale Discovery Multi Spot Assay (MSD: #K15025C-2) 
as per manufacturer’s instructions. 20μL of neat BAL per sample was loaded onto the plate in triplicate 
along with an appropriate standard curve. Briefly, the MSD system is comparable to colourimetric 
sandwich ELISAs. A capture antibody is bound to a carbon electrode at the bottom of a proprietary 96 
well plate, which in this instance bind and hold TNFα and IL-1β present in the BAL. A detection antibody 
conjugated with a proprietary electrochemi-luminescent then binds to any captured TNFα or IL-1β; 
which, in the presence of the activated electrode, will emit light at 620nm. Significance was then 
calculated with a two-tailed Mann-Whitney U Test. Significance was then calculated with a two-tailed 
Mann-Whitney U Test. 
 
2.3.10 Sircol Assay 
Media harvested as per 2.2.4.2 was analyzed for collagen I-IV content by the Sircol collagen assay 
(Biocolor: # S1000) as per manufacturer’s instructions. Briefly the assay relies on the binding, and 
colourimetric detection of Sirius Red dye to Gly-X-Y repeats (Ramshaw et al., 1998) present in the helixes 
of acid soluble collagen I-IV in a concentration dependant manner, with concentrations determined 
against a serially diluted standard curve prepared from 20μg/mL collagen I. Significance was then 
calculated with a two-tailed Mann-Whitney U Test. 
 
2.3.11 Immuno-Cytochemistry 
Cells were prepared as described in 2.2.4.1 prior to staining. Cells were permeabilized with 0.1% Triton 
X-100 in 1x PBS for 30 minutes at room temperature and washed 3 times, for 5 minutes each, with 1x 
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PBST. Cells were blocked with 3% BSA in 1x PBST for 1 hour at room temperature prior to incubation 
with primary antibodies diluted in blocking solution overnight at 4°C. Cells were washed 3 times with 1x 
PBST prior to incubation with isotype and species appropriate fluorochrome conjugated secondary 
antibody diluted in blocking solution for 2 hours at room temperature in the dark. Cells were washed 3 
times with 1x PBST followed by 1 wash with 1x PBS, a drop of DAPI (4',6-diamidino-2-phenylindole) 
containing mounting media was placed on a glass slide and the coverslips was gently laid on top. Slides 
were then left in the dark overnight at 4°C before visualization by confocal microscopy. Blank and 
secondary only controls were used in all instances. 
 
2.3.12 Immuno-Histochemistry 
Formalin fixed tissue was embedded in paraffin blocks before being sectioned and placed on a glass 
slide. Paraffin was removed from the slide by washing in 98.5% Xylenes for 5 minutes at room 
temperature followed by 2 washes in 95% ethanol for 5 minutes before being placed in cold dH20 until 
ready for antigen retrieval. Ethylenediaminetetraacetic acid (EDTA) at pH 8.0 was pre-boiled in a 
microwave, slides were placed in a rack then lowered gently into the EDTA which was then boiled for a 
further 10 minutes, before being left to cool at room temperature for 20 minutes. Slides were removed 
and excess EDTA removed with a dry cloth and a hydrophobic barrier was drawn around the tissue 
section with a PAP pen. The staining protocol used is the same as described above for ICC. Blank and 
secondary only controls were used in all instances. 
 
2.3.13 Confocal Microscopy 
All images were acquired on a Leica TCS-SP-2UV confocal microscope at x63 magnification unless 
otherwise stated. Excitation lasers for fluorescein isothiocyanate (FITC) and tetramethyl rhodamine 
isothiocyanate (TRITC) dyes were standardized for each experiment, with DAPI dye set by eye for each 
image as required. Images were taken through the centre of the cell as determined by the presence of 
the most intense DAPI stain.  
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2.3.14 Statistical Analysis 
Due to the small sample sizes a normal distribution could not be assumed, therefore the non-parametric 
Mann-Whitney U test was used to test for statistical significance. However, for clarity of presentation data 
in graphs were displayed as mean + SEM. Western blot band density was not analysed statistically due to 
their semi-quantitative nature. To allow comparison between blots epithelial markers were standardised 
to the untreated control, with mesenchymal markers standardised to TGF-β1 stimulated controls. In each 
case, this value was set at 1 and accordingly lacked error bars when plotted. 
 
2.4 Cell Staining 
2.4.1 Haematoxylin & Eosin 
Cells were prepared as described in 2.2.4.1 prior to staining. Cells were permeabilized with 0.1% Triton 
X-100 in 1x PBS for 5 minutes at room temperature, followed by 2 quick washes with dH20 followed by a 
5 minute was in dH20. Acidified haematoxylin (Thermo Scientific: #6765003) was added to each sample 
for 4 minutes at room temperature, followed by the above wash protocol. Alcoholized eosin (Thermo 
Scientific: #6766007) stain was added to each sample for 30 seconds, followed by the above wash 
protocol. Samples were left inverted to dry before being stored in the dark prior to photography. 
 
2.4.2 Trypan Blue 
For trypan blue exclusion cells were culture on 48 well plates. Media for each treatment was harvested, 
and cells washed once with 1x PBS, which was added to collected media. Cells were then trypsinized, 
with following trypsin neutralization as per 2.2.2.4, and added to collected media and wash. Samples 
were centrifuged at 500 x g for 5 minutes at room temperature, supernatant was discarded and cell 
pellet was re-suspended in 250µL of DMEM media and cells counted. 250µL of 0.4% trypan blue dye was 
added to each sample, mixed thoroughly and incubated for 3 minutes at room temperature. Two counts 
of 50 cells from each sample were performed and the percentage of viable cells excluding trypan blue 




3 Primary Samples Display Increased 
Fibrotic and Inflammatory Markers 
Throughout this project I have where possible used primary human cells and samples, isolated from lung 
transplant recipients at the Freeman Hospital in Newcastle-upon-Tyne. The benefits of using these are 
cells are that they are more physiologically relevant to a living human, and hence the disease models 
being investigated; and the association of these cells with tissue and BAL samples isolated from the same 
patients allows for greater integration into a disease model still. 
There are however some downsides, the cells are cultured submerged in media on collagen coated glass 
or plastic, which bears little relationship to their in vivo setting. Their proliferative ability is also somewhat 
limited when compared to a cell line population, although again probably increased over that occurring 
in vivo which means that it is often difficult to generate a sufficient cell number to experiment on. There 
is also perhaps more of a variation in results between patients, however when an effect that is conserved 
between distinct patients is described, it is perhaps more striking than reproducibility within a cell line.  
 
3.1 Cytokine Expression in BOS Patients 
Throughout this study I will be using recombinant TGF-β1, TNFα and IL-1β to stimulate cells mimicking 
the environment that is present in the lung during the development of OB. It is routine for post-
transplant patients at the Freeman to come in for regular assessments, at which point samples, including 
the cells I use, tissue sections and BAL fluid are taken. Over time a longitudinal database of patient 
samples has accrued which in association with clinical notes allows tracking of the environment within a 
patients lung in respect to disease initiation, progression or escalation post-transplant. 
It is well recognized in clinical practice that BOS is often first diagnosed or progresses more rapidly 
following a significant episode of acute inflammation or airway injury. However that association is based 
on the observation that immune cells are increased, therefore facilitating a greater release of immune 
factors, in the lavage and also on histological evidence of inflammation having occurred within the tissue. 
Therefore, it was decided to directly assay BAL samples isolated from post-transplant patients at 
recurring check-ups for the presence or absence of both TNFα and IL-1β.  
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3.1.1 TGF-β1 Expression in BOS Patients 
Due to the availability of several studies (Elssner et al., 2000; Ramirez et al., 2008) demonstrating elevated 
levels of TGF-β1 in the BAL of BOS patients , the scarcity of sample and the expense of custom MSD 
plates it was decided not to assay for TGF-β1. Below is a figure reproduced from the paper by Elssner et 
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3.1.2 TNFα Expression in BOS Patients 
BAL samples from patients at the Freeman Hospital in Newcastle-upon-Tyne were assessed for the 
presence of TNFα using a Meso Scale Discovery Multi Spot Assay as described in 2.3.9. Values were 
derived from the associated standard curve. In all cases data is presented in two forms, raw and then 
adjusted (all samples adjusted to 100% BAL return) to account for the variation in percentage of BAL 
returned from the lung, which in some instances was as low as 5%. I would like to thank Dr Rahul Mahida 
for collating the clinical samples and linking them with the requisite patient details, and Miss Monika 
Suwara with whom I jointly performed the MSD assay. 
Patients were grouped into those who had a clinical diagnostic of BOS (Stages 1-3 as per ISHLT 
guidelines) (Estenne et al., 2002)), and those without. The BOS group was then further split into samples 
occurring up to 6 months before diagnosis of BOS, up to 3 months before diagnosis, at diagnosis, up to 
3 months post diagnosis and up to 6 months post diagnosis of BOS. Statistical significance was assessed 
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3.1.3 IL-1β Expression in BOS Patients 
BAL samples from patients at the Freeman Hospital in Newcastle-upon-Tyne were assessed for the 
presence of IL-1β using a Meso Scale Discovery Multi Spot Assay. Values were derived from the 
associated standard curve. In all cases data is presented in two forms, raw and then adjusted to account 
for the percentage of BAL returned from the lung. 
Patients were grouped into those who had a clinical diagnostic of BOS (Stages 1-3 as per ISHLT 
guidelines) (Estenne et al., 2002)), and those without. The BOS group was then further split into samples 
occurring up to 6 months before diagnosis of BOS, up to 3 months before diagnosis, at diagnosis, up to 
3 months post diagnosis and up to 6 months post diagnosis of BOS. Statistical significance was assessed 
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The mean percentage recovery of BAL was lower in BOS patients (24%) than in post-transplant patients 
without BOS (28%) (p<0.05). Looking at TNFα, correcting for recovery increased the level of significance 
for all groups compared to the without BOS group, induced significance in the 3 and 6 month post 
diagnosis groups, and increased the detected levels of TNFα in the total BOS group so that it was now 
significantly elevated, as opposed to lowered when compared to the without BOS groups. Looking at IL-
1β both non corrected and corrected data were significant, with correction increasing the level of 
significance. Anecdotally the recovery of BAL was lowest in BOS patients just after diagnosis (13% - for 3 
months post diagnosis) which may account for the gain in statistical significance observed in TNFα for 
the post diagnosis groups. In the 3 months leading up to diagnosis with BOS recovery was in line with 
the mean (24%). Unless otherwise specifically mentioned I will be basing my discussions on the corrected 
data set. 
Both TNFα and IL-1β were significantly elevated in the total BOS diagnosed group compared to the 
without BOS group, suggesting that both TNFα and IL-1β play a key role in the development of BOS and 
OB. However the total BOS diagnosed group covered all samples from each diagnosed patient, which in 
some cases could range up to 2 years before diagnosis. To focus on the relevance of TNFα and IL-1β to 
BOS more closely I split the BOS diagnosis into groups containing all samples 6 months before diagnosis, 
3 months before diagnosis, at diagnosis, 3 months post diagnosis and 6 months post diagnosis. Samples 
in the 3 month groups were also counted in the relevant 6 month group.  
Detected TNFα and IL-1β was significantly higher than both the total with BOS and total without BOS 
groups for all samples. Levels of TNFα and IL-1β at diagnosis of BOS were roughly similar to those 6 
months before diagnosis, and there was a drop in levels of both in the 3 and 6 months post diagnosis 
groups. This drop is likely due to an increase in immuno-suppression post diagnosis. Most interestingly 
there was a significant peak in both TNFα and IL-1β 3 months before the diagnosis of BOS, which was 
seemingly not present at or after diagnosis. This acute burst of inflammation may be a key step in the 
development of BOS driving the increase in OB, potentially by interaction with the elevated levels of 
TGF-β1 that others have detected. 
Poor recovery of BAL from the diseased lung is well recognized but there are few guidelines to help 
standardize protocol, or explanations as to why recovery is so poor (Löfdahl et al., 2005; Schildge et al., 
2007). Looking at the pathology of BOS there are several reasons why recovery may be so poor, firstly 
obliterated airways may act as sinks for the lavage fluid, preventing it from being retrieved. Secondly, 
with fibrosis of the airways the count of Clara cell secreting cells may be decreased meaning that the 
 59 
 
airways are more liable to collapse trapping lavage fluid, although this is likely only to effect the smaller 
airways.  
This has direct relevance to the process of correction, and BOS, not perhaps for IL-1β where both non-
corrected and corrected samples were strongly significant; but for TNFα where significance for the post 
diagnosis samples was only achieved after correction. Are the cytokine levels detected due to the low 
volumes recovered being closely associated with a pro-fibrotic and pro-inflammatory airway plug, which 
when corrected scale upwards significantly, or are they representative of the whole lung? Whilst the 
paper by Schildge et al. attributes no difference in cell and cytokine levels to the recovery rate in various 
diseases (Schildge et al., 2007) , and yet they are using a cut off value of 30% return, which is higher than 
mean recovery for both BOS and non BOS groups. 
The actual level of TNFα, and perhaps IL-1β, present in the lung is likely higher still as by assessing BAL 
only the soluble forms of each protein are being measured. TNFα exists as both an active and 
membrane found trimer and in this assay only the soluble form is being measured, as such any 
contribution to inflammation by the membrane bound isoform is being missed. Once secreted both 
cytokines are not necessarily free within the airway or alveolar space, an unknown proportion become 
bound in the ECM.  
Heparan sulphate (Parish, 2006) is a widely studied mediator of this binding, and it can have a diverse 
role on cytokine mediated signalling. Binding with heparan sulphate can protect cytokines from 
degradation in the extracellular space by masking proteolytic sites, thus prolonging their lifespan (Sadir 
et al., 2004) and has also been implicated in facilitating oligomerization of cytokines, a step as previously 
described which is key for optimal signalling (Hoogewerf et al., 1997). Heparan sulphate in the ECM can 
also effectively mask cytokines or present them more efficiently to receptors depending on how the 
cytokine is bound, effectively acting as a reservoir of cytokines within the lung.  
There are few studies looking at the role of heparan sulphate in the development of lung disease and 
non-specifically looking at the development of BOS. However interestingly one study looking at ROS 
degradation of the ECM mediated by asbestos described a reduced occurrence of inflammation and 
fibrosis, when heparan sulphate was protected from degradation (Kliment et al., 2008).  
There are therefore several ways in which the ECM may be affecting detection of cytokines in the above 
samples and BOS as a whole. The peaked release 3 months before diagnosis may refer to the activation 
or release of cytokines from the ECM, either because of its stimulation or degradation. The hypothesis 
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that soluble TNFα contributes to a more fibrotic and inflammatory response than its membrane bound 
pre-cursor may fit here (Oikonomou et al., 2006), if a large quantity soluble TNFα was being held inactive 
in the ECM then it's release could initiate an inflammatory driven fibrosis upon its release, which may 
correlate with the release seen 3 months before diagnosis. This would require some other factor to 
induce the activation or cleavage of TNFα from the ECM. 
Alternatively cytokines may be being held active and for longer periods within the ECM in BOS patients 
compared to healthy controls. These are just hypotheses and a more detailed study which encompasses 
measurements of BAL, cellular and ECM cytokine levels in both diseased and non-diseased patients 
would be required determine the true physiological levels of cytokines in disease compared to controls. 




3.2 Primary Bronchial Epithelial Cells 
Alongside BAL samples, airway brushings are also conducted post-transplant from which it is possible to 
derive and culture airway epithelial cells. The protocol for isolation and culture is described in 2.2.2 and 
in the paper by Forrest et al. (Forrest et al., 2005). It has been observed that isolated PBECs change 
appearance and display a decrease in proliferative ability through passage events. Ideally, upon receipt 
of brushings, PBECs would be dispersed into the required number of culture vessels, and experimented 
upon when confluent without passage. However when cells were split too diffusely there was a significant 
reduction in culture establishment, and those that did establish tended to display excessively 
mesenchymal phenotypes, either due to resident fibroblasts being able to survive and proliferate, or 
stress inducing epithelial cells into a more mesenchymal character. Therefore, to achieve the required 
sample sizes with appropriate cell numbers some passaging must occur. 
The following experiments attempt to describe changes within the cells at the protein level throughout 
culture, and what if any impact this may have on later experiments investigating EMT. 
 
3.2.1 Characterization of Passage Effects in PBECs 
When cells arrive in the lab they are pelleted as described in 2.2.2.3 and plated out as P0 in duplicate 
T25 tissue culture flasks. These cells are then cultured as per 2.2.2.4 until the required number of 
confluent tissue culture vessels can be achieved. Throughout culture the cell morphology changes as the 
cells appear to de-differentiate quickly. In order to characterize this change a series of experiments were 
performed at passage (P) numbers 1 through 4, investigating the expression of various epithelial and 
mesenchymal markers, hypothesizing that cells would gradually lose specialized epithelial marker 
expression such as CCSP, retain general epithelial character and possibly gain some mesenchymal or 
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Fibronectin is an ECM protein that is often released by fibroblasts during the wound healing process to 
form a provisional matrix with other quick release factors such as fibrin and hyaluron allowing for extra 
motility of epithelial and mesenchymal cells to assist resolving the wound (Valenick et al., 2005; Chow et 
al., 2010). As such its expression is often associated with the development of fibrosis, in these pure un-
stimulated epithelial cultures it's low level of expression was to be expected. AQP-5 is typically associated 
with Type I pneumocytes (Funaki et al., 1998) and so its lack of expression was also to be expected. 
E-cadherin (Van Roy and Berx, 2008) and ZO-1 (Fanning and Anderson, 2009) are both tight junction 
proteins responsible for maintaining epithelial sheet integrity, and are not associated with a particular 
differentiated form of epithelial cell. Their loss is associated with a transition into a more motile and 
invasive mesenchymal character as described above. In the wound healing response there is thought to 
be a reduction but not complete loss of expression, as epithelial cells loosen but do not completely 
detach their associations with each other. The consistent expression throughout the above expression 
would suggest that cells are maintaining a generally epithelial character through to at least P4. 
Vimentin is an intermediate filamentous protein and is thought to be expressed in mesenchymal cells 
(Steinert and Roop, 1988). As such it is often used as a marker of EMT (Gilles et al., 1999) for epithelial 
cells that have gained the more motile invasive phenotype of mesenchymal cells. That it is detected 
throughout culture suggests that either a baseline level of vimentin is to be expected in epithelial cells, or 
that in culture PBECs display mesenchymal characteristics, perhaps due to the requirement to move and 
cover the tissue culture surface or due the culture environment itself. A comparison of a long term 
confluent culture with a dividing cells, or with air liquid interface (ALI) cultures would be one way of 
confirming this. 
CCSP and SFP-A are both associated with differentiated epithelial cells, Clara cells and Type II 
pneumocytes respectively. In PBEC cultures I had hypothesized that CCSP would be present and then 
lost as cells de-differentiated in culture, with no SFP-A detected at all. However both forms were present 
throughout all passages. Further reading about SFP-A demonstrated that it was often expressed by both 
Clara cells and, with some evidence of expression in alveolar macrophages (Walker et al., 1986), perhaps 
accounting for the evidence of SFP-A staining seen. This provides an explanation for the detection of 
SFP-A however the maintenance of markers of differentiated cells in vivo is more puzzling. Once again 
however with wider reading evidence of expression outside of these specific cells, and even outside of 
the lung itself has described (Peri et al., 1993; Lacaze-Masmonteil, 1995). This suggests two possibilities, 
most likely is that this is a baseline expression of SFP-A and CCSP in epithelial cells that have already de-
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differentiated, the second being that Clara cells are able to maintain their phenotype within culture and 
continue expressing CCSP and SFP-A, which is difficult to agree with in light of the expression of other 
markers discussed below. 
Cytokeratins-14 and 17 are thought to be markers specific to basal epithelial cells from all tissues, as 
such in the lung they would be associated with the larger airways (Troyanovsky et al., 1989; Purkis et al., 
1990; Ghosh et al., 2011). Therefore I had hypothesized that their expression may increase throughout 
culture as epithelial cells revert to a more de-differentiated state. However this was not the case, 
cytokeratin-14 was initially detected but this detection was lost by western blotting beyond P2, P3 for ICC. 
All cells seemingly displayed cytokeratin-14 at early passage which suggested that either all PBECs are 
capable of its expression in vitro or that early in culture all surviving cells display basal cell characteristics. 
The subsequent loss of expression leads me to favour the second explanation, as a loss of basal cells 
would fit with the concurrent loss of proliferative ability in culture. If attempts were made to immortalize 
these cells it would be interesting to see if cytokeratin-14 expression was maintained. Cytokeratin-17 
mimicked the pattern shown by cytokeratin-14 in ICC, however the quality of the antibody was very poor 
as can be seen in the western blot, and in Appendix 8.3. Due to the inability to confirm antibody 
specificity by western blotting the ICC findings should also be discounted. 
Cytokeratin-19 is also thought to mark proliferative epithelial cells, but it is not associated specifically with 
any epithelial sub-population such as SFP-A, CCSP or cytokeratins-14 and 17 (Stasiak et al., 1989; Michel 
et al., 1996). Whilst not detected by ICC it was detected by western blot at all passage points, with no 
variation in expression. How this correlates with the drop in cytokeratin-14 and 17 expression is not clear. 
It is possible by not being expressed in any particular proliferative cell type that cytokeratin-19 may 
describe an innate proliferative ability, which is maintained in cells throughout culture. A supposition 
which may be reinforced by the association of cytokertain-19 with the development of several cancers 
(Alix-Panabières et al., 2009). 
The myofibroblast marker αSMA (Hinz, 2007) was included as a negative control as I initially 
hypothesized that its expression would only be induced under pro-fibrotic conditions. However, faint 
levels were detected by western blot and ICC in both P3 and P4. This suggests that in culture even when 
un-stimulated that PBEC cultures are gradually differentiating towards a mesenchymal phenotype. 
Interestingly αSMA was dropped from the panel of markers I used to assess EMT as there was no 
detectable variation in expression after any stimulation, with a low baseline level expressed throughout. 
The stimulants used on cells therefore may not be sufficient to drive epithelial cells towards a 
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myofibroblast like phenotype in culture, or this change may require a longer time course than for other 
markers such as fibronectin, vimentin and pro-MMP-9, which would fit with the temporal occurrence of 
myofibroblasts in the wound healing process. 
This mixed bag of results demonstrates that measuring EMT can be difficult and that a variety of markers 
should be assessed. This effect is described in a study by Chai et al. who investigated the expression of 
common epithelial and mesenchymal markers in several epithelial and fibroblast cell lines and found 
significant crossover of expression, concluding that there is no single reliable marker of either an 
epithelial or mesenchymal cell (Chai et al., 2010), which fits well with the idea of EMT being a spectrum.  
My project is predominantly focused on measuring EMT in PBEC cultures, and the relative importance of 
key signalling proteins in driving this transition. As such a viable and proliferative population with a 
strong innate epithelial character would make the ideal point to act as a baseline for EMT experiments. 
Cells proliferated well up until P4 so any time point before that would be suitable to use for 
experimentation. Due to the loss of some epithelial marker expression, and the gain of αSMA expression 
after P2 I chose to not go beyond this passage point with future experiments. Whilst there is still 
evidence of some mesenchymal protein, vimentin, expression before P2 it was present at a steady 
baseline, making it possible to measure transitions from this point. 
 
3.2.2 TGF-β1, TNFα & IL-1β dose response  
With an appropriate time point that provided sufficient PBECs of epithelial character, and with 
proliferative ability and evidence of the role of TGF-β1, TNFα and IL-1β expression detected in the BAL 
of BOS patients. I next investigated the response of PBECs to stimulation with these factors both in 
isolation and together. There have been several previous studies which have described the interplay 
between TGF-β1 and TNFα or IL-1β (Borthwick et al., 2010; Câmara and Jarai, 2010; Yamauchi et al., 
2010), including from within this research group however I felt that it was important to demonstrate that 
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These results demonstrate that EMT in PBECs is driven by TGF-β1, was capable of reducing expression of 
E-cadherin at 5, 10 and 20ng/mL doses whilst simultaneously increasing expression of fibronectin at all 
doses, without impacting on cell viability. There was a clear increase in effect stepping up from 5ng/mL 
to 10ng/mL of TGF-β1 but little detectable difference between 10ng/mL and 20ng/mL treatments at the 
protein level and so it was decided to use a 10ng/mL dose through further experiments. The paper by 
Elssner et al. (see Figure 10) detected a mean of 5ng/mL TGF-β1 in the BAL of BOS patients (Elssner et 
al., 2000), although as discussed this figure may be higher still if ECM bound TGF-β1 was factored in. 
Whilst a 5ng/mL dose of TGF-β1 was capable of driving EMT in vitro I felt that the stronger effects 
demonstrated by the 10ng/mL dose would provide a more consistent mesenchymal shift to investigate. 
TNFα alone only very slightly induced, fibronectin expression at 10ng/mL with, a slight increase in 
expression at 20ng/mL and evidence of a decrease in E-cadherin at this same dose, 5ng/mL having no 
effect on either marker. Cell viability was reduced by approximately 5% 24 hours after stimulation, but 
remained constant after this initial drop. Interestingly IL-1β had no effect on cell viability, morphology or 
expression of E-cadherin and fibronectin at any dose. This suggests that neither TNFα or IL-1β are 
capable of driving fibrosis in our PBEC culture system as the doses use exceed their detected peak in the 
BAL (0.8ng/mL and 5ng/mL 3 months before BOS diagnosis respectively), this may be because they act 
over a longer period than TGF-β1 and we are simply missing the effect, although this becomes difficult 
to assay in cells which are innately losing their epithelial character over time. Another cause may be that 
EMT is not driven by inflammatory mediators, and such factors induce a pro-fibrotic effect by either 
inducing or recruiting other cells than drive fibrosis, or act as intermediaries in driving EMT. 
When used in conjunction with TGF-β1 however the results were more intriguing. TNFα at both 10ng/mL 
and 20ng/mL was capable of strongly accentuating the loss of E-cadherin and gain in fibronectin seen in 
both 5 and 10ng/mL TGF-β1 stimulations. With the largest loss of E-cadherin and gain in fibronectin 
seen when using the highest doses of each. IL-1β at 10ng/mL did not detectably influence the TGF-β1 
driven loss of E-cadherin or gain in fibronectin, yet at 20ng/mL it accentuated the response in both the 5 
and 10ng/mL TGF-β1 stimulations, although to a lesser degree than both TNFα stimulations. These 
results provide clear evidence that inflammatory mediators such as TNFα and IL-1β are capable of acting 
in synergy with TGF-β1 to drive fibrosis by EMT in PBEC cultures. The doses of required to initiate this 
effect are higher than those detected in the BAL of BOS patients before diagnosis, but are within an 
order of magnitude of those figures, and as previously discussed BAL measurements do not account for 
the bound quantities of cytokines. 
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Whilst TNFα had a larger accentuative effect on TGF-β1 than IL-1β it is difficult to directly relate these 
findings to the disease model. Approximately 5 times the amount of IL-1β compared to TNFα was 
detected in BAL samples, therefore it is possible that a 50ng/mL dose of IL-1β would have a comparative 
effect, to that of 10ng/mL TNFα. Other factors may also play an important role such as receptor 
expression, dissociation constant between receptor and ligand, ability of ECM coating to sequester and 
inhibit or assist with oligomerization. Nevertheless, in vitro TNFα produces the largest accentuative effect 
at a reasonable dose and so it was decided that a 20ng/mL dose would be used in future experiments. 
Whilst changes in E-cadherin and fibronectin expression levels were detected by western blotting the 
changes in PBEC morphology in response to stimulation were, whilst detectable, rather conserved. 
Comparable A549 photo-micrographs show a much greater morphological shift from a uniform 
cobblestone appearance to one containing tightly clustered cell foci with a spindle like appearance. This 
may be due to several factors, most obviously A549 cells are cell line of a different cell type, it may be 
that the immortalized nature of A549s makes them more susceptible to EMT, or that the Type II cells that 
they represent are themselves more susceptible. A549 cells also proliferate more rapidly than PBECs, the 
morphological transition may be linked closely to linked to cell cycle and as such the more rapidly 
dividing A549 cells undergo this more rapidly. 
In the introduction, I discussed whether EMT could be viewed as a discrete occurrence, where an 
epithelial cell switches completely to a mesenchymal phenotype; or whether a continuous spectrum of 
marker expression and cell activity was observed. These findings would suggest it is the latter, with 
isolated epithelial cells capable of expressing both epithelial and mesenchymal proteins, mesenchymal 
proteins increasing over time and passage in culture. Differing doses of pro-inflammatory and pro-
fibrotic stimuli also induced differing severities of EMT in cultured cells, again suggesting that cells were 
transitioning over a spectrum rather than switching character directly. 
In summary in this chapter I have demonstrated the epithelial character of isolated PBECs and decided 
upon a maximum passage number from which to best assess EMT. The levels of the pro-fibrotic TGF-β1 
and the inflammatory TNFα and IL-1β were assessed in the BAL of post-transplant patients. A significant 
elevation of TNFα and IL-1β was detected in those diagnosed with BOS compared to those without, with 
a marked increase 3 months before diagnosis. This data was used to determine a suitable dose of TGF-
β1 to drive EMT in vitro in PBEC cultures, and the accentuative effect of TNFα and IL-1β was confirmed 
and a suitable dose of TNFα decided upon.   
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4 TAK-1 Mediates Synergistic Signalling 
I decided to investigate the synergistic signalling between TGF-β1 and TNFα at the intracellular signalling 
level by inhibiting the action of key signalling proteins and observing the effect on EMT and also on the 
phosphorylation of these same proteins.  
In the first instance the function of each protein was chemically inhibited with an appropriate dose 
determined from experiments in A549 cells. EMT was assessed by observing changes in EMT markers, a 
decrease in E-cadherin and cytokeratin-19, an increase in fibronectin and vimentin and an increase in the 
secretion of pro-MMP-9 and collagens I-IV. By assessing the impact of inhibition on EMT and also the 
phosphorylation of signalling proteins it was possible to develop a putative signalling method that 
described the observed synergy between TGF-β1 and TNFα. These findings were then verified where 
possible by using siRNA knockdown of the same signalling proteins. 
 
4.1 Mothers against decapentaplegic-3 
With TGF-β1 driving EMT it was logical to begin investigation of the signalling mechanisms by 
investigating the canonical TGF-β signalling pathway. TGF-β1 signalling forms part of the TGF-β super-
family signalling group along with other factors such as the bone morphogenic proteins (BMP). The 
SMAD family of proteins are the major constituents of TGF-β super-family signalling; of which there are 8 
isoforms. SMADs are typically split into three categories, receptor (r)SMADs (1, 2, 3, 5 and 8), co-
activating (co)SMAD (4) and inhibitory (i)SMADs (6 and 7). All SMADs contain a c-terminal MAD 
homology domain (MH2) region which regulates the binding of SMAD proteins to each other, as well as 
other regulatory proteins. The rSMADs and coSMAD also contain an N-terminal MAD homology domain, 
which facilitates DNA binding and also contains nuclear localization and export signals. The coSMAD and 
iSMADs are conserved for all arms of the TGF-β super-family, with SMAD2 and SMAD3 acting as the 
rSMADs for TGF-β1 signalling. SMAD3, 48 kDa, and SMAD2, 55 kDa, were first described in mammalian 
systems in 1996 (Eppert et al., 1996; Zhang et al., 1996). 
In un-stimulated cells SMAD2/3 are inactivated in two ways, firstly by self-binding between their own 
MH1 and MH2 regions inhibits oligomer formation, nuclear translocation and DNA binding, secondly the 
un-phosphorylated rSMADs are held in the cell membrane by SARA. SARA displays a higher dissociation 
constant with un-phosphorylated rSMAD monomers than they do with each other, and so is capable of 
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limiting random activations. SARA also plays a key role in the activation of SMAD signalling however, 
upon activation of the TGF-R1 kinase by TGF-β1 binding, SARA presents the un-phosphorylated rSMAD 
to the receptor, allowing for the phosphorylation of SMAD2/3.  
Phosphorylation occurs at the C-terminal of the rSMAD proteins, Ser465 and Ser467 for SMAD2 and 
Ser423 and Ser425 for SMAD3, which removes the auto-inhibitory effects of self-binding, and also 
greatly reduces the affinity between the rSMAD and SARA, freeing SMAD2/3 into the cytoplasm. Once 
freed these rSMADs are capable of forming heterodimers with SMAD4, or heterotrimers with SMAD4 
and another rSMAD molecule, mediated by interactions between the MH2 regions. The mechanisms of 
dimer or trimer formation, and the differing impacts are not well understood, but evidence of differing 
transcriptional responses has been described (Inman and Hill, 2002). 
The exposed MH2 region of SMAD2/3 also contains a nuclear localization signal which can facilitate a 
co-SMAD independent localization into the nucleus by associating with importin proteins to pass 
through nuclear pores, which are then cleaved by the actions of RAs-related Nuclear protein (RAN) a 
GTPase. Nuclear translocation can also occur in association with SMAD4 , although it is achieved in an 
importin independent manner through direct interaction with nuclear pore proteins. Although rSMAD 
complexes can translocate to the nucleus without SMAD4 it is thought that they will remain 
transcriptionally inactive in its absence, as although SMAD3, but not SMAD2 (Dennler et al., 1999), is 
capable of binding directly to SMAD binding elements (SBE) within the genome its affinity is low (Shi et 
al., 1998). Other co-factors such as p300, recruited in the presence of SMAD4 (De Caestecker et al., 
2000), are required to stabilise this binding. Activated rSMADs however can form complexes with SMAD4 
in the nucleus (Pierreux et al., 2000), suggesting that nuclear import conditions can provide another level 
of control within the SMAD pathway. 
These co-factors can be transcriptionally active in their own right, and upon association with a SMAD 
oligomer induce an alternative transcriptional event, or they may be transcriptionally inactive and simply 
facilitate a stronger bond between a SMAD oligomer and a SBE (Feng and Derynck, 2005). Whatever 
their mechanism a large number of proteins have been implicated in modulation of SMAD DNA binding, 
and it is this mixture of various SMAD oligomers associated with a wide array of co-factors that allows for 
a wide range of specific responses to an, initially, rather simple appearing signalling pathway. To my 
knowledge there is no evidence of activation of the canonical SMAD pathway by either TNFα or IL-1β, 




After initiating the desired transcriptional event rSMADs are shuttled back to the cytoplasm, SMAD4 
contains a nuclear export signal, however this is masked when in association with rSMADs, and as such is 
thought to be used to cycle itself back into the cytoplasm (Pierreux et al., 2000). Upon de-
phosphorylation by phosphatases such as protein phosphatase 1A (PP1A) rSMADs disassociate from 
SMAD4, which can then cycle back to the cytoplasm independently, and other co-factors; and are 
exported from the nucleus (Lin et al., 2006). Un-phosphorylated rSMADs are exported from the nucleus 
by the same proteins that are capable of importing them (Xu et al., 2002), the exact mechanism that 
defines direction of transit is unknown although it may be due to the self-masking ability of the rSMADs 
or the changes within the C-terminal region. 
It was initially thought that out of SMAD2 and SMAD3, SMAD2 might be the key factor in response to 
TGF-β1 stimulation, with SMAD3 acting as a redundant or modulatory protein as knocking out SMAD2 
(Heyer et al., 1999) but not SMAD3 (Zhu et al., 1998) resulted in an embryo lethal phenotype in mice. 
However later work in fibroblast isolated from knockout mouse embryos suggested that the opposite 
was true, with SMAD3 initiating the response to TGF-β1 stimulation, which could then be modulated by 
SMAD2 (Yang et al., 2003), which added yet another level of regulation to the canonical signalling 
pathway. It has also been shown that SMAD3 may play more of a role in the development of the fibrotic 
response, as in primary hepatic stellate cells SMAD3 overexpression resulted in increased expression of 
mesenchymal markers such as fibronectin and collagen I, compared to the same cells over-expressing 
SMAD2 (Uemura et al., 2005). As such it was decided that SMAD3 rather than SMAD2 would be the 
subject of investigation in our system. 
TGF-β1 is a major driver of fibrosis, and of EMT; and therefore understanding the contribution of its 
canonical signalling pathway to EMT is the logical first step in understanding TGF-β1 driven, TNFα 
accentuated EMT. The following results outline my attempts to understand SMAD3 phosphorylation in 
response to TGF-β1 or TNFα stimulation as well as its role, and importance, in the subsequent 
occurrence of EMT in our OB model system. 
 
4.1.1 Phosphorylation Response of SMAD3 
As discussed in 1.3 phosphorylation is often one of the key steps in protein activation. As such 
understanding of when protein phosphorylation occurs temporally can provide information about order 
of activation within a signalling cascade. The phosphorylation and subsequent activity of SMAD3 has 
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been discussed above. SMAD3 is key mediator of TGF-β1 signalling, with no activity in response to TNFα 
described. I therefore hypothesized that phosphorylation of Ser423 and Ser425 in the carboxyl terminal 
of SMAD3 would occur in response to TGF-β1 alone, with TNFα having no impact either alone or when 
used in conjunction with TGF-β1. 
PBECs were cultured in 6 well collagen coated plates until confluent and stimulated with TGF-β1 or TNFα. 
Cells were harvested at 0, 0.5, 1, 5, 10, 30 and 60 minute time points. Whole cell PBEC lysate was 
immuno-precipitated for total SMAD3, under denaturing conditions, with the resulting lysate probed for 
pSMAD3 (Ser423 and Ser425) by indirect ELISA. Neat lysate from the 30 minute stimulation was analyzed 
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TGF-β1 induced a significant phosphorylation of SMAD3 at 30 minutes, which was also the peak 
phosphorylation value an effect which was maintained at 60 minutes, significance was nearly obtained at 
10 minutes (p=0.058). TNFα alone had no impact on SMAD3 phosphorylation at any time point, when 
used in conjunction with TGF-β1. 
These results confirm that in PBECs activation of SMAD3 is purely driven by TGF-β1, with TNFα 
displaying no role in activation. 
 
4.1.2 Chemical Inhibition of SMAD3 
Investigating the phosphorylation of signalling proteins in response to TGF-β1 or TNFα is one means of 
investigating their role in EMT. However, the previous data demonstrates that SMAD3 was activated in 
response to TGF-β1, not that it plays a role in EMT. To investigate relevance to EMT SMAD3 activity was 
chemically inhibited by Specific Inhibitor of SMAD3 (SMADi). SMADi functions by selectively blocking 
phosphorylation of SMAD3, but not SMAD2, thus inhibiting the formation of a transcriptionally active 
complex with SMAD4 (Jinnin et al., 2006) with an IC50 of 3µM determined in primary human fibroblast 
cultures. 
A dose response curve looking at cell viability, morphology and effect on EMT after pre-treatment with 1, 
5, 10 and 20μM doses of SMADi prior to stimulation with TGF-β1 and TNFα for 72 hours was performed 
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Inhibition of SMAD3 resulted in a dose dependant decrease in cell viability in all cells, a decrease that 
was perhaps exacerbated upon TNFα alone stimulation. The higher doses of 10µM and 20µM were the 
only doses capable of inhibiting EMT, both morphologically and at the protein level. The 20µM dose 
most strongly inhibited the morphological shift associated with EMT, but did not provide an appreciable 
inhibition EMT at the protein level over the 10µM dose; therefore a dose of 10μM SMADi, which retained 
viability at a higher level, was used in all future experiments. 
 
4.1.2.1 Chemical Inhibit ion of SMAD3, Effect on EMT 
Endpoint 
With an appropriate dose of SMADi decided upon in A549 cells the next step was to observe what effect 
this would have on EMT in PBECs. n=4 PBEC cultures from distinct patients were stimulated with TGF-β1 
or TNFα for 72 hours after a 1 hour pre-treatment with 10μM SMADi. Cell lysate and culture media was 
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The results described above provide strong evidence, that SMAD3 activation plays a key role in TGF-β1 
driven EMT. A 10µM dose of SMADi did not affect viability of PBECs compared to untreated controls. 
Pre-treatment with SMADi strongly inhibited the loss of E-cadherin expression, gain in fibronectin 
expression and increase in collagens I-IV secretion in response to TGF-β1, whilst also inducing a small 
reduction in the expression of vimentin and secretion of pro-MMP-9. PBECs pre-treated with SMADi also 
showed reduced levels of EMT in PBECs stimulated with TGF-β1 and TNFα when compared to untreated 
controls, however with the exception of collagen an accentuated response was still observed when 
compared to SMADi treated, TGF-β1 stimulated PBECs. Interestingly SMADi induced a reduction in 





4.1.2.2 Chemical Inhibit ion of SMAD3, Effect on 
Phosphorylation 
As seen in Figure 19 SMAD3 is phosphorylated in response to TGF-β1 alone, with no apparent role for 
TNFα. However, it is important to understand if SMAD3 phosphorylation is leading to activation of other 
signalling pathways, therefore I proceeded to investigate the effect of SMADi pre-treatment on the 
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SMAD3 was phosphorylated in response to TGF-β1 with no evidence of phosphorylation in response to 
TNFα alone, or in co-stimulation. There was also no detectable variation in intensity of phosphorylation 
between TGF-β1 alone and co-stimulated cells. SMADi strongly inhibited the phosphorylation of SMAD3 
whilst not affecting total levels. No difference in the phosphorylation of IKKβ, p38 or JNK-1/2 was 
detected in response to pre-treatment with SMADi, suggesting that these pathways operate 
independently or upstream of SMAD3. TAK1 however displayed an increase in phosphorylation in 
response to TGF-β1 alone when PBECs were treated with SMADi. 
 
4.1.3 siRNA Knockdown of SMAD3 
SMAD3 targeting siRNA (SMADsi) was used to knockdown SMAD3 in order to validate the findings 
generated using SMADi. A dose response assay; for cell viability, morphology and effect on EMT after a 
24 hour pre-treatment with 1, 5, and 10nM doses of SMADsi (ATCAAGGGATTTCCTATGGAA), delivered 
through lipid transfection of adherent cultures prior to stimulation with TGF-β1 and TNFα for 72 hours, 
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SMAD3 expression was reduced in a dose dependant manner by pre-treatment with SMADsi, with a 
general but shallow decrease in cell viability. The loss of E-cadherin expression in response to TGF-β1 or 
TNFα stimulation was also inhibited in a dose dependant manner, with a 10nM dose of SMADsi capable 
of returning levels to baseline. The gain of fibronectin in response to TGF-β1 or TNFα stimulation was 
weakly inhibited by the 1nM dose of SMADsi, with a strong effect seen at 5nM. The 10nM dose of 
SMADsi increased the detected levels of fibronectin for all stimulations compared with the 5nM 
treatment group. Therefore although the 10nM dose induced the strongest recovery of E-cadherin, a 
5nM dose which inhibited fibronectin expression more efficiently, and without affecting un-stimulated 
expression, was used for all future experiments. 
 
4.1.3.1 siRNA Knockdown of SMAD3, Effect on EMT 
Endpoint 
With an appropriate dose of SMADsi confirmed for use in PBECs I proceeded to investigate what effect 
SMAD3 knockdown had on EMT. n=3 PBEC cultures from distinct patients were stimulated with TGF-β1 
or TNFα for 72 hours after a 24 hour pre-treatment with 5nM SMADsi or a sequence scrambled control. 
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The data presented above validates the findings described with SMADi in 4.1.2. A 5nM dose of SMADsi 
derived from the screen described in 4.1.3 induced approximately a 75% knockdown in detected total 
SMAD3, with the subsequent loss of detected phospho-SMAD3 without affecting PBEC viability. Pre-
treatment of PBECs with SMADsi strongly inhibited the loss of E-cadherin and the gain of fibronectin and 
vimentin intracellularly, as well as the increase in secretion of pro-MMP-9 and collagens I-IV into the 
media in response to TGF-β1 stimulation, and upon co-stimulation in comparison to untreated controls. 
However, as with SMADi evidence of a residual accentuation was observed when comparing PBECs pre-
treated with SMADsi and stimulated with TGF-β1 and TNFα with equivalent TGF-β1 alone stimulated 
PBECs, confirming that SMAD3 alone does not mediate accentuated EMT. Interestingly SMADsi pre-
treatment also reduced collagen expression for all stimulations beyond that of untreated, un-stimulated 
controls, similarly to the effect observed with SMADi. 
4.1.4 Localization of SMAD3 
Both chemical inhibition and siRNA knockdown of SMAD3 suggested that it plays a key role in EMT, and 
the phosphorylation assays indicate that solely TGF-β1 alone is capable of driving its phosphorylation. 
However as discussed above phosphorylation alone does not constitute transcriptional activity as the 
rSMADs are required to translocate to the nucleus and bind with co-factors to alter transcription. To 
investigate this further I looked at the localization of both total and phospho-SMAD3 30 minutes post 
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Both ICC and lysate fractionation protocols demonstrated that phospho-SMAD3 localized to the nucleus 
in response to both TGF-β1 alone and TGF-β1 with TNFα stimulations, unlike in Figure 19 there was no 
detectable difference in the level of phosphorylation between TGF-β1 and co-stimulated PBECs. 
However, the results for the total-SMAD3 were conflicting; ICC showed a diffuse level of total-SMAD-3 
throughout the cell, whereas lysate fractionation showed a greater localisation to the cytoplasm. It is 
possible that proteins present in the nuclear fraction are being degraded due to their longer isolation 
protocol and hence longer time in detergent solutions, however I can present no data to support this 
and the protocol is designed to limit protein degradation. Therefore, although the phospho-SMAD3 
results correlate with previous findings the lack of reliable total-SMAD3 data means it is not possible to 
comment on phospho-SMAD3 localization in this system. 
 
4.1.5 SMAD3 Protein Associations 
As discussed previously the binding efficiency of SMAD3 to SBEs is low and often requires SMAD4 
mediated association with a variety of co-factors (Shi et al., 1998; Dennler et al., 1999). It was therefore 
decided to investigate the associations of SMAD3 with other selected proteins, after stimulation, assessed 
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Neither total nor phosphorylated forms of TAK1 were associated with SMAD3 30 minutes post-
stimulation. c-Jun was constitutively associated at this time point, however its phosphorylated form was 
not. 
 
4.1.6 SMAD3 Discussion 
The role of SMAD3 in the accentuation of TGF-β1 driven fibrosis by TNFα was investigated first due to its 
well described role in canonical TGF-β1 signalling. To summarize the data presented in the preceding 
sub-chapter: SMAD3 was phosphorylated by TGF-β1 alone peaking towards the later time points of 30 
and 60 minutes, TNFα alone had no effect on phosphorylation. Inhibition and knockdown of SMAD3 
strongly limited TGF-β1 driven EMT although seemingly did not affect the accentuation of TNFα, 
although this was difficult to determine due to the very weak EMT driving effect of TNFα alone.  
SMADsi was also capable of strongly inhibiting TGF-β1 driven EMT, yet in this instance when comparing 
PBECs within the treated group the effects are less clear with a relative reduction in the accentuated 
increase in fibronectin and vimentin expression and pro-MMP-9 secretion. The continued accentuation 
of EMT in chemically inhibited cells may be due to residual un-inhibited SMAD3 signalling providing a 
reduced fibrotic development which TNFα can still accentuate, with a smaller accentuation seen with 
SMADsi due to a stronger inhibitory; based on the lack of detection of any phospho-SMAD3 after 
SMADsi.  
This suggested that SMAD3 does not play a direct role in the accentuation of EMT, acting more as the 
base inducer of fibrosis, with another signalling protein driving the accentuation. However what is not 
known is if this signalling protein is also stimulated by TGF-β1, which may explain the residual EMT seen 
in some instances after TGF-β1 alone stimulation, or after co-stimulation. Another interesting finding, was 
that upon SMAD3 inhibition TAK1 phosphorylation was increased in TGF-β1 alone stimulated PBECs. This 
may indicate that there is some level of redundancy in TGF-β1 signalling, which may be responsible for 
the low levels of EMT detected in inhibited PBECs rather than, or in conjunction with, residual SMAD 
activity. Whilst evidence of redundancy has not previously been described a synergistic mechanism by 
which rSMADs7 and TAK1 act co-operatively through ATF-2 to induce transcription (Sano et al., 1999; 
Monzen et al., 2001). It does however demonstrate the requirement for SMAD3 activity to drive EMT, as 
                                                 
7 Used because one paper utilises TGF-β1 and the other a BMP cocktail, hence different rSMADs were investigated. 
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even though TAK1 and JNK-2 remained active after SMAD3 inhibition they were not capable of strongly 
driving EMT, if at all. 
The exception to this effect of residual EMT after inhibition was collagen I-IV secretion. In un-treated cells 
collagen secretion was increased by TGF-β1 but not by TNFα, which also did not accentuate TGF-β1 
driven secretion upon co-stimulation; with a very slight decrease in secretion actually observed upon co-
stimulation. Both SMADi and SMADsi very strongly inhibited the secretion of collagen beyond the 
baseline levels detected from control cells. These findings would suggest that TGF-β1 canonical signalling 
is the key mediator of collagen secretion, with TNFα playing no role; and also that some form of 
constitutive SMAD3 activation is occurring in PBECs to maintain a baseline of secretion. 
The requirement for a baseline of SMAD3 activity in maintenance of collagen expression in pulmonary 
fibroblasts has previously been described (Luzina et al., 2006), whereby stimulation with chemokine 
CCL18 induced secretion of collagen, but with a requirement for active SMAD3 (Chen et al., 1999, 2000). 
Several other groups have demonstrated that TNFα is capable of inhibiting collagen secretion either 
through NF-κB or the MAPK (Armendariz-Borunda et al., 1992; Verrecchia et al., 2002) with one group 
proposing that p38 may be the key mediator of this effect (Varela-Rey et al., 2002). In their paper Varela-
Rey et al. demonstrate that TNFα inhibits p38 phosphorylation and by mimicking this effect with an 
inhibitor of p38 they were able to limit the production of collagen after TGF-β1 stimulation. They do not 
however directly demonstrate this relationship by co-stimulating cells with TGF-β1 and TNFα (Varela-Rey 
et al., 2002). The mechanisms of SMAD inhibition by TNFα I describe above would also provide a 
mechanism by which TNFα could inhibit the primarily TGF-β1 driven secretion of collagen. 
It is important to point out however that in another study TNFα induced collagen gene expression 
through the less common TNFR2, and not TNFR1, in intestinal myofibroblasts (Theiss et al., 2005). A 
tangential area of research that I performed looked at the role of differing TNFα receptors in 
accentuating EMT 8.7, which demonstrated that PBECs do not express TNFR2. This may explain why no 
accentuation in collagen secretion was observed both in this work and in the other referenced studies 
that do not differentiate between receptor expression. 
As a final comment, in hindsight the very strong blocking of SMAD3 activity by chemical inhibition and 
siRNA knockdown demonstrated its importance as a driver of fibrosis. However, due to the weak effect 
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4.2 IkB kinase Beta 
The IKK family of proteins (IKKα/1, IKKβ/IKK2 and IKKγ/NF-κB essential modulator [NEMO]) play a key 
role in the canonical NF-κB activation pathway by factors such as TNFα and IL-1β. IKKα and β contain 
kinase sites and are responsible primarily for the phosphorylation of Iκ-Bα and subsequent activation of 
NF-κB signalling. IKKγ does not contain a kinase site but is required for IKKα/β kinase activity (Yamaoka 
et al., 1998), recruiting them into a larger IKK complex. 
The exact makeup of this complex is not fully understood, and variations likely demonstrate a level of 
control that is currently not understood. Both IKKα and IKKβ bind to IKKγ through a conserved sequence 
at their C-terminal, to various N-terminal sequences of IKKγ (May et al., 2000; Tegethoff et al., 2003). 
Further experiments demonstrated that IKKβ binds to IKKγ with a higher efficiency, although given the 
conserved C-terminal of IKKα and IKKβ it is not known what mediates this effect (May et al., 2000); 
although weaker co-bindings have been implicated in this effect (Miller and Zandi, 2001). This is also 
balanced somewhat by the demonstration that IKKα and IKKβ preferentially form hetrodimers over 
homodimers in vivo before binding with IKKγ (Huynh et al., 2000). It is thought that IKKγ binds with IKKα 
and IKKβ in a 1:1 ratio, but as mentioned above the exact makeup of the complexes is poorly 
understood, with hexamer8 (Agou et al., 2004) and octamer (Tegethoff et al., 2003) forms proposed, with 
the latter allowing for the binding of two IKKα/β heterodimers.  
In un-stimulated cells IKKα and IKKβ are thought to be inactive due to a lack of phosphorylation in their 
respective activation loops, hiding their kinase site, with activation mediated by activation of IKKγ. Several 
methods of IKKγ activation have been proposed, phosphorylation at Ser85 by Ataxia Telangiectasia 
Mutated (ATM) in the nucleus (Wu et al., 2006), or polyubiquitination of Lys285 (Abbott et al., 2004) and 
Lys399 (Sun et al., 2004) residues by RIP2 and TRAF6 respectively. Whether all these activations are 
required or just examples of control of function depending on stimuli is not known. 
It is thought that the ubiquitination of IKKγ brings the IKK complex into association with other important 
factors in NF-κB signal modulation such as RIP1 (Ea et al., 2006)which is itself polyubiqitinated, or with 
TAK1 associated with polyubiqitinated TAB proteins (Wang et al., 2001). This association allows for the 
phosphorylation of IKKα at Ser176 and Ser180 residues and of IKKβ at Ser177 and Ser181 (Delhase et al., 
1999). The main role of activated IKKβ, over IKKα, is the phosphorylation of Iκ-Bα; which masks the 
nuclear localization signal of active NF-κB dimers, holding them in the cytoplasm (Jacobs and Harrison, 
                                                 
8 Three IKKγ monomers with three IKKα or IKKβ 
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1998). Active IKKβ phosphorylates Iκ-Bα at Ser32 and Ser36 residues (DiDonato et al., 1996) which 
recruits an E3 ubiquitin ligase to Iκ-Bα which is phosphorylated in a Lys48 dependant manner at Lys21 
and Lys22 (Alkalay, 1995) prior to degradation in the proteasome. 
Both IKKα and IKKβ play roles outside of this degradation of Iκ-Bα, with both having roles in NF-κB 
subunit modification. Both p100 and p105 contain residues that match those of Iκ-Bα, and are thought 
to act in a similar way, by inactivating their NF-κB dimer partner in the cytoplasm. It was, and often still is, 
thought that p105 is transcribed from the NFKB1 gene and subsequently cleaved into its active p50 form. 
However it was demonstrated that p50 is actually produced alongside p105 by modifications made 
during translation (Lin et al., 1998). However IKKβ can cleave p105 by phosphorylating Ser927 and 
Ser932 residues of p105 leading to ubiquitination and proteasome processing, which either leads to the 
complete degradation of p105, or the production of p50 (Cohen et al., 2004). Degradation of p105 can 
free the inactive dimer, whereas cleavage of p105 to p50 can produce an already formed active dimer 
pairing, independent of Iκ-Bα activity. Similarly, IKKα is capable of cleaving p100 into its active p52 form, 
although in this instance the majority of p52 is formed by cleavage of p100. IKKα phosphorylates p100 at 
Ser866 and Ser870 which as above leads to ubiquitination and subsequent cleavage of p100 (Senftleben 
et al., 2001). 
Mechanisms for the termination of IKKβ mediated signalling are poorly understood. One proposed 
mechanism is auto-inhibition whereby IKKβ phosphorylated in its activation loop phosphorylates its own 
C-terminal region weakening its association with IKKγ and thus terminate its activation (Delhase et al., 
1999; May et al., 2002). Another is the usage of phosphatases such as PP2A, which have been shown to 
associate with phosphorylated IKK complexes, remove the phosphate groups from the activation loop 
and decrease their kinase activity (Prajapati et al., 2004); or de-ubiquitinating enzymes such as A20 which 
remove the ubiquitin scaffolds that mediate the phosphorylation of signalling components (Wertz et al., 
2004). Increased production of inhibitory proteins has also been implicated, including Iκ-Bα, transcription 
of which is regulated by NF-κB dimers in a negative feedback loop (Scott et al., 1993; Hoffmann et al., 
2002). 
Several studies have demonstrated that of IKKα and IKKβ, IKKβ plays a more important role in canonical 
NF-κB signalling (Hu et al., 1999; Li et al., 1999) and this is now generally accepted to be the case. As 
such I focused my attention on IKKβ over IKKα. TNFα is present at elevated levels before the 
development of BOS, and accentuates TGF-β1 driven EMT in PBECs. As this accentuative activity was not 
controlled by SMAD3 the next logical pathway to investigate was the canonical TNFα cascade utilising 
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NF-κB, with IKKβ being a key kinase regulating its transcriptional activity. The following results outline my 
attempts to understand IKKβ phosphorylation in response to TGF-β1 or TNFα stimulation as well as its 
role, and importance, in the subsequent occurrence of EMT in our OB model system. 
 
4.2.1 Phosphorylation Response of IKKα/β 
PBECs were cultured in 6 well collagen coated plates until confluent and stimulated with TGF-β1 or TNFα. 
Cells were harvested at 0, 0.5, 1, 5, 10, 30 and 60 minute time points. Whole cell PBEC lysate was 
immuno-precipitated for total SMAD3, under denaturing conditions, with the resulting lysate probed for 
pIKKβ (Ser177 and Ser181) by indirect ELISA. Neat lysate from the 30 minute stimulation was analyzed by 
Western blot for both total and phospho forms of IKKβ. 
The antibodies used in this protocol targeted both IKKα and IKKβ, although as demonstrated in 
APPENDIX IKKα was usually only detected via western blots loaded with a very high lysate. Western 
blotting allows for the differentiation of IKK isoforms based on their different electrophoretic mobility, 
however the immuno-precipitation and indirect ELISA protocols allow for no such separation. No IKKα 
was detected by western blotting of the immuno-precipitated lysate, and a single band was observed 
after Coomassie staining of the agarose gel, nevertheless it is likely that there is some contamination of 
















t. in PBEC ly
α (20ng/mL) 
ificant phosph











that of TNFα 





n did not ind
o-precipitated
ficant phosph
ough to 30 m
alone (all p<0





















n resulted in 
77 + Ser181) 
er denaturing






























TNFα alone and in combination with TGF-β1 induced significant phosphorylation of IKKα/β from 1 
minute, which peaked at 10 minutes and lasted through to 30 minutes, at 60 minutes levels were 
returned to baseline. Interestingly TGF-β1 alone did not increase phosphorylation at any time-point. 
 
4.2.2 Chemical Inhibition of IKKβ 
As previous experiments have demonstrated that TNFα alone had little if any effect on the development 
of EMT, the focus was on the response to co-stimulation. This was especially true due to the above 
results demonstrating that co-stimulation with TGF-β1 increased TNFα mediated IKKβ phosphorylation, 
whilst not phosphorylating IKK itself. 
IKK-2 (IKKβ) Inhibitor IV (IKKi) is a cell permeable inhibitor of IKKβ isolated from fungi and functions by 
blocking ATP binding sites, and hence kinase activity responsible for phosphorylation of Iκ-Bα . Due to 
the wide range of signalling responses that IKKβ is involved in several papers have previously utilised IKKi 
and accordingly described an IC50. In human monocytes a dose of between 170 and 320nM was capable 
of limiting TNFα production by half (Podolin et al., 2005), whereas in a cell free system, whereby IKKβ was 
immuno-precipitated from human synovial fibroblast cells and used in a kinase assay, an IC50 of 11µM 
was described (Kishore et al., 2003). A dose response curve looking at cell viability, morphology and 
effect on EMT after pre-treatment with 1, 5, 10 and 20μM doses of IKKi prior to stimulation with TGF-β1 
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IKKi at doses of 5µM and above was capable of strongly inhibiting the loss of E-cadherin expression in 
response to stimulation with TGF-β1 or TNFα with no benefit observed at the higher 10 and 20 µM 
doses. A 5µM dose of IKKi was also capable of inhibiting the gain of fibronectin expression, but to a 
lesser extent than the 10 and 20µM doses. Morphologically only the 20µM dose of IKKi was capable of 
inhibiting EMT, maintaining cells cobblestone like appearance, with the lower doses displaying little if any 
benefit compared to controls. Interestingly all doses of IKKi were, when used in association with TNFα 
alone, capable of inducing a striated mesenchymal like appearance. Based purely on ability to inhibit 
EMT a 20µM dose of IKKi would be used, however at this and the 10µM dose there was a large decrease 
in viability for all stimulations. Therefore in all future experiments a 5μM dose of IKKi was used which was 
capable of inhibiting EMT to a lesser degree but maintained cell viability at more normal levels. 
 
4.2.2.1 Chemical Inhibit ion of IKKβ ,  Effect on EMT Endpoint 
With an appropriate dose of IKKi decided upon in A549 cells the next step was to observe what effect 
this would have on EMT in PBECs. n=4 PBEC cultures from distinct patients were stimulated with TGF-β1 
or TNFα for 72 hours after a 1 hour pre-treatment with 5μM IKKi. Cell lysate and culture media was 
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The results above suggest that IKK plays a role in the TNFα mediated accentuation of TGF-β1 driven EMT. 
A 5µM dose of IKKi induced a small decrease in PBEC viability compare to untreated controls, with pre-
treatment strongly inhibiting the accentuated loss of E-cadherin, gain in fibronectin and vimentin, and a 
slight decrease in the accentuated secretion of pro-MMP-9. As collagen I-IV secretion does not display 
an accentuated response normally no reduction in this effect was observed. Interestingly pre-treatment 
with IKKi also inhibited the TGF-β1 driven EMT, albeit relatively weakly for all markers, excepting collagen.  
Collagen I-IV secretion which was usually significantly elevated in response to TGF-β1 stimulation was in 
this instance non-significantly elevated, and it is difficult to discern if IKKi had any impact on this elevation. 
This lack of significance may be due to a degradation of samples which were stored for a longer period 
of time before assay than other experimental groups, however as the baseline level of secretion from the 
un-stimulated cells was similar to that of other experimental groups it seems unlikely to be the case. 
 
4.2.2.2 Chemical Inhibit ion of IKKβ, Effect on 
Phosphorylation 
As seen in Figure 28 IKKβ is phosphorylated in response to TNFα, displaying a slight increase upon co-
stimulation with TGF-β1, with no effect seen with TGF-β1 alone. To investigate possible mechanisms that 
may explain how IKKβ may be phosphorylated differentially upon co-stimulation, I investigated the effect 
of IKKi pre-treatment on the phosphorylation of other key signalling proteins, in this instance with Iκ-Bα 
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IKKβ was phosphorylated in response to TNFα with no evidence TGF-β1 having an impact either alone, 
or in co-stimulation. IKKi did not inhibit the phosphorylation of IKKβ due to its method of action, which is 
to block kinase activity in an ATP competitive manner, but not its activation. To investigate IKKi activity 
understanding of the kinase activity of IKKβ was required. Iκ-Bα, which is phosphorylated by activated 
IKKβ, is one such substrate. In uninhibited PBECs the pattern of Iκ-Bα phosphorylation was the same as 
that of IKKβ, however upon pre-treatment with IKKi this phosphorylation was completely blocked, 
suggesting that IKKβ kinase activity was being inhibited. Interestingly Iκ-Bα was not degraded, as 
previously discussed, post stimulation. 
 
4.2.3 siRNA Knockdown of IKKβ 
IKKβ targeting siRNA (IKKsi) was used to knockdown IKKβ in order to validate the findings generated 
using IKKi. A dose response assay for cell viability, morphology and effect on EMT after a 24 hour pre-
treatment with 0.1, 0.5, and 1nM doses of IKKsi (CTGGAGAAGTACAGCGAGCAA), delivered through lipid 
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IKKβ expression was reduced in a dose dependant manner by pre-treatment with IKKsi, with a strong 
decrease in cell viability. The loss of E-cadherin expression and gain of fibronectin expression in response 
to TGF-β1 or TNFα stimulation was also inhibited in a dose dependant manner, with a 5nM dose of IKKsi 
producing the strongest effect. Interestingly at the highest dose of IKKsi along with TNFα stimulation 
induced a larger loss of cell viability, especially evident at the highest dose of 5nM than the other 
stimulations. Therefore although the 1 and 5nM doses most strongly inhibited EMT, a 0.1nM dose which 
still limited EMT, but did not significantly reduce cell viability was used for all future experiments. 
 
4.2.3.1 siRNA Knockdown of IKKβ ,  Effect on EMT Endpoint 
With an appropriate dose of IKKsi confirmed for use in PBECs I proceeded to investigate what effect IKKβ 
knockdown had on EMT. n=3 PBEC cultures from distinct patients were stimulated with TGF-β1 or TNFα 
for 72 hours after a 24 hour pre-treatment with 0.1nM IKKsi or a sequence scrambled control. Cell lysate 
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The results described above suggest that IKKβ plays a role in the accentuation of TGF-β1 driven EMT. A 
0.1nM dose of IKKsi strongly knocked down levels of IKKβ with the subsequent reduction in detection of 
phosphorylated IKKβ, and reduced the accentuative effect of TNFα in the TGF-β1 driven loss of E-
cadherin, gain of fibronectin and vimentin expression and increase in pro-MMP-9 secretion. IKKsi also 
weakly inhibited the TGF-β1 alone driven loss of E-cadherin with a similar weak effect on other markers 
of EMT. The one exception was the secretion of collagens I-IV that displayed no accentuated response in 
untreated cells with IKKsi not significantly reducing the TGF-β1 driven increase. 
 
4.2.4 IKKβ Discussion 
By previously demonstrating that SMAD3 mediates either all or the majority of TGF-β1 signalling that 
drives EMT, with no evidence of accentuatory activity, if anything a slight inhibitory effect was 
demonstrated, it was next decided to investigate IKKβ, part of the canonical TNFα NF-κB cascade. To 
summarize the data presented in the preceding sub-chapter: IKKβ was phosphorylated by TNFα but not 
TGF-β1 alone, with TGF-β1 having no effect on TNFα driven IKKβ phosphorylation in co-stimulated 
samples. Inhibition and knockdown of IKKβ inhibited the accentuation of EMT by TNFα and in some 
instances inhibited TGF-β1 driven EMT as well, more so after chemical inhibition than siRNA knockdown. 
Inhibition of IKKβ inhibited its phosphorylation of Iκ-Bα and this its functionality. However TAK1 and JNK-
2 were still phosphorylated in response to TNFα stimulation, but did not accentuate EMT suggesting that 
IKKβ is crucial in this role, with TAK1 playing an activating role and JNK-2 either no role or a modulatory 
one. 
The indirect ELISA assays for both IKKα and IKKβ, however IKKα was not usually detected by western blot. 
By looking at later figures such as Figure 53 where a sufficient quantity of lysate was used for IKKα to be 
detected it is possible to see that IKKα follows a similar pattern to IKKβ. However by looking at another 
example blot in this case Figure 39 it is possible in this instance to observe a difference between the 
TNFα alone, and co-stimulated samples. This suggests that TGF-β1 can accentuate IKKβ phosphorylation 
but only to a small degree, a mechanism to facilitate this phosphorylation has been described, using the 
MAPK TAK1 to induce IKK NF-κB signalling (Mao et al., 2011).  
This effect is perhaps more apparent when looking at the effect of inhibiting IKKβ; as was hypothesized 
inhibition reduced TNFα accentuation of TGF-β1 driven EMT. However, there was also a slight inhibition 
of TGF-β1 driven EMT, which was most evident when using E-cadherin as a marker for both IKKi and 
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IKKsi. In general, the effect was more apparent when using IKKi, which raises the possibility of a non-
specific effect, the question being where this non-specific inhibition is occurring. In the studies initially 
describing the effects of IKKi a screen of effect on other signalling proteins was also performed. In one 
instance the next most inhibited molecule was IKKα demonstrating a 20 fold difference between the 
respective IC50 amounts (Podolin et al., 2005); in the other study a 200 fold difference was observed, with 
in this instance the next most inhibited molecule after IKKβ being p38 (Kishore et al., 2003). Interestingly 
the latter paper demonstrated that IKKi had a 5 fold stronger inhibitory effect on an IKKα/IKKβ 
heterodimer than on IKKβ alone. As discussed in 4.2 IKKα and IKKβ preferentially form this heterodimer in 
vivo (Huynh et al., 2000), from this it is possible to speculate that I underestimated the role of IKKα in the 
accentuation of TGF-β1 driven EMT. However, it is also possible that the chemical inhibitor could be 
inhibiting some other signalling protein. 
In the SMAD3 discussion I talk about the seemingly SMAD3 dependant, non-TNFα accentuated up-
regulation of collagen and the findings outlined above would seem to confirm this effect. I hypothesized 
that the production of collagen was mediated purely through SMAD3 and did not involve the as yet 
unknown accentuatory protein, thus preventing TNFα from playing a role. When using the chemical 
inhibitor a significant increase in response to TGF-β1 was not obtained and it was difficult to discern if 
IKKi had any impact, I can present no explanation for this lack off effect as in all other samples tested 
significance was obtained. However, in the IKKsi experiment where a clear significant increase in collagen 
secretion was demonstrated IKKsi had no inhibitory effect, which would lend credence to this hypothesis.  
One interesting observation not linked directly to the study at hand was that IKKi and IKKsi both seemed 
to have a greater effect on PBEC viability than the other chemical inhibitors, most evident with IKKsi. The 
siRNA used to knock down IKKβ was very effacious, able to knockdown approximately 90% of detected 
IKKβ after 24 hours with a 0.1nM dose. At doses beyond this where 100% inhibition, or near to, was 
achieved there was a very rapid decrease in viability. TNFR1 is capable of inducing cell death by 
recruiting alternative proteins into the receptor complex. Instead of the TRAF mediated NF-κB activation, 
Fas-Associated protein with Death Domain (FADD) can be recruited and initiate cell death through the 
caspase cascade; although it is thought that this effect is usually masked by the inhibitory effects of NF-
κB signalling on FADD (Micheau and Tschopp, 2003). By chemically inhibiting IKKβ activity, it is possible 
that I am inducing a block in this protective NF-κB signalling, with a resultant increase in death signalling. 
Looking more specifically at the role of IKKα and IKKβ a similar inhibitory effect was described, in one 
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4.3 TGF-β activated kinase 1 
As shown in 4.2.2 and 4.2.3 inhibition and siRNA knockdown of IKKβ limited the TNFα mediated 
accentuation of EMT, whilst also slightly inhibiting TGF-β1 driven EMT. A mechanism or protein, which 
facilitated the transference of TGF-β1 signalling through the IKK complex, may therefore be a key player 
in the accentuative process. One potential protein that is receiving much interest is TAK1; a 67 kDa 
serine-threonine kinase which can both activate and is activated by a diverse range of signalling proteins. 
First described as a mediator of non-canonical TGF-β signalling (Yamaguchi et al., 1995) it has now been 
shown that TAK1 can be stimulated by TLR family ligands such as lipopolysaccharide (Ear et al., 2010), 
and other factors such as IL-1β (Fan, Yu, Mao, et al., 2010) and TNFα (Ea et al., 2006). However, the 
mechanisms that facilitate TAK1 activation and its downstream effects remain poorly understood and 
results described in the literature are often conflicting. 
Prior to stimulation with TGF-β1 it is thought that TAK1 exists bound to a TRAF6-TAB2 or TAB3 complex, 
which is itself associated with TGFβR1 (Sorrentino et al., 2008). Upon stimulation with TGF-β1 the hetero-
tetramer complex of TGFβR1 and TGFβR2 proteins as described in 1.3.1 is formed, which facilitates the 
auto-poly-ubiquitination of TRAF6 (Xia et al., 2009) in a Lys63 dependant manner, without the use of 
TGF-R1 kinase activity. This auto-poly-ubiquitination results in the activation of TRAFs E3 ubiquitin ligase 
ability, poly-ubiquitinating TAK1 at the Lys158 (Mao et al., 2011) and Lys34 (Sorrentino et al., 2008) 
residues of which only Lys158 was shown to be required for subsequent activity. Upon ubiquitination 
TAK1 is released from its association with TRAF6, it is unknown if TAB2 or 3 remain associated with TAK1 
at this point, and forms a new complex with TAB1 (Kim et al., 2009). An alternative hypothesis is that 
TAK1-TAB1 interactions and TAK1-TAB2/3 interactions are independent, with TAB2/3 requiring other 
cellular apparatus to induce the auto-phosphorylation of TAK1, whereas TAB1 is capable of achieving 
this effect alone (Scholz et al., 2010). 
Upon binding with TAK1, TAB1 is itself auto-phosphorylated, which in turn facilitates the auto-
phosphorylation of key residues within the hypothesized activation loop of TAK1 such as Thr178, Thr184 
and Thr187 (Singhirunnusorn et al., 2005). Phosphorylation of these key resides is thought to occur 
sequentially, starting with Thr178 which augments auto-phosphorylation followed by phosphorylation of 
Thr184 and Thr187 thought to be required for TAK1 kinase activity. It is thought that constitutive TAB1 
binding is required for maintenance of this activation (Kishimoto et al., 2000). Phosphorylation of Ser192 
has been shown to be required to facilitate TAB1 binding to TAK1, with the subsequent phosphorylation 
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of the other described residues (Scholz et al., 2010). Phosphorylation of other sites not within this 
activation loop have been described during large scale phosphorylation analysis by mass spectrometry 
(Dephoure et al., 2008) but no details of their activity are described in the literature. It is not known 
whether specific phosphorylation events are associated with a particular stimulus, TAB protein, or indeed, 
if co-phosphorylation is required, or improves, kinase activity. 
Activation of TAK1 by TNFα occurs in a similar manner to activation by TGF-β1 albeit with different 
receptor scaffold proteins involved in the recruitment and polyubiquitination of TAK1. As TAK1 is now 
thought to be key in mediating IKK-NF-κB activity I have already described the mechanism of its 
activation in 1.3.2. The same is true of activation by IL-1β stimulation as TAK1 is once again a key factor 
in its downstream signalling; details of this activation are described in 1.3.3. 
It is worth mentioning that as TRAF6 plays an important role in the ubiquitination of TAK1 in both TGFβR 
and IL-1βR signalling that it may itself play an important synergistic role. This is especially true in light of 
its ability to polyubiquitinate different residues of TAK1 depending on which receptor complex it is 
associated with Lys34 (Sorrentino et al., 2008) with TGFβR, Lys209 (Fan, Yu, Mao, et al., 2010) with IL-1βR 
and a seemingly conserved Lys158. As above, it is not known if the varying ubiquitination responses are 
specific to a certain upstream stimuli or interactions with TAB proteins. 
Once activated TAK1 is able to mediate downstream signalling events by its kinase activity. TAK1 has 
been shown to directly phosphorylate both IKKα, IKKβ (4.2) and JNK-1/2 and is also required for the 
activation of p38, ERK, NLK and has been shown to modulate the function of IKKγ (Ohkawara et al., 2004; 
Fan, Yu, Mao, et al., 2010; Fan, Yu, Shi, et al., 2010; Mao et al., 2011; Yang et al., 2011). There is currently 
no evidence in the literature describing any non-kinase activities by TAK1, and TAK1 is thought to be 
localized solely within the cytoplasm. The duration of phosphorylation has also not been described, and 
likely varies depending on stimulation, however at some point TAK1 is de-phosphorylated by the 
phosphatase PP2A. In addition, no data is presented as to whether TAK1 is subsequently degraded or if 
it cycles back into an association with TRAF and TAB proteins, ready for a new signalling event. 
As mentioned in the opening paragraph of this section TAK1 is the very definition of a pleiotropic 
molecule with its ability to respond to a wide variety of stimuli and interact with an equally wide range of 
signalling mediators. From the brief description above it is possible to see several distinct levels where 
modulation of signalling response can occur, namely TAB association, residue ubiquitination and 
phosphorylation and downstream interaction among others, and because of this it is easy to understand 
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why findings are often conflicting and difficult to interpret. However, it also presents a large and 
interesting area to research, and greater understanding of the control mechanisms and outcomes 
relating to TAK1 stimulation, may in the short-term explain the synergy between TGF-β1 and TNFα that I 
am investigating, and in the long-term describe potential therapeutic targets. The following results 
outline my attempts to understand TAK1 phosphorylation in response to TGF-β1 or TNFα as well as its 
role, and importance, in the subsequent occurrence of EMT in our OB model system. 
 
4.3.1 Phosphorylation Response of TAK1 
As with SMAD3 and IKKβ, I investigated the phosphorylation of TAK1 in response to stimulation with 
TGF-β1 or TNFα as an assay for TAK1 activation. In this instance though I attempted to investigate three 
distinct phosphorylation sites located within the activation loop of TAK1 Ser192, Thr184 and Thr187, to 
describe which, if any, responded to stimulation, if there was a differing response between the residues 
or if co-stimulation resulted in accentuated or prolonged activation. Unfortunately, the phospho-TAK1 
(Ser192) antibody failed to demonstrate reproducible results and therefore no assays are shown for this 
residue. 
PBECs were cultured in 6 well collagen coated plates until confluent and stimulated with TGF-β1 or TNFα. 
Cells were harvested at 0, 0.5, 1, 5, 10, 30 and 60 minute time points. Whole cell PBEC lysate was 
immuno-precipitated for total TAK1, under denaturing conditions, with the resulting lysate probed for 
phospho-TAK1 (Thr184 or Thr187) by indirect ELISA. Neat lysate from the 30 minute stimulation was 
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The phosphorylation response of the Thr187 residue seems to provide strong evidence for the role of 
TAK1 in the described accentuation of TGF-β1 EMT by TNFα. TGF-β1 stimulation induced a significant 
increase in phosphorylation from 1 minute onwards with a peak at 10 minutes, whereas TNFα induced a 
significant increase in phosphorylation from 10 minutes onwards peaking at 30 minutes. In general, TNFα 
seemed to induce a smaller and delayed increase in phosphorylation of TAK1. Co-stimulation resulted in 
a significant increase in phosphorylation, compared to un-stimulated controls, from 1 minute onwards, 
again peaking at 10 minutes. An accentuative effect was seen from 5 minutes onwards, ascertained by 
simply combining the individual TGF-β1 and TNFα amounts. This accentuation was strongly maintained 
even out to 60 minutes where the individual stimulations were trending back towards baseline. 
In contrast, phosphorylation of Thr184 seemed dependant on TNFα alone. However, it is worth 
considering that TGF-β1 is able to induce a delayed phosphorylation of this residue. TNFα induced 
significant phosphorylation from 1 minute, peaking at 5 minutes and returning to near baseline by 60 
minutes. An accentuative response was only observed at 60 minutes, this seems to be due to the 
declining level of phosphorylation induced by TNFα stimulation alone in comparison to the maintenance 
of phosphorylation due to co-stimulation. 
Whilst these experiments look at the phosphorylation of certain TAK1 residues, they do not describe 
whether co-phosphorylation was occurring on single TAK1 molecules. A better understanding of this 
might describe a mechanism that allows for specificity of function from such a pleiotropic molecule, 
especially in light of the multiple sites of poly-ubiquitination described in the literature. Attempts to assay 
this are described in 4.3.6. However, the findings do confirm that TAK1 Thr187 can respond to TGF-β1 
and TNFα co-stimulation in an accentuated fashion, therefore I next decided to inhibit TAK1 function to 
evaluate its role in EMT, and to elucidate downstream signalling mechanisms.  
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4.3.2 Chemical Inhibition of TAK1 
5Z-7-Oxozeaenol (TAKi) is a cell permeable inhibitor of TAK1 isolated from fungi and functions by 
blocking ATP binding sites, and hence kinase activity, in an irreversible fashion. The initial paper 
describing the effects of TAKi determined that the IC50 in 293-IL-1R19 and mouse embryonic fibroblast 
cells was 8nM (Ninomiya-Tsuji et al., 2003). A dose response curve looking at cell viability, morphology 
and effect on EMT after pre-treatment with 0.1, 0.5, 1 and 5μM doses of TAKi prior to stimulation with 
TGF-β1 and TNFα for 72 hours was performed in triplicate using A549 cells. 
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At a 1µM dose of TAKi, cell viability was maintained at approximately 85% for all stimulations. A 1μM 
dose was also capable of strongly inhibiting the morphological shift from a cobblestone like epithelial 
appearance towards a striated mesenchymal phenotype, and inhibited the concurrent decrease in E-
cadherin and increase in fibronectin expression at the protein level without influencing baseline 
expression as seen with the 5μM dose. Therefore, a dose of 1μM TAKi was used in all future experiments. 
 
4.3.2.1 Chemical Inhibit ion of TAK1, Effect on EMT Endpoint 
With an appropriate dose of TAKi decided upon in A549 cells the next step was to observe what effect 
this would have on EMT in PBECs. n=6 PBEC cultures from distinct patients were stimulated with TGF-β1 
or TNFα for 72 hours after a 1 hour pre-treatment with 1μM TAKi. Cell lysate and culture media was 





















































































































The results described above provide evidence, that TAK1 activation plays a key role in the subsequent 
occurrence of EMT. Pre-treatment of PBECs with a 1µM dose of TAKi strongly inhibited the loss of E-
cadherin expression and the gain of fibronectin and vimentin expression, as well as the increase in 
secretion of collagens I-IV into the media in response to TGF-β1 stimulation. TAKi also strongly inhibited 
the accentuation of EMT in response to TGF-β1 and TNFα co-stimulation for the markers described 
above. Interestingly TAKi consistently increased the secretion of pro-MMP-9 into the media, with the 
results most apparent in the media from cells treated with TNFα. 
 
4.3.2.2 Chemical Inhibit ion of TAK1, Effect on 
Phosphorylation 
As seen in Figure 35 TAK1 displays an accentuated phosphorylation of its Thr187 residue in response to 
co-stimulation with TGF-β1 and TNFα. I therefore proceeded to investigate the effect of TAKi pre-
treatment on the phosphorylation of other key signalling proteins 30 minutes after stimulation with TGF-
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No difference in the phosphorylation of SMAD3 or p38 following stimulation with TGF-β1 or TNFα in the 
presence of TAKi was demonstrated; however TAK1 phosphorylation was completely inhibited. 
Interestingly phosphorylation of IKKβ and JNK-1/2 in response to stimulation was strongly inhibited, 
suggesting that TAK1 plays a key role in the activation of these proteins, and provides further evidence 
for the potential role of TAK1 as a convergence point for the accentuative effect of TNFα on TGF-β1 
driven EMT. Surprisingly, TAKi inhibited TAK1 phosphorylation, even though its described activity was to 
inhibit ATP binding and hence kinase activity. It is possible that this inhibition of phosphorylation is an 
un-described effect of TAKi or that TAK1 phosphorylation is unstable if not in a complex in a similar 
fashion to that described SMAD3, or inhibits itself in a similar fashion to IKKβ. 
 
4.3.3 siRNA Knockdown of TAK1 
TAK1 targeting siRNA (TAKsi) was used to knockdown TAK1 in order to validate the findings generated 
using TAKi. A dose response assay for cell viability, morphology and effect on EMT after a 24 hour pre-
treatment with 1, 5, and 10nM doses of TAKsi (AAGATGGTATATACCAAGTTA), delivered through lipid 
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TAK1 expression was reduced in a dose dependant manner by pre-treatment with TAKsi, with an 
associated decrease in cell viability. The loss of E-cadherin and gain in fibronectin expression in response 
to TGF-β1 or TNFα stimulation was also inhibited in a dose dependant manner up to a 5nM dose, 
beyond which there was no appreciable benefit. Anecdotally it was observed that the higher doses of 
TAKsi, or the requisite higher dose of lipid transfection reagent10, caused large numbers of cells to 
detach from the culture surface. With a 5nM dose this effect was observe at around 72 hours post 
knockdown, whereas with the 10nM dose this was seen at 24 hours. These cells were counted as part of 
the viability assay, and separate counts of the attached and detached populations showed no variation in 
viability. However, their innate characteristics and response may differ from the normal adherent PBEC 
cultures. Therefore, an intermediate dose, which did not induce cell detachment, of 3nM TAKsi was used 
in all future experiments. 
 
4.3.3.1 siRNA Knockdown of TAK1, Effect on EMT Endpoint 
With an appropriate dose of TAKsi confirmed for use in PBECs, I proceeded to investigate what effect 
TAK1 knockdown had on EMT. n=5 PBEC cultures from distinct patients were stimulated with TGF-β1 or 
TNFα for 72 hours after a 24 hour pre-treatment with 3nM TAKsi or a sequence scrambled control. Cell 
lysate and culture media was retained and EMT was assessed using a variety of markers. 
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The data presented above validates the findings described with TAKi in 4.3.2, with the inhibitory effect on 
EMT being even more striking. The 3nM dose of TAKsi derived from the screen outlined in figure 4.3.3 
induced an approximately 80% knockdown in detected TAK1 protein, without significantly affecting cell 
viability. This dose also did not result in a large number of cells detaching from the culture surface, as 
mentioned above, suggesting that the culture as a whole was retaining its “normal” PBEC character. Pre-
treatment of PBECs with TAKsi strongly inhibited the loss of E-cadherin and the gain of fibronectin and 
vimentin intracellularly, as well as the increase in secretion of pro-MMP-9 and collagens I-IV into the 
media in response to TGF-β1 stimulation. TAKsi also strongly inhibited the accentuation of EMT in 
response to TGF-β1 and TNFα co-stimulation for the markers described above. Unlike the TAKi results 
described in figure 4.3.2.1 blocking TAK1 knockdown did not result in increased secretion of pro-MMP-9. 
 
4.3.4 Localization of TAK1 
Both chemical inhibition and siRNA knockdown of TAK1 suggested that it plays a key role in EMT. When 
observing the phosphorylation cascade of key signalling proteins TAK1 displayed an accentuative 
response to co-stimulation with TGF-β1 and TNFα, whilst phosphorylating to a lesser degree upon 
stimulation by either factor. It was also observed that TAK1 might transmit its signal downstream by JNK-
1/2 or IKKβ. To investigate this further I looked at the localization of both total and phospho-TAK1 30 
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When assessed by ICC total-TAK1 localization was unchanged under all conditions, maintaining a diffuse 
cytoplasmic stain. However, nuclear localization of phospho-TAK1 was increased following stimulation 
with both TGF-β1 and, to a lesser extent, TNFα compared to control cells. Co-stimulation with TGF-β1 
and TNFα resulted in an accentuated nuclear localisation of phospho-TAK1 compared to either 
stimulation alone. To confirm the observed nuclear translocation of TAK1, nuclear and non-nuclear 
fractions were prepared from PBECs treated with TGF-β1 or TNFα for 30mins. As with SMAD3 attempts 
to confirm these findings using lysate fractionation again generated conflicting results, however, in this 
instance it was with the phosphorylated as opposed to total form of the protein. ICC showed a clear 
preference for TAK1 nuclear localisation with little if any phospho-TAK1 appearing in the cytoplasm (with 
the exception of co-stimulated cells). However, after protein fractionation phospho-TAK1 was detected 
only in the cytoplasm for all stimulations. Therefore, once again it is not possible to comment on TAK1 
localization without further investigations. 
 
4.3.5 TAK1 Tissue Staining 
With TAK1 playing a key role in EMT in my post-transplant cell culture model I next proceeded to assay 
for TAK1 activation and localisation in fibrotic and normal lung sequential tissue sections, isolated from 
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Total TAK1 was located throughout all airway cells and there was no detectable difference in the intensity 
of expression between normal and OB lung tissue. In contrast, levels of phospho-TAK1 were higher in 
epithelial cells in OB tissue compared to normal. It was also noted that phospho-TAK1 displayed 
evidence of nuclear localization that was more pronounced in OB tissue. However, there was significant 
non-specific staining of the ciliated regions of the airway by the anti phospho-TAK1 antibody making it 
difficult to conclude that TAK1 phosphorylation is increased in OB tissue. Attempts were made to nullify 
this effect by blocking samples with antibodies against microtubule proteins such as α and β-tubulin and 
other structural proteins such as β-actin to no avail.  
 
4.3.6 Further Investigations into TAK1 Activity 
In light of the potential nuclear localisation of TAK1 described in Figure 42 and Figure 43 along with the 
fact that TAK1 contains no described nuclear localization signal, but interacts with a wide variety of 
proteins, it was thought that investigating TAK1-protein interactions might help explain this localization 
effect. As discussed above the TAB family of proteins are known to have a strong association with TAK1 
and appear to help modulate its function. As described in previously TAK1 is also capable of inducing 
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At 30 minutes TAB1 was associated with TAK1 under all stimulations, TAB2 and TAB3 were associated 
only in the presence of TGF-β1. Upon co-stimulation TAK1-TAB2 association was lost. SMAD3 and JNK-1 
did not associate with TAK1 however; JNK-2 and IKKβ were associated under all stimulations. c-Jun was 
detected only upon co-stimulation with TGF-β1 and TNFα. However, this experiment was limited to a 
single time point due to the volume of cells required for immuno-precipitation. 
Attempts were also made to immuno-precipitate proteins using the various anti phospho-TAK1 
antibodies with the aim of investigating the resulting lysates for specific protein associations and the 
occurrence of co-phosphorylation. However, probing neat lysate with phospho-TAK1 antibodies resulted 
in yields greater than that achieved by precipitating with the total form, which suggested that the 
phospho-TAK1 was pulling out non-specific proteins; confirmed by Coomassie staining of SDS-PAGE 
separated lysates, and potentially explain the non-specific effects seen in Figure 43. Performing a two-
step immune-precipitation using total-TAK1 followed by phospho-TAK1 antibodies resulted in a lysate so 
dilute that no bands were detectable by Coomassie staining. 
 
4.3.7 TAK1 Discussion 
Prior investigation had shown that TGF-β1 but not TNFα was capable of inducing the canonical SMAD 
signalling response; with inhibition of SMAD3 limiting TGF-β1 driven EMT, with an unknown activity in 
relation to the accentuative effect of TNFα. Inhibition of IKKβ not only limited the accentuative effect of 
TNFα on EMT but also inhibited the driving effect of TGF-β1, which in conjunction with previously 
detected accentuated TAK1 phosphorylation was the catalyst to look at TAK1 as a potential mediator of 
this signalling crosstalk. 
To summarize the data presented in the preceding sub-chapter: the Thr187 residue of TAK1 is 
phosphorylated in response to both TGF-β1 and TNFα alone, with an accentuated response upon co-
stimulation, whereas Thr184 is phosphorylated only in response to TNFα. Inhibition and knockdown of 
TAK1 limited both TGF-β1 driven EMT and its accentuation by TNFα; and also inhibited the 
phosphorylation of IKKβ and JNK-2 but not SMAD3 further developing the putative signalling mechanism. 
As well as the increased phosphorylation of the Thr187 residue in response to stimulation TAK1 
phosphorylated potentially translocated to the nucleus, although results were conflicting, an effect not 
previously described. A similar effect was also observed in sequential sections taken from normal and OB 
lung, where increased phosphorylation of TAK1 (Thr187) and nuclear localization were observed in OB 
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sections compared to normal lung, although there was strong non-specific binding of the phospho-
TAK1 antibody. TAB1 was shown to associate with TAK1 under all stimulations with a potentially 
accentuated association upon co-stimulation, TAB2 and TAB3 bound only in the presence of TGF-β1 
with TAB2 binding lost upon co-stimulation with TNFα. IKKβ and JNK-2 associated with TAK1 at 30 
minutes after stimulation with TGF-β1 or TNFα, c-Jun was associated only upon co-stimulation. 
The inhibition of TGF-β1 driven EMT by TAKi and TAKsi suggests that TAK1 may play a key role in driving 
EMT. However in 4.1.2.2 it was demonstrated that activated TAK1 was not capable of driving EMT alone, 
as SMAD3 phosphorylation was not inhibited by TAKi this suggests that TAK1 activity is required for TGF-
β1 driven EMT, but is not the actual driver; instead suggesting that TAK1, or its downstream mediators, 
are in some way assisting the activity of SMAD3, possibly by co-factor recruitment or through synergistic 
activity as already discussed in 4.1.6 (Sano et al., 1999; Monzen et al., 2001). As IKKβ is key to the 
accentuation of EMT and is a substrate of TAK1, the lack of IKKβ mediated accentuation after TAK1 
inhibition is un-surprising. From these results, it is possible to hypothesize that TGF-β1 activation of TAK1 
is able to modulate its response to TNFα thus inducing a different, pro-fibrotic, NF-κB transcriptional 
activity leading to the observed accentuation of effect. 
In the introduction to this section I highlighted the multiple levels of control apparent during the 
activation of TAK1, and how these may help describe the accentuative response seen upon co-
stimulation with TGF-β1 and TNFα. I hypothesized that these residues may phosphorylate independently, 
possibly in response to different stimuli, with co-stimulation perhaps inducing pro-longed or accentuated 
phosphorylation. Comparing the intensity of phosphorylation between the residues is not possible using 
with the techniques used as a host of conflicting factors come into play, so any comparison can be based 
only on the trends of response.  
That Thr184 and Thr187 are activated differentially in response to stimuli is very interesting and does 
provide evidence that modulation of TAK1 function may be possible in response to co-stimulation. The 
most elegant way in which to investigate this would be to generate Thr184 or Thr187 mutants and then 
assess TAK1 kinase activity across a range of substrates, along with other downstream markers. This may 
help identify if Thr184 or Thr187 had a preferred substrate or downstream effectors. I attempted to 
investigate this by immuno-precipitating using anti phospho-TAK1 antibodies but as described in 4.3.6 
these attempts were unsuccessful. I also hypothesized that co-phosphorylation may also help explain the 




The above effect was interesting in relation to understanding underlying cell signalling methods, 
however my project was also firmly based in translating these findings into a disease model. As such the 
accentuated and prolonged phosphorylation of the Thr187 residue upon co-stimulation with TGF-β1 and 
TNFα is perhaps more interesting. With heightened TGF-β1 and TNFα detected in the BAL of OB 
patients, it is possible to see how the Thr187 residue of TAK1 could become hyper or constitutively 
activated. Combined with the later inhibitory experiments that showed the importance of TAK1 in EMT, 
and the presence of phosphorylated TAK1 in OB epithelial cells it is possible to construct a clinically 
relevant hypothesis, whereby increased or altered TAK1 activity is mediating the fibrotic development of 
disease, through alteration of downstream signalling.  
To my knowledge there is no data that associates a particular mutation of TAK1 or any of the TAB 
proteins with a disease, which suggests that whilst TAK1 may mediate disease progression, it is not in 
itself an initiating factor, although of course it is possible that this has simply not been looked at. The 
only result in the literature demonstrates no association of mutated TAK1 with several different cancers 
(Kondo et al., 1998). 
Whilst no data linking mutations of TAK1 or the TAB family have been described, there are numerous 
examples where TAK1 is identified as playing a key role in the development of disease. We have 
described a role for a TAK1 mediated synergy between TGF-β1 and TNFα in OB, however the pro-
fibrotic, pro-inflammatory milieu found in the disease and mimicked in our culture models is not specific 
to just OB. Taken alongside the seemingly ubiquitous expression of TAK1 we propose that this method 
of action may be conserved in other disease states. IPF a disease of unknown aetiology is characterized 
by a progressive, chronic fibrosing of the alveolae. TGF-β1 driven EMT of the resident type II 
pneumocyte progenitor cell population is thought to play a key role in this process (Kim et al., 2006). 
There is some debate as to the role of inflammation in IPF (Behr et al., 2009), which may fit nicely with 
our hypothesis that whilst inflammatory markers are present, they require the pro-fibrotic effects of TGF-
β1 to have a profound impact. 
Other organ and disease models suggest a possible role for our TAK1 mediated synergistic hypothesis; 
in the kidney TGF-β1 has been shown to play an important role in the development of fibrosis by EMT 
(Liu, 2010), alongside this a role for inflammatory mediators secreted from leukocytes has also been 
described (Lange-Sperandio et al., 2007). Similarly within the development of liver fibrosis, a potential 
TGF-β1 driven EMT (Zeisberg et al., 2007) exists within an inflammatory milieu (Connolly et al., 2009), 
although in this instance there is no link between inflammation and EMT. 
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Whilst mutations of TAK1 itself do not seem to associate with the development of lung cancer (Kondo et 
al., 1998), the synergistic phosphorylation in response to TGF-β1 and TNFα may play a key role in 
tumorigenesis. Numerous papers link TAK1 with the development of cancer however, the suggested role 
varies widely. Suppression of TAK1 has demonstrated a ROS driven tumour cell specific apoptotic effect 
(Omori et al., 2010), also activation of TAK1 has been shown to induce NF-κB activation resulting in 
increased production of Iκ-Bα which in turn limited the anti-apotopic effects of NF-κB (Arsura et al., 
2003). Conflictingly TAK1 mRNA levels analyzed from head and neck squamous cell cancer patients were 
reduced in relapsing patients (Honorato et al., 2008). TAK1 has also been shown to have tumour 
suppressive capabilities, mediated by the suppression of IKK (Bettermann et al., 2010), in an NF-κB 
independent fashion. As mentioned previously the role NF-κB in tumorigenesis and cancer maintenance 
is poorly understood; so it seems reasonable that the role of TAK1 as an upstream modulator of NF-κB 
and canonical TGF-β1 signalling may also lack clarity.  
The previously mentioned SnoN has also been described as an important oncogenic protein, up-
regulated in several different cancer cells in that it acts to inhibit the anti-proliferative action of TGF-β 
signalling (dysregulation of which is a key characteristic of certain cancers), facilitating oncogenic 
transformation of effected cells. A non-functional mutant failed to inhibit SMAD transcriptional activity 
and hence blocked this oncogenic transformation. An interaction between TAK1 and the oncogenic Ski-
related novel protein N (SnoN), an inhibitor of SMAD transcriptional activity, would seem to fit well with a 
hyper-activated model whereby TAK1 accentuates EMT leading to cancer progression, however it 
appears that there is currently only a single paper investigating the activity of SnoN and TAK1 in a cancer 
setting; which suggests that whilst SnoN plays a key role in autophagic resistance to anti-cancer 
treatment it did so in a TAK1 independent manner (Smith et al., 2010). 
The potential localization of TAK1 to the nucleus was not expected. Initially I hypothesized that TAK1 
would function in the cytoplasm, modulating other proteins, such as JNK-2 or its downstream effectors, 
which would translocate to the nucleus. However, it became apparent that the nuclear translocation of 
TAK1 has been described previously. TAK1 itself does not contain a described nuclear translocation 
signal, although this does not necessarily mean that it is unable to translocate on its own; also no 
evidence of direct action with the genome has been presented, but this may be because it has not been 
investigated previously. In comparison the localization of ERK-1/2 remained poorly explained until a 
novel translocation method was discovered (Chuderland et al., 2008), and so it is possible that such a 
mechanism may subsequently be described for TAK1. Although the conflicting results raised in Figure 42, 
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and non-specific binding of phospho-TAK1 antibodies in Figure 43 mean further investigations into TAK1 
localisation are required. 
To my knowledge three papers describe a nuclear localization of TAK1; the first describes localization in 
response to IL6 treatment with an increased kinase activity in both cellular compartments (Kojima et al., 
2005). Secondly a more recent paper described the translocation of TAK1 into the nucleus in association 
with the previously mentioned SnoN (Kajino et al., 2007). In this instance, TAK1 is required for the TGF-β 
mediated degradation of SnoN and therefore the activation of SMAD transcriptional activity. In this 
system it is possible that our accentuated activation of TAK1 may result in an even greater inhibition of 
SnoN activity and an increase in resultant SMAD transcriptional activity, facilitating an even stronger 
fibrotic response. 
The final paper has looked at this effect in the most detail and describes TAK1 as existing within both the 
cytoplasm and the nucleus in its un-phosphorylated state, the paper does not look at phosphorylation of 
TAK1 itself. Stimulation with TNFα or LPS had no effect on cellular distribution, nor did blocking nuclear 
export either, suggesting that TAK1 was not being trafficked (Ear et al., 2010). In my system total TAK1 
and phospho-TAK1 were detected in both the nuclear and non-nuclear fractions, in agreement with the 
paper, however I did not block nuclear-trafficking. This raises the important question of how TAK1, if it 
does not traffic between the cytoplasm and the nucleus can become activated in the nucleus? The three 
described papers and my work contribute partially to the understanding of this process; however a more 
in-depth investigation is required to fully understand the mechanism behind, either how translocation is 
achieved or how activation in the nucleus occurs, and the subsequent activity of TAK1 in the nucleus. A 
ChIP assay for TAK1 would be able to describe a DNA binding role for TAK1, however in practice the 
required number of PBECs to perform this assay satisfactorily was prohibitive. In light of the modulatory 
role for TAK1 in SMAD3 driven EMT I hypothesized that TAK1 may be translocating to the nucleus with 
SMAD3 acting as a co-factor to induce or sustain its transcriptional activity. 
By immuno-precipitating TAK1 under non-denaturing conditions I hoped to investigate which if any TAB 
proteins were associated with TAK1 under varying stimulations, as well as identifying downstream TAK1-
protein interactions, such as the above mentioned TAK1-SMAD3 interaction. Confirming its description in 
the literature, TAB1 was constitutively associated with TAK1 at 30 minutes, when stimulated with TGF-β1 
or TNFα, with a potentially accentuative association upon co-stimulation, although a more accurate 
outcome measurement is desirable. Both TAB2 and TAB3 were found to be associated with TAK1 at 30 
minutes after stimulation with TGF-β1, with TNFα alone inducing no association. Upon co-stimulation 
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however the TGF-β1 mediated binding of TAB2 to TAK1 was inhibited, with no effect upon TAB3 binding 
observed. The TGF-β1 mediated association of TAB3 with TAK1, which was maintained under co-
stimulation, may provide a mechanism for the hypothesized alteration of IKKβ and NF-κB transcriptional 
activity in response to co-stimulation although no evidence of altered transcription in response to 
differential TAB binding has been described in the literature. 
It is difficult to draw conclusions from these findings due to the limited time-points sampled, again an 
product of limited cell populations, nevertheless the TAB2 findings in particular demonstrate the interplay 
between TGF-β1 and TNFα. For example after stimulation with TNFα alone TAB1 may be more free to 
induce phosphorylation of the Thr184 residue of TAK1. Does the accentuated association of TAB1 
directly lead to the accentuated phosphorylation of TAK1 Thr187. To understand this more fully a wider 
array of time-points would need to be studied, and most importantly an understanding of whether there 
is competition for binding of TAK1 between the TABs, and if so what affect the absence of a particular 
TAB can have on phosphorylation and downstream signalling. 
The downstream associations of TAK1 are again interesting. TAK1 was not shown to associate with 
SMAD3 at a 30 minute time-point, which suggests that TAK1 is not acting as a co-factor with SMAD3. 
Both IKKβ and JNK-2, but seemingly not JNK-1 are associated with TAK1 at this time point after 
stimulation, although there was no noticeable variation between stimulations. Whilst it is unknown if 
TAK1 is directly binding to IKKβ or JNK-2, as this assay just shows an association it does provide clear 
evidence that TAK1 is in some way inducing their subsequent phosphorylation. Perhaps more 
interestingly is the association of c-Jun with TAK1 only upon co-stimulation. As a component of the AP-1 
transcription factor c-Jun is important in regulating genes involved in many different cell responses, 
including but not limited to cellular differentiation. By displaying an association with TAK1 only upon co-
stimulation this may describe the mechanism whereby the accentuated signalling response is interacting 
with the genome initiating the EMT. 
This binding may also help describe the nuclear localization of TAK1 as IKKβ, JNK-2 and c-Jun are known 
to be able to translocate to the nucleus, and TAK1 may be piggybacking in association with these factors. 
The obvious way to investigate this effect would be to immuno-precipitate the nuclear and cytoplasmic 
fractions, however as with a ChIP assay the number of PBECs required to generate a suitably sized 
nuclear fraction was prohibitive. Once again the above discussion must be couched with the 
understanding that only a single time-point was observed, and results may differ accordingly. 
 148 
 
In the discussion sections for SMAD3 and IKKβ I constructed a hypothesis of collagen I-IV secretion being 
independent of the then unknown accentuatory protein. With TAK1 potentially filling this role, and due to 
the strong inhibitory effect of both TAKi and TAKsi it is necessary to reconsider this hypothesis. The only 
hypothesis I can construct to fit these new findings is that TAK1 plays some form of modulatory role in 
relation to SMAD3 activity, although not directly due to the lack of detected association, possibly by 
activating co-activating transcription factors in a way which is not affected by TNFα stimulation although 
I can present no data to support this supposition either directly or from the literature. 
TAKi, but not TAKsi, pre-treatment consistently induced an increase in pro-MMP-9 secretion, seemingly 
magnifying the normal response to stimulation with TGF-β1 or TNFα. My initial thoughts were either that; 
in our cell system TAK1 is more involved in the production of TIMPs and hence the suppression of pro-
MMP-9 secretion, or that I was observing an off target effect of the chemical inhibitor. However the only 
references linking TAK1 and pro-MMP-9 secretion in the literature describe a mechanism which follows 
the expected hypothesis, namely that TNFα (Srivastava et al., 2007) and TGF-β1 are capable of increasing 
secretion, with several papers postulating that TAK1 is required for this to occur.  
As discussed in 4.1.6 I investigated the role of the different TNFα receptors in accentuating EMT 8.7, to 
investigate this receptor specific isoforms of TNFα were used, at the same dose for the generic 
recombinant TNFα used throughout my project. As PBECs only expressed TNFαR1 accentuation of EMT 
was only observed with TNFαR1 specific TNFα. Pre-treatment with TAKi strongly reduced this 
accentuation, which then suggested that it was the generic TNFα that was driving the increased secretion 
of pro-MMP-9, as opposed to TAKi. 
The only hypothesis that I can propose to explain this effect presumes non-specific effects from both 
TAKi and TNFα. If the non-receptor specific isoform of TNFα is binding to a receptor other than TNFR1, 
potentially due to the relatively high concentrations used, it may induce a signalling response utilising 
unknown signalling proteins. If we then hypothesized that this unknown pathway was responsible for the 
maintenance of TIMP production, and also contained a protein which was effected by off target effects 
of TAKi, or itself modulated by TAK1, then it is possible to see a mechanism where de-regulated and 
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5 JNK-2 Modulates TAK-1 Activity 
5.1 MAPK p38 
The MAPK p38 family of 38kDa proteins consists of four members p38α, β, γ and δ displaying 
approximately 60% sequence homology, of which p38α was the first described (Han et al., 1994) 
responding to LPS stimulation. It is now thought that the main role of p38 signalling is to respond to 
stress stimuli. As well as being the first discovered p38, p38α is also the most widely studied in part due 
to its ubiquitous expression with the other family members displaying a more tissue specific expression 
(Cuenda and Rousseau, 2007). p38 and the other MAPKs which I will discuss later share a similar 
structure, consisting of two distinct lobes between which the kinase site sits, with co-phosphorylation of 
threonine and tyrosine residues separated by a single amino acid, which in the case of p38 is Thr180-
Gly-Tyr182, of the activation loop required to allow substrate binding.  
p38 activation sits at the bottom of a multifaceted cascade, directly activated by MAP2Ks which are in 
turn activated by MAP3Ks activation of which is usually receptor coupled but may be as a result of 
intracellular activation. p38 has been shown to be phosphorylated by the following MAP2Ks, MKK3,4 and 
6. MKK3 and 6 are thought to be very selective for p38 over ERK-1/2 and JNK-/1 (Dérijard et al., 1995; 
Raingeaud et al., 1996; Terada et al., 1999) and are also thought to be the main activators of p38, with 
MKK4, which can also activate JNK-1/2, required only in response to certain stresses (Brancho et al., 
2003). The use of MKK3 and MKK6 is itself likely to be cell and stimulus dependant, although with some 
demonstrated overlap (Enslen, 1998), with one study demonstrating that CD4 T cells utilized MKK3 to a 
greater extent than MKK6, whilst T cell progenitors preferentially used MKK6 (Tanaka et al., 2002). 
These MAP2Ks require activation themselves, again by co-phosphorylation of their activation loop, by 
MAP3Ks, at this level there is much greater overlap of function, again covered in more detail in the 
review by Rubinfeld et al (Rubinfeld and Seger, 2005), including ASK1, TAK1, MLK2 and MEKK3 among 
others. Whilst these activations and those of the MAPKs themselves can occur as direct kinase 
interactions, as with the other signalling mechanisms already described the role of scaffold proteins is 
now widely being investigated. The scaffold protein osomosensing scaffold for MEKK3 (OSM) forms a 
scaffold that recruits and facilitates the activation of MEKK3, MKK3 and p38 in a cascade in response to 
osmotic stress (Uhlik et al., 2003), although no mechanism for this recruitment was or has been described, 
so the usage of poly-ubiquitin chains in this system is unknown. 
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This wide variety of activating proteins means that p38 can be activated by numerous different stimuli, of 
direct importance to my study however is its response to TGF-β1 and TNFα, and response to both has 
been demonstrated (Wysk, 1999; Wang et al., 2002). TGF-β1 activation of p38 utilizes the non-canonical 
pathway described in 1.3.4 utilising TRAF6 and TAK1 (Yamashita et al., 2008), although p38 can 
subsequently activate this canonical arm (Furukawa et al., 2003); with TNFα and IL-1β also utilising this 
activatory mechanism (McDermott and O’Neill, 2002; Royuela et al., 2008), although other activating 
pathways are used as well depending on stimuli. The localization and activity of p38 in response to 
stimuli is poorly understood; p38 is thought to reside in the cytoplasm in its un-stimulated state with 
some reports stating that nuclear localization is specifically mediated by DNA damage signals (Wood et 
al., 2009) although others describe phosphorylated p38 in the nucleus in un-stimulated cells (Lu et al., 
2006; Gorog et al., 2009). 
When nuclear localized, the export of p38 is mediated by its downstream substrates such as MAPK 
activated protein kinase (APK)-2 and 5 which both contain nuclear localization and nuclear export signals, 
upon binding with these substrates in the nucleus the localization signal is masked and the complex 
exported (Seternes et al., 2002; Gorog et al., 2009). This led to the hypothesis that mitogen activated 
protein kinase activated protein kinase (MAPKAPK)-2/5 may be responsible for p38 nuclear localization 
as well with signals masked depending on other stimuli, however MAPKAPK-2 knockout experiments 
demonstrated an elevated nuclear localisation of p38 (Gorog et al., 2009). Interestingly TAB1 is capable 
of binding and phosphorylating p38, which leads to a reduction p38 signalling activity and also 
decreases nuclear localization (Lu et al., 2006), from which it is possible to hypothesize that p38 
activating factors such as MKK3 may also act as mediators of localisation, although to date this has not 
been described.  
p38 interacts with a huge variety of substrates including the MAPKAPKs mentioned above as well as 
other factors such as ATF-1, p65, FADD inhibitors and p53, for a more in depth coverage see the review 
by Cargnello et al (Cargnello and Roux, 2011). This wide range of substrates allows p38 to modulate 
several other signalling pathways either directly or indirectly, for example p38 through its substrate 
mitogen and stress activated protein kinase 1 (MSK1) is capable of phosphorylating p65, which important 
in p65 transcriptional activity in response to TNFα (Vermeulen et al., 2003). Alternatively, as well as being 
phosphorylated by TAB1, p38 is itself capable of phosphorylating TAB1 inhibiting it's activation of TAK1 
and the subsequent downstream signalling that it mediates (Cheung et al., 2003). 
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As with all the other areas of this introduction, inactivation of p38 is also poorly understood. Inhibitory 
methods such as those described already through TAB1 mediated inactivation (Lu et al., 2006), and 
potential negative feedback through inhibition of TAK1 activity (Cheung et al., 2003). De-phosphorylation 
of p38 has also been shown to play a key role in the regulation of p38 activity, traditional phosphatases 
such as the previously discussed PP2A which removes singular phosphate groups from the p38 
activation loop. Interestingly de-phosphorylation of Thr180 completely inhibits p38 activity, whereas de-
phosphorylation of Tyr182 leads to a 20 fold reduction in kinase activity (Zhang et al., 2008), which may 
provide a means of tuning p38 response. As well as these more generic phosphatases special MAPK 
phosphatases (MKP)s which can de-phosphorylate both residues of MAPK have been described with 
MKP-1, 4 and 5 having been shown to de-phosphorylate p38 (Owens and Keyse, 2007). 
 
5.1.1 Chemical Inhibition of p38 
Previous assays of phosphorylation in PBECs 4.1.2.2, 4.2.2.2 and 4.3.2.2 had demonstrated that p38 was 
not phosphorylated in response to TGF-β1 or TNFα, but displayed a constant level of phosphorylation 
after stimulations, which was not affected by any inhibitory treatment used so far. Prior to assessing 
phosphorylation across a time course I decided to chemically inhibit its function. SB 203580 (p38i) is a 
well characterized cell-permeable inhibitor of p38 that blocks ATP binding required for kinase function 
(Tong et al., 1997). As with the inhibitor of IKKβ a variety of IC50 doses have been described, with a 50-
100nM dose inhibiting TNFα production in the THP-1 human monocyte cell line, or mechanistically a 
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A 10µM dose of p38i was, at the morphological level, capable of slightly inhibiting EMT in response to 
TGF-β1 or TNFα, however the effect was very mild. No dose of p38i inhibited the TGF-β1 driven and 
TNFα accentuated loss of E-cadherin and gain in fibronectin expression significantly. A slight inhibition of 
the accentuated production of fibronectin was observed at 20µM, but conversely this high dose was also 
down-regulating E-cadherin expression in its own right when comparing un-stimulated cells. Due to the 
lack of inhibitory effect, choosing a dose of p38i for future experiments was difficult; nevertheless, a 
10µM dose was chosen and used over the 20µM dose due to its reduced effect on cell viability and 
weaker impact on baseline levels of E-cadherin. 
 
5.1 .1 . 1 Chemical Inhibit ion of p38, Effect on EMT Endpoint 
With an appropriate dose of p38i decided upon in A549 cells the next step was to observe what effect 
this would have on EMT in PBECs. n=3 PBEC cultures from distinct patients were stimulated with TGF-β1 
or TNFα for 72 hours after a 1 hour pre-treatment with 10μM p38i. Cell lysate and culture media was 














































































The above results demonstrate that along with not phosphorylating in response to TGF-β1 or TNFα 
stimulation, p38 does not appear to play a role in EMT for the assessed markers. Due to this surprising 
outcome it was decided to not investigate the role of p38 further, and to focus on other potential 
downstream mediators of TAK1.  
 
5.1.2 p38 Discussion 
Stimulation with TGF-β1 or TNFα had not induced phosphorylation of p38 in previous experiments, 
therefore I moved straight into chemical inhibition of p38 to confirm this lack of role before initiating 
other more involved experiments. p38i did not limit either TGF-β1 driven EMT or its accentuation by 
TNFα, confirming in our system that it did not play a direct role. 
This finding was somewhat surprising as numerous studies have demonstrated p38 activation in 
response to TGF-β1 (Varela-Rey et al., 2002; Yamashita et al., 2008; Kolosova et al., 2010) and TNF 
(Varela-Rey et al., 2002; Royuela et al., 2008), has been strongly implicated in the development of EMT 
(Kolosova et al., 2010; Lv et al., 2011) and also in OB (Ramirez et al., 2006) with a p38δ inhibitor11 
recently approved for use in treatment of IPF (Moran, 2011). However with the data to hand it is only 
possible to conclude that p38 does not play a role in our system; interestingly our group has previously 
demonstrated this effect in A549 cells, whereby p38 phosphorylation was increased by TNFα stimulation, 
but played no role in the subsequent development of EMT (Borthwick et al., 2011). 
One possibility is that the chemical inhibitor used is not blocking p38 activity, or all p38 activity. It has 
been demonstrated that p38i inhibits p38α and β more strongly than p38γ or δ (Davies et al., 2000). It is 
therefore possible, especially in light of a p38δ inhibitor entering clinical use (Moran, 2011) that we are 
not inhibiting the correct isoform. However in a study investigating the role of p38 in the development of 
EMT in a pulmonary epithelial cell line used half the dose of p38i and strongly inhibited the expression of 
fibronectin and secretion of collagen I (Kolosova et al., 2010). Similarly this does not account for the lack 
of change in phosphorylation seen upon stimulation, using an antibody that can detect all isoforms of 
p38 (Avitzour et al., 2007); also in a previous paper our group has demonstrated a change of p38 
phosphorylation using the same antibodies (Borthwick et al., 2011). Whilst not displaying a lack of effect, 
p38 phosphorylation has been shown to inhibit TGF-β1 driven EMT, protecting against the loss of E-
                                                 
11 Esbriet (Pirfenidone), InterMune 
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cadherin, and gain of vimentin expression by inhibiting TAK1 activity (Strippoli et al., 2010) suggesting 
that the role of p38 may be cell type dependant. 
As with IKKi, p38i does not block the phosphorylation of p38, but rather its kinase activity, as such to 
investigate efficacy of inhibitor a specific p38 substrate is required; due to the often overlapping roles for 
MAPKs it can be difficult to isolate such a substrate. There are several kits available that facilitate a cell 
free kinase/substrate assay using antibodies raised against p38, and other groups have modified p38 to 
allow for a more specific pull down (Szafranska et al., 2005). The transcription factor myocyte-enhancer 
factor 2C is phosphorylated selectively by p38 but not ERK2 or JNK1 (Han et al., 1997), and as such may 
have served as a good target for a cell based system. However, due to the lack of phosphorylation seen 
in previous PBEC experiments, and the poor effect of the inhibitor at doses higher than those described 
in other positive studies (Kolosova et al., 2010; Lv et al., 2011) it was decided to halt investigations into 




5.2 Extracellular signal-regulated-1/2 
The MAPK ERK family of proteins are encoded for by two genes, MAPK1 and MAPK3 which encode the 
ubiquitously expressed 42 kDa ERK-2 and 44 kDa ERK-1 proteins respectively, and were the first MAPKs 
to be discovered (Boulton et al., 1990) and display approximately 85% sequence homology (Boulton et 
al., 1991). As with p38 both ERK-1 and ERK-2 are formed of two lobes with a catalytic groove running 
between which is activated by co-phosphorylation of threonine and tyrosine residues in the activation 
loop; separated by glutamate in a Thr202-Glu-Tyr204 arrangement for ERK-1 and Thr185-Glu-Tyr187 for 
ERK-2, with tyrosine phosphorylation occurring before threonine (Ferrell Jr., 1997). Some evidence of 
redundancy between ERK-1 and ERK-2 has been demonstrated (Voisin et al., 2010) however several 
non-redundant functions have also been described (Hatano et al., 2003; Li and Johnson, 2006). 
ERK-1/2 signalling follows a broadly similar pattern to that of p38 utilising a similar cascade but with 
different key components. Receptor stimulation, and both TGF-β1 (Lee et al., 2007) and TNFα12 
(Kakiashvili et al., 2011) have been shown to be able to activate ERK-1/2. This leads to the activation of 
small GTPases such as Ras and Rap which are capable of activating MAP3Ks; with the rapidly accelerated 
fibrosarcoma (RAF) family of proteins specifically associated with ERK-1/2 activation (Hagemann and 
Rapp, 1999) and other less specific MAP3Ks such as MEKK1 (Karandikar et al., 2000), also associated with 
JNK activation (Xia, 2000). Downstream of this the MAP2Ks MEK1 and 2 specifically activate ERK-1/2 by 
phosphorylation of its activation loop (Catalanotti et al., 2009). Efficient signal transduction is thought to 
mediated by association of the various components with the scaffold protein kinase suppressor of Ras-1 
(KSR1) (Therrien et al., 1996). 
ERK-1/2 reside in the cytoplasm in their un-stimulated state held in place by several scaffold proteins 
(Tanoue et al., 2000; Perlson et al., 2006), upon phosphorylation within the activation loop they are 
released into the cytoplasm. In this state ERK-1/2 is not capable of nuclear translocation and requires 
further phosphorylation, by unknown means, in a region outside of the activation loop, which allows 
ERK-1/2 to associate with nuclear import proteins and translocate to the nucleus, however it was shown 
that this phosphorylation and not just nuclear import protein association was required for this transition 
(Chuderland et al., 2008). Within the nucleus ERK-1/2 are capable of activating numerous different 
transcription factors including c-Jun13 (Morton et al., 2003), c-Fos (Murphy et al., 2002), NF-κB (Peng et 
                                                 
12 TNFα is proposed to act through epidermal growth factor receptor (EFGR) rather than TNFR. 
13 Differentially to JNK-1/2 mediated phosphorylation. 
 160 
 
al., 2010) and more exclusively for ERK-1/2 the E twenty-six-like transcription factor 1 (ELK1) (Gille et al., 
1995). 
Although the majority of activated ERK-1/2 translocates to the nucleus a fraction remains in the 
cytoplasm where it is capable of interacting with numerous factors including MAPK-interacting kinase-
1/2 (MNK1, 2) (Waskiewicz et al., 1997) and the ribosomal S6 kinase (RSK) family of proteins (Chen et al., 
1992), although these are also often located in the nucleus as well. In both instances these kinases are 
capable of interacting with other transcription factors for example the RSK2 is capable of 
phosphorylating Iκ-Bα initiating NF-κB signalling in an IKK independent manner (Peng et al., 2010) 
As with p38 deactivation of ERK-1/2 signalling can be achieved through generic phosphatases such as 
PP2A (Kins et al., 2003), with the dual de-phosphorylating MKP-3 showing strong associations with ERK-
1/2 (Kim et al., 2003). 
 
5.2.1 Chemical Inhibition of ERK-1/2 
A reliable phospho-ERK-1/2 antibody was never worked up, hence why it was not used in other 
phosphorylation panels. Example blots are included with the chemical inhibitor data. Due to this lack of 
reliable assay, and with the limited results acquired suggesting that it ERK-1/2 was not phosphorylated 
by TGF-β1 or TNFα it was decided that, as with p38, prior to assessing phosphorylation across a time 
course I would chemically inhibit ERK-1/2 activity. 
FR180204 (ERKi) is a cell-permeable inhibitor of ERK-1/2 which blocks ATP binding required for kinase 
function (Ohori et al., 2005) with the same paper describing an IC50 of 500nM when analyzing the 
phosphorylation of myelin basic protein, a substrate of ERK-1/2 in a cell free system, and a dose of 
3.1µM inhibiting the activation of AP-1 by half in Mv1Lu cells14. 
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ERKi was not capable of inhibiting EMT either morphologically or at the protein level at any dose, with 
higher doses of 10 and 20µM decreasing the baseline level of E-cadherin expression. To verify this lack 
of role in EMT I decided to use a 5µM dose of ERKi and perform the standard screen in PBECs to 
determine if other markers of EMT were also unaffected. 
 
5.2.1 .1 Chemical Inhibit ion of ERK-1/2, Effect on EMT Endpoint 
With an appropriate dose of ERKi decided upon in A549 cells the next step was to observe what effect 
this would have on EMT in PBECs. n=3 PBEC cultures from distinct patients were stimulated with TGF-β1 
or TNFα for 72 hours after a 1 hour pre-treatment with 5μM ERKi. Cell lysate and culture media was 














































































As with p38 the above results demonstrate that ERK-1/2 does not play a role in either TGF-β1 driven 
EMT, or its accentuation by TNFα for the assessed markers, in the case of vimentin ERKi was increased 
EMT compared to untreated controls. ERKi phosphorylation was difficult to assay, but displayed no 
change upon stimulation, and was not inhibited by ERKi. 
 
5.2.2 ERK-1/2 Discussion 
Stimulation with TGF-β1 or TNFα had not induced phosphorylation of ERK-1/2 in the limited experiments 
where a signal was detected, therefore I moved straight into chemical inhibition of ERK-1/2 to confirm 
this lack of role before initiating other more involved experiments. Similarly to p38i, ERKi did not limit 
either TGF-β1 driven EMT or its accentuation by TNFα, confirming in our system that it did not play a 
direct role. Whilst detection of total ERK-1/2 was feasible and did not vary upon stimulation or inhibition 
detection of the phosphorylated form required the use of excessively high lysate concentrations, 
although again when detectable there was no variation in the level of phosphorylation. 
These results were again surprising as ERK-1/2 has been implicated in EMT (Lee et al., 2007; Strippoli et 
al., 2008; Kakiashvili et al., 2011) and is capable of being activated by TAK1 (Nishimura et al., 2009) 
although it is thought that p38 and JNK-1/2 are more strongly activated by the typical MAP2Ks activated 
TAK1. Alternative splice variants are produced from MAPK1 and MAPK3 (Strausberg et al., 2002) and a 
novel effect from one of these splice variants has been described (Shaul et al., 2009). However this splice 
variant produces a smaller ERK-1 protein which is detectable as a distinct band under the normal ERK-1 
and ERK-2 bands (Aebersold et al., 2004), and was not observed, and there is no data to suggest that 
ERKi would have less of an effect on these variants due to the high degree of homology.  
Therefore the only conclusion to draw is that in this system ERK-1/2 and p38 play little role in the 
development of EMT. The lack of change in phosphorylation upon stimulation or after TAK1 inhibition 
suggests both that TGF-β1 or TNFα are not utilising these pathways in PBECs, and also that activation of 
each is not mediated by TAK1. As discussed in the various introductory sections there are numerous 
other stimuli and MAP3K/MAP2Ks that are capable of activating p38 and ERK-1/2 and it may be that 
these are their preferred cascades in PBECs. The final MAPK I investigated was JNK-1/2 which already 
displayed a phosphorylation response to simulation which was effected by inhibition of TAK1 its 
upstream mediator.  
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5.3 c-Jun N-terminal kinase-1/2 
The JNK family of MAPK proteins consists of three members JNK-1, 2 and 3 encoded for by the JNK1,2 
and 3 genes respectively, with several variants of each capable of being produced. JNK-1 and 2 are 
thought to ubiquitously expressed (Kallunki et al., 1994) whereas JNK-3 (Mohit et al., 1995) is thought to 
be specific to neuronal cells. The main target of JNK-1, 46 kDa, and JNK-2, 55 kDa, is control the AP-1 
transcription factor especially through activation of c-Jun one of its components with JNK-2 displaying a 
higher affinity (Kallunki et al., 1994); although redundancy has been demonstrated in relation to other 
substrates (Kosters et al., 2009). Activation of JNK-1/2 is mediated by the co-phosphorylation of Thr183-
Pro-Tyr185 within the activation loop of each form, which facilitates substrate binding. 
Initiation of JNK-1/2 signalling is thought to be mediated by the usage of GTPases such as RAC-1 and 
RAC-2 when signalling in response to growth factor receptors such as EGFR (Minden et al., 1995); with 
these factors being less important on TNFR and IL-1R mediated JNK-1/2 activation (Minden et al., 1995), 
suggesting that upstream kinases, sometimes termed MAP4Ks, such as the archetypal MAP4K (Su et al., 
1997) playing more of a role. Whatever the means of activation a wide variety of MAP3Ks are capable of 
responding to stimulation including MEKK1 (Xia, 2000) and importantly TAK1 (Wang et al., 2001; Mao et 
al., 2011). At the MAP2K level MKK4 and 7 have been shown to be key non-redundant regulators of 
JNK-1/2 co-phosphorylation required for its efficient activation. MKK4 has been shown to preferentially 
phosphorylate the Tyr185 residue, whereas MKK7 targets Thr183 (Lawler et al., 1998). Phosphorylation of 
Thr183 alone leads to a 10 fold reduction in kinase activity, whereas phosphorylation of Tyr185 alone 
leads to complete inhibition of activity (Khokhlatchev et al., 1997). Activation of JNK-1/2 is once again 
thought to be mediated by associated scaffold proteins such as the JNK-interacting protein (JIP) family of 
proteins which can recruit and activate JNK-1/2 along with its upstream effectors (Matsuguchi et al., 
2003). 
Once activated the main and first described function of JNK-1/2 is to activate the AP-1 transcription 
factor component c-Jun (Hibi et al., 1993), which when dimerized with other AP-1 components such as 
c-Fos can rapidly alter transcription with the dimer composition controlling specificity of interaction with 
DNA (Angel and Karin, 1991), and also interactions with other transcription factors such as SMAD3 
(Verrecchia et al., 2000) and NF-κB (Shyu et al., 2008). Activation of c-Jun is achieved by phosphorylation 
of Ser63 and Ser73 specifically by JNK-1/2 with other proteins such as ERK capable of phosphorylating 
different residues. Phosphorylation of Ser63 and Ser73 is thought to control activation of c-Jun with 
alternative phosphorylation determining its associations (Hibi et al., 1993; Minden et al., 1995).  
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As with previous MAPKs discussed JNK-1/2 signalling can be de-activated through generic phosphatases 
such as PP2A, which can decrease as opposed to completely inhibit activity (Khokhlatchev et al., 1997) as 
well as dual de-phosphorylating MKPs such as MKP1 (Mizuno et al., 2004) and MKP7 (Tanoue et al., 
2001). 
 
5.3.1 Phosphorylation Response of JNK-1/2 
In previous work JNK-1/2 was phosphorylated by both TGF-β1 or TNFα with a possibly accentuated 
response seen upon co-stimulation. To verify this, and also investigate the initiation and duration of 
phosphorylation a time course experiment was performed. 
PBECs were cultured in 6 well collagen coated plates until confluent and stimulated with TGF-β1 or TNFα. 
Cells were harvested at 0, 0.5, 1, 5, 10, 30 and 60 minute time points. Whole cell PBEC lysate was 
immuno-precipitated for total SMAD3, under denaturing conditions, with the resulting lysate probed for 
pJNK-1/2 (both Thr183 and Tyr185) by indirect ELISA. Neat lysate from the 30 minute stimulation was 
analyzed by Western blot for both total and phospho forms of JNK-1/2. 
As with the IKKα/β phospho-time course the antibodies used in this protocol targeted both isoforms of 
JNK. Unlike IKKα/β both isoforms of JNK were strongly detected in total and phosphorylated forms, and 
although JNK-1 phosphorylation was not affected by TGF-β1 or TNFα stimulation its phosphorylation 
was blocked by chemical inhibition of TAK1, therefore separating the relative contributions of JNK-1 or 
JNK-2 to the results below is not possible, although western blots at a 30 minute time point would 
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Both TGF-β1 and TNFα induced significant phosphorylation of JNK-1/2 from 5 minutes up until 30 
minutes, at 60 minutes levels were returned to near baseline. Co-stimulation however induced a 
significant increase in phosphorylation from 1 minute, which lasted beyond 60 minutes. Most 
interestingly, however was the nature of the response to co-stimulation, an accentuative phosphorylation 
occurred at both 1 and 60 minute time points, with the level of phosphorylation remaining high at all 
time points. 
 
5.3.2 Chemical Inhibition of JNK-1/2 
With previous results demonstrating that TAK1 may phosphorylate JNK-1/2 as a downstream mediator, 
and with JNK-1/2 phosphorylating in response to both TGF-β1 and TNFα investigations into its role in 
EMT were required. 
JNK Inhibitor II (JNKi) is a cell permeable inhibitor of JNK-1/2 and 3 that acts by blocking ATP binding 
sites required for kinase activity. In a cell free kinase assay an of JNK mediated phosphorylation of the 
transcription factor c-Jun an IC50 of 50nM was described with the same paper describing an in vitro IC50 
of 5-10µM when looking at c-Jun phosphorylation in Jurkat cells15 (Bennett et al., 2001).  
A dose response curve looking at cell viability, morphology and effect on EMT after pre-treatment with 1, 
5, 10 and 20μM doses of JNKi prior to stimulation with TGF-β1 and TNFα for 72 hours was performed in 
triplicate using A549 cells. 
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JNKi strongly inhibits both TGF-β1 driven EMT and its accentuation by TNFα morphologically and at the 
protein level. A 20µM dose inhibited all facets of EMT most efficiently yet induced a large decrease in cell 
viability compared to untreated controls. At the protein level, there was no added benefit at using a 
20µM dose over 10µM, and looking at E-cadherin alone 5µM JNKi inhibited its loss to the same degree 
as 10 and 20µM doses of JNKi. In future experiments a 5μM dose of JNKi was used which was capable of 
strongly inhibiting EMT at the protein level with very little reduction in cell viability. 
 
5.3.2.1 Chemical Inhibit ion of JNK-1/2, Effect on EMT 
Endpoint 
With an appropriate dose of JNKi decided upon in A549 cells the next step was to observe what effect 
this would have on EMT in PBECs. n=4 PBEC cultures from distinct patients were stimulated with TGF-β1 
or TNFα for 72 hours after a 1 hour pre-treatment with 5μM JNKi. Cell lysate and culture media was 
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The results described above provide strong evidence, that JNK-1/2 activation plays a key role in the 
subsequent occurrence of EMT. Pre-treatment of PBECs with a 5µM dose of JNKi strongly inhibited the 
loss of E-cadherin expression and the gain of fibronectin and vimentin expression, as well as the increase 
in secretion of collagens I-IV and pro-MMP-9 into the media in response to TGF-β1 stimulation. JNKi also 
strongly limited the accentuative effect of TNFα for all markers of EMT. 
 
5.3.2.2 Chemical Inhibit ion of JNK-1/2, Effect on 
Phosphorylation 
JNK-2 has previously been shown to phosphorylate in response to both TGF-β1 and TNFα, with an 
accentuated and extended phosphorylation of JNK-1/2 in response to co-stimulation. It was also 
demonstrated that JNK-1/2 phosphorylation could be inhibited, by the upstream inhibition of TAK1. To 
verify the proposed location of JNK-1/2 in this signalling cascade I investigated the effect of JNKi pre-
treatment on the phosphorylation of other key signalling proteins, in this instance with the addition of c-
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JNK-2 was phosphorylated in response to TGF-β1 or TNFα alone and displayed an accentuated 
phosphorylation upon co-stimulation, phospho-JNK1 was detected in all stimulations with no variation 
between. Due to the described inhibitory activity of JNKi it was thought that phosphorylation would not 
be affected, however surprisingly phosphorylation of both JNK-1 and JNK-2 was blocked by pre-
treatment with JNKi, possibly due to similar mechanisms discussed for TAKi. c-Jun, a substrate of JNK-1/2, 
was phosphorylated by both TGF-β1 or TNFα alone, with an accentuative phosphorylation upon co-
stimulation; upon pre-treatment with JNKi this phosphorylation was completely blocked. This confirms 
that JNK-1/2 sit below TAK1 and with IKKβ and SMAD3 acting independently. 
 
5.3.3 siRNA Knockdown of JNK-1/2 
JNKi inhibited both JNK-1 and JNK-2 phosphorylation, siRNA knockdown of each isoform would help 
better understand the relative importance of JNK-1 and JNK-2 in EMT, whilst also confirming the work 
performed with JNKi. siRNA targeting JNK-1 (JNK1si - GTGGAAAGAATTGATATATAA) or JNK-2 (JNK2si - 
GCCGUCCUUUUCAGAACCAT) were used in a dose response assay for cell viability, morphology and 
effect on EMT after a 24 hour pre-treatment with 1, 5, and 10nM doses of siRNA delivered through lipid 
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JNK1si knocked down JNK-1 in a dose dependant manner without affecting expression of JNK-2, 
however knockdown of JNK-1 did not inhibit the TGF-β1 driven loss of E-cadherin or gain of fibronectin, 
or the accentuation of this effect by TNFα. There was a trend for decreased viability upon increased dose, 
which was amplified in TNFα alone treated cells especially at the 10nM dose, therefore a dose of 5nM 
JNK1si was used in future experiments. 
JNK2si knocked down JNK-2 in a dose dependant manner without affecting expression of JNK-1. JNK2si 
also inhibited TGF-β1 driven loss of E-cadherin or gain of fibronectin, or the accentuation of this effect 
by TNFα in a dose dependant manner with the greatest effect seen with the 10nM dose. There was a 
very slight trend for decreased viability upon increased dose, and therefore a 10nM dose was used in 
further experiments. 
 
5.3.3.1 siRNA Knockdown of JNK-1/2, Effect on EMT 
Endpoint 
With appropriate doses of JNKsi confirmed for use in PBECs I proceeded to investigate what effect 
knockdown of JNK-1 or JNK-2 had on EMT. n=3 PBEC cultures from distinct patients were stimulated 
with TGF-β1 or TNFα for 72 hours after a 24 hour pre-treatment with 5nM JNK1si, 10nM JNK2si or a 
sequence scrambled control. Cell lysate and culture media was retained and EMT was assessed using a 
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The results above confirm that JNK-2 plays a key role in EMT for all of the markers assayed, with 
knockdown of total protein inhibiting the loss of E-cadherin expression, gain in vimentin and fibronectin 
expression and increase in pro-MMP-9 and collagens I-IV secretion. Interestingly knockdown of JNK-1, 
which is not phosphorylated by either TGF-β1 or TNFα, and plays no role in controlling the expression of 
E-cadherin, fibronectin or vimentin was able to strongly inhibit the secretion of pro-MMP-9 and 
collagens I-IV. In the case of collagen secretion JNK1si was actually more effective than JNK2si at 
reducing collagen secretion, increasing levels to below that of baseline un-stimulated cells. 
 
5.3.4 Localization of JNK-1/2 
Both chemical inhibition and siRNA knockdown of JNK-2 suggest that it plays a key role in EMT, and 
siRNA knockdown of JNK-1 implicated it in the control of collagen and protease secretion. JNK-1/2 is 
also known to interact with the c-Jun transcription factor which can translocate to the nucleus, and TAK1 
which we have demonstrated localizes to the nucleus by unknown means. I therefore hypothesized that 
JNK-1/2 may be mediating this localization of TAK1 in association with a transcription factor such as c-
Jun, to investigate this I first looked at localization of both total and phospho-JNK-1/2 30 minutes post 
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Total-JNK-1/2 localization was unchanged under all conditions as assessed by western blot, located most 
strongly in the cytoplasm with some evidence of nuclear localization. Conflicting results for phospho-
JNK-1/2 were described; ICC demonstrated a pronounced increase in phosphorylation and nuclear 
localization in response to TGF-β1 or TNFα alone, with a potentially accentuated effect upon co-
stimulation. However, western blotting showed that whilst phospho-JNK-1/2 was activated in the 
cytoplasm in the aforementioned pattern, phospho-JNK-1/2 levels in the nucleus did not vary upon 
stimulation, and detected levels were greatly reduced. 
 
5.3.5 Further JNK-1/2 Work 
To validate previous work that showed JNK-1/2 associating with TAK1 and potentially c-Jun, and also to 


































































At 30 minutes neither SMAD3 nor IKKβ were associated with JNK-1/2 under any stimulation, c-Jun and 
TAK1 were both associated but there was no variation in strength of association between stimulations. 
Phospho-c-Jun was not associated with JNK-1/2 after stimulation with TGF-β1 or TNFα alone, however 
upon co-stimulation an association was detected. As with the TAK1 investigation before it this 
experiment was limited to a single time-point so it is possible that associations may have varied outside 
of this. 
 
5.3.6 JNK-1/2 Discussion 
Prior investigation had shown that TGF-β1 but not TNFα was capable of inducing the canonical SMAD 
signalling response; with inhibition of SMAD3 limiting TGF-β1 driven EMT, with an unknown activity in 
relation to the accentuative effect of TNFα. Inhibition of IKKβ not only limited the accentuative effect of 
TNFα on EMT but also inhibited the driving effect of TGF-β1, which in conjunction with previously 
detected accentuated TAK1 phosphorylation was the catalyst to look at TAK1 as a potential mediator of 
this signalling crosstalk. 
To summarize the data presented in the preceding sub-chapter: TGF-β1 or TNFα phosphorylate JNK-1/2 
with an accentuated and prolonged phosphorylation upon co-stimulation, with c-Jun displaying a similar 
pattern. Western blots suggested that JNK-2 was being phosphorylated preferentially to JNK-1. Chemical 
inhibition of JNK-1/2 strongly inhibited TGF-β1 driven EMT and its accentuation by TNFα for all markers, 
siRNA knockdown of JNK-2 had a similar effect, whereas knockdown of JNK-1 only inhibited the 
secretion of pro-MMP-9 and collagens I-IV. JNKi inhibited the phosphorylation of JNK-2 and c-Jun 
without altering the phosphorylation of other signalling proteins. JNK-2 displayed some evidence of 
nuclear localisation on phosphorylation but significant levels were also detected in the cytoplasm. TAK1 
and c-Jun were constitutively associated with JNK-1/2, phospho-c-Jun was associated only upon co-
stimulation. 
In 4.2.4 I proposed that IKKβ activity was driving the TNFα mediated accentuation of EMT, with TAK1 
purely playing an activating role, and JNK-2 no role even though activated. In 4.3.7 I revised this 
hypothesis to describe a potential modulation of IKKβ NF-κB activity by TAK1 as a result of differential 
protein associations, and with TAK1 and JNK-2 modulating SMAD3 activity. However in light of the fact 
that inhibition of JNK-1/2 strongly blocks TGF-β1 driven EMT and its accentuation it is now apparent that 
JNK-1/2 most likely through the action of c-Jun is modulating both SMAD3 (Sano et al., 1999; Verrecchia 
 187 
 
et al., 2001) and NF-κB (Liu et al., 2000; Wang and Sonenshein, 2005) transcriptional activity inducing 
EMT and its accentuation upon co-stimulation. 
JNKi targeted both JNK-1 and JNK-2 and strongly blocked EMT development in all markers, when using 
JNK-1 or JNK-2 specific siRNA JNK-2 was confirmed as playing the key role in this development. JNK1si 
however whilst not affecting E-cadherin, fibronectin or vimentin expression strongly inhibited the 
secretion of pro-MMP-9 and collagens I-IV for all stimulations. That JNK2si was also capable of strongly 
inhibiting this secretion suggests that JNK-1 and JNK-2 are working co-operatively; as far as I am aware a 
single paper has demonstrated a similar effect, whereby JNK-1 phosphorylates JNK-2 before both 
phosphorylating p53 at different activation residues (Oleinik et al., 2007) . However in this instance JNK-1 
displays increased phosphorylation whereas in my results only a basal level was detected, suggesting that 
it is the presence of JNK-1 rather than it's activation that is required. Another group working in primary 
tracheal cells has demonstrated an important role for JNK-1 in mediating TGF-β1 SMAD3 driven EMT, 
especially when looking at collagen I expression (Alcorn et al., 2008; Velden et al., 2011), interestingly 
their results suggested that EMT was independent of JNK-2. Due to the higher efficiencies of JNK-2 
binding with c-Jun (Kallunki et al., 1994) this may suggest than an alternative transcriptional component 
is being activated, although downstream mechanisms were not discussed. 
Total c-Jun was detected at lower levels than in stimulated cells, between which there was no variation, 
this may be explained by the fact that JNK-1/2 activated c-Jun is capable of inducing its own 
transcription in a positive feedback loop (Angel et al., 1988; Minden et al., 1994). With accentuated 
activation of TAK1 and JNK-2, c-Jun phosphorylation is itself accentuated; in an environment whereby 
TAK1 and JNK-2 are constitutively activated, such as that present in OB continued activation of c-Jun 
could lead to excessive activation of JUN, with this excess c-Jun perhaps capable of interacting with NF-
κB and inducing accentuated EMT. 
In our model a I have described a distinct MAPK cascade through TAK1, JNK-2 and c-Jun with no 
evidence of p38 or ERK-1/2 involvement, in the following section I attempt to outline my final signalling 
hypothesis, and areas where I feel further work is required.  
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6 Final Remarks 
I have discussed specific results in their relevant chapters, so this final section is an attempt to briefly 
outline the findings which I think are most important, to discuss areas of the work which, with the benefit 
of hindsight, may have been better undertaken and to briefly discuss where I envisage this work could 
lead. 
Firstly the work performed with Dr Rahul Mahida and Monika Suwara, which is still ongoing, provides 
strong evidence that both TNFα and IL-1β are present in the airway space of the lung, with their 
occurrence appearing to peak before the diagnosis of BO, which complements previous studies looking 
at TGF-β1 (Elssner et al., 2000) in the BAL and inflammatory mediators released from BAL immune cells 
(Hodge et al., 2009). The results I present represent analysis of my contribution to the work, further 
analysis and characterisation of patient samples is underway, which may assist with the debate over 
neutrophilic or non-neutrophilic BOS (Vanaudenaerde, Meyts, et al., 2008), as well as to the treatment of 
lung transplant recipients. 
Secondly I have demonstrated a mechanism by which the accentuation of TGF-β1 driven EMT by TNFα 
may occur. TGF-β1 signals through the canonical SMAD pathway, utilising SMAD3 but requiring TAK1 
and JNK-2 activation, although TAK1 and JNK-2 are not capable of driving EMT themselves. Neither 
TAK1 nor JNK-2 is directly associating with SMAD3 but downstream mediators may be influencing its 
transcriptional efficacy. TNFα signals through TAK1 and activates IKKβ and JNK-2, which without TGF-β1 
stimulation does not strongly induce EMT. IKKβ activation is directly required for the accentuation of 
TGF-β1 driven EMT with JNK-2 modulating this effect. 
Upon co-stimulation TGF-β1 drives EMT through SMAD3 and TNFα accentuates this effect through IKKβ. 
TAK1 and JNK-2 do not directly drive either effect but are required by both, TAK1 and JNK-2 may be 
modulating SMAD3 activity possibly through c-Jun. TAK-1 activates IKKβ and upon co-stimulation with 
TGF-β1 may be initiating a more pro-fibrotic IKKβ NF-κB transcriptional activity, possibly through 
differential phosphorylation or TAB association. Alternatively, as JNK-2 was shown to also facilitate this 
accentuation and c-Jun was shown to be more strongly activated after co-stimulation modulation of NF-
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If I was to carry on this investigation there are two key points that I would focus in on. Firstly by 
manipulating the phosphorylation of specific TAK1 residues (potentially through the use of blocking 
antibodies or selective mutations within a cell line), as well as TAB protein association and observing the 
effect on NF-κB transcriptional activity it would be possible to demonstrate if the synergistic effect was 
modulated at this level. Similar techniques have been already used to describe the activation mechanism 
of TAK1 (Sakurai et al., 2002; Singhirunnusorn et al., 2005; Yu et al., 2008), by using these techniques it 
may be possible to describe how TAK1 can mediate so many differing outcomes. Secondly I would 
investigate the role of c-Jun on AP-1 (through further IP experiments, ChIP and the use of selective 
mutation of c-Jun), particularly its own transcriptional ability and how its activation can alter SMAD3 
(Sano et al., 1999; Verrecchia et al., 2001) and NF-κB activity (Liu et al., 2000; Wang and Sonenshein, 
2005) in relation to EMT. 
Due to the key role of TAK1, JNK-1 and c-Jun in numerous cell signalling events blanket inhibition of 
their function in vivo would likely do more harm them good. However targeted inhibition, both 
temporally and spatially, of the accentuated phosphorylation in response to pro-fibrotic and pro-
inflammatory factors may help limit the development of fibrosis in OB, and due to the ubiquitous nature 
of these proteins, potentially other disorders with a similar pathophysiology, for example a recent study 
in a mouse kidney fibrosis has described a similar key role for TAK1 in regulation both inflammation and 
fibrosis (Ma et al., 2011) 
6.1 Critiques 
Looking back at the work I have performed for this thesis perhaps the greatest criticism I can make is that 
it alternated between trying to be a basic science project whilst at the same time attempting to directly 
tie findings in with a disease model; and as such may not be as strong as if I had focused specifically on 
one arm. The use of PBECs provided a strong link to diseased tissue, and when used in association with 
other samples isolated from the same patients at the same time point can be very powerful, however the 
only true instance where I leveraged this in my thesis was by observing the phosphorylation of TAK1 in 
lung epithelium of patients with BOS. At the same time, the use of PBECs in several instances limited 
further experiments into the more molecular side of my project, such as ChIP assays, and large-scale 
screens of phospho proteins that would have been more feasible in a cell line. 
As such, I may have been better served to more robustly investigate the mechanistic action in a cell line 
population, before attempting to replicate key findings in PBECs, and then taking this further by linking in 
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with the longitudinal catalogue of patient samples. However following the path that I did necessitated me 
to think laterally and develop alternative assays to cope with limited cell numbers. The immuno-
precipitation and indirect ELISA protocol being the prime example of this, rather cobbled together 
because of trial and error it provided perhaps the most interesting results of my project.  
As well as the A549 (Lieber et al., 1976) cell line that I have discussed there are several other widely used 
human lung epithelial cell lines such as the 16HBE (Viallet et al., 1994) and BEAS-2B (Reddel et al., 1988) 
lines. Both of these lines would have born more resemblance to the primary cells used as they were both 
initially derived from the bronchus as opposed to cultured adenocarcinoma cells. However, as with A549 
cells both display significant abnormalities in chromosome number and in both instances were virally 
immortalized with human papilloma virus E6 and E7, and simian virus 40 early region oncogenes 
respectively.  
It has been postulated that chromosome abnormalities in cells immortalized in this fashion arise due to 
the stresses put on cells by the conflicting actions of natural telomeric shortening, and senescence 
against the virally induced oncogenes maintaining proliferation. Co-expression of telomerase reverse 
transcriptase (TRT) during the generation of cell lines is thought to reduce these stresses and thus the 
generation of cytogenetic abnormalities (Vogelstein and Kinzler, 2004). In order to generate a more 
physiologically relevant population human bronchial cell lines have been generated using the addition of 
TRT and alternative oncogenes that maintain a normal chromosome number, and displayed 
maintenance of pseudo-stratified morphology. However, whilst this technique did extend cell life span it 
was not to the same extent as seen after traditional viral immortalization (Fulcher et al., 2009).  
These attempts to improve the physiological relevance of cells used for investigations could and should 
be carried over into primary cell work, as the culture of PBECs as a submerged monolayer monoculture 
is very removed from their in vivo setting. For example, current PBEC culture protocol stipulates the use 
of collagen I, which as I have discussed in the introduction is often laid down as a provisional matrix after 
wound healing; as opposed to collagen IV that is associated with homeostasis. It is therefore possible 
that epithelial cells cultured on a collagen I matrix are more likely respond to remodelling stimuli and that 
after initial establishment of culture a collagen IV matrix should be introduced. 
Secondly the techniques that I used to pick apart signalling events were rather blunt, by looking at the 
phosphorylation of signalling proteins it was possible to tell that they responded to stimulation and may 
be involved in EMT, with inhibition of these same proteins confirming this involvement. However, what 
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was not demonstrated was the relevant importance of each signalling arm in the contribution to EMT, or 
what if any interplay or redundancy existed between them, such as that discussed for SMAD3 and TAK1. 
Although this process is required to identify proteins that are important, perhaps it would have been 
better to focus in on one specific protein such as TAK1, perhaps carrying out the work outlined in 6, 
rather than attempting to investigate all components equally. 
The temporal activation of the various signalling proteins is an area of particular further interest. 
Activation of specific residues of key proteins was assessed at multiple time points in response to the 
standard panel of TGF-β1 or TNFα (up to 60 minutes); however, their responses to chemical and siRNA-
mediated inhibition were investigated only at 30 minutes. As such, important activations of proteins not 
assessed in detail such as p38 or ERK-1/2 may have been missed. Temporal phosphorylation data in 
inhibited cells would allow stronger conclusions to be drawn about the order of the signalling cascade 
leading to the development of EMT, highlighting areas of particular interest. For example, why is SMAD3, 
identified as key in TAK1 activation, phosphorylated at a later time point? Does the earlier co-activation 
of proteins such as TAK1 (Thr187) prime SMAD3 to respond in a different manner to TGF-β1 leading to 
EMT? How long is activation of proteins such as JNK-1/2 upon co-stimulation maintained for, and is this 
the mechanism that is inducing EMT? 
Alongside this investigations into the different responses of phospho-residues on the same protein both 
due to stimulation and temporally should be performed. The differential regulation of TAK1 Thr184 and 
Thr187 may be mimicked by other proteins such as SMAD3 that contains several other phospho residues 
other than those investigated (Ser423 + Ser425). Perhaps phosphorylation of one of these residues is 
required for the phosphorylation of other molecules such as TAK1, but not in controlling the 
development of EMT. 
Finally, whilst I have described a mechanism that can explain how TNFα accentuates TGF-β1 driven EMT, 
and highlight key areas where dysregulation may occur, I do not describe how this might come about in 
a disease state. It is still not known why the normally conflicting functions of TGF-β1 and TNFα are 
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8.1 Patient Details 
BAL Cytokine Assay Non-BOS Patient Details 
Tx # Sex Age at Tx Reason for TX Sample # 
1206 F 21 CF 3 
1231 M 57 FA 3 
1237 M 45 PF 3 
1243 M 54 α1 AD 4 
1244 F 49 COPD 3 
1254 F 20 CF 3 
1263 M 26 CF 5 
1268 M 64 Asbestosis 5 
1272 M 42 CF 3 
1275 M 62 PF 6 
1300 M 54 IPF 3 
1312 M 29 CF 4 
1317 M 45 α1 AD 5 
1327 M 52 PH 4 
1330 M 27 CF 3 
1333 M 57 Emphysema 3 
1323 M 46 FLD 5 
1348 M 25 CF 3 
1374 F 19 CF 3 
1378 M 63 PF 3 
1379 M 26 CF 5 
1459 M 60 Bronchiectasis 3 
1460 F 29 CF 3 
1498 M 46 FLD 4 
1519 M 24 CF 3 
1546 M 28 CF 5 
Appendix Figure 1 – BAL Cytokine Assay Non-BOS Patient Details 
26 patients (5 female, 21 male) with a mean age of 41.2 years and median age of 45 years (19 - 64). All 
patients gave distinct samples. 
CF = Cystic Fibrosis, FA = Fibrosing Alveolitis, PF = Pulmonary Fibrosis, α1 AD = α1 Antitrypsin 
Deficiency, COPD = Chronic Obstructive Piulmonary Disorder, IPF = Idiopathic Pulmonary Fibrosis and 




BAL Cytokine Assay BOS Patient Details 
Tx # Sex Age at Tx Reason For Tx BOS Diagnosis Months post Tx Sample # 
1203 M 39 CF 3 3 
1241 M 34 CF 15 4 
1259 F 23 CF 12 4 
1273 M 25 CF 15 4 
1283 M 63 FA 9 6 
1284 M 50 Emphysema 24 7 
1298 F 63 Emphysema 10 4 
1301 M 58 Emphysema 20 5 
1304 M 26 CF 19 9 
1325 F 63 FLD 12 3 
1334 F 33 Emphysema 12 5 
1335 M 54 α1 AD 9 6 
1352 F 54 Emphysema 10 3 
1372 M 43 FLD 13 6 
1383 F 28 CF 12 5 
1384 M 36 Silicosis 26 5 
1399 F 46 COPD 12 8 
1403 M 46 Hystiocytosis X 15 6 
1424 F 30 CF 12 4 
1450 M 40 α1 AD 22 6 
1453 M 47 COPD 3 3 
1475 M 61 FLD 21 3 
1488 M 52 Bronchiectasis 18 3 
1501 M 48 Asthma 18 5 
1510 M 48 COPD 11 5 
Appendix Figure 2 - BAL Cytokine Assay BOS Patient Details 
25 patients (8 female, 17 male) with a mean age of 44.4 years and median age of 46 years (23 - 63), 
mean diagnosis of BOS was 14.1 months (3 – 26). All patients gave distinct samples. 
CF = Cystic Fibrosis, FA = Fibrosing Alveolitis, FLD = Fibrotic Lung Disease, α1 AD = α1 Antitrypsin 




Cultured Primary Cell Patient Details 
TW # Age at Tx Sex Years Post Transplant 
1057 51 F 4 
1065 63 F 4 
1072 64 F 4 
1073 50 M 4 
1078 55 M 4 
1079 51 M 4 
1080 51 F 4 
1081 34 F 4 
1088 33 F 4 
1095 54 M 4 
1099 47 M 4 
1112 63 M 9 
1113 65 M 3 
1121 61 M 3 
1122 54 F 3 
1125 53 M 7 
1130 61 M 4 
1132 60 M 3 
1134 24 F 4 
1135 47 F 3 
1140 56 M 3 
1145 63 M 3 
1150 26 M 3 
1151 27 M 3 
1153 53 F 11 
1158 65 F 3 
1159 24 M 3 
1168 36 F 3 
1172 52 F 3 
1174 44 F 3 
1178 29 F 4 
1184 27 M 3 
1186 27 M 3 
1208 54 F 6 
1213 54 M 3 
1215 30 F 2 
1221 35 F 2 
1222 33 M 3 
1225 44 F 4 
1226 48 F 2 
1232 56 M 2 
1238 50 F 6 
1239 56 F 2 
1243 24 M 3 
1245 51 F 2 
1246 35 F 2 
1247 58 M 2 
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1248 48 F 2 
1256 38 M 2 
1259 62 M 6 
1261 55 M 2 
1273 26 F 2 
1274 53 M 2 
1276 64 F 2 
1278 57 F 2 
1279 51 F 5 
1280 38 M 2 
1282 30 M 2 
1285 55 M 2 
1300 28 M 1 
Appendix Figure 3 – Cultured Primary Cell Patient Details 
60 patients (29 female, 31 male) with a mean age of 46.2 years and median age of 51 years (24 – 65). Of 
the 60 patients 21 underwent surgery for Chronic obstructive piulmonary disorder, 19 for cystic fibrosis, 
11 for idiopathic pulmonary fibrosis, 3 for bronchiectasis, 3 for lymphangioleiomyomatosis, 2 for sarcoid 




8.2 BAL Significance Data 
Green shading indicates significance of p<0.05, red shading indicates significance of p>0.05, tested by 
two-tailed Mann-Whitney U Test. 
TNFα  
Group Mean (pg/mL) S.E.M. Sig. To Non OB Sig to Non OB C. 
OB + 6 C. 129.22 67.56 n/a 0.1639
OB + 6 20.66 9.71 0.7014 n/a
OB + 3 C. 171.60 101.46 n/a 0.1944
OB + 3 26.25 14.64 0.7030 n/a
OB 0 C. 267.46 108.80 n/a 0.0001
OB 0 61.77 33.62 0.0005 n/a
OB - 3 C. 701.12 374.74 n/a 0.0014
OB - 3 105.17 51.37 0.0007 n/a
OB - 6 C. 271.18 139.09 n/a 0.0169
OB - 6 43.86 22.27 0.0343 n/a
OB C. 108.77 46.49 n/a 0.0104
OB 16.86 5.41 0.0407 n/a
Non OB C. 77.95 29.06  
Non OB 24.79 11.75  
Appendix Figure 4 - TNFα statistical significance 
 
IL-1β  
Group Mean (pg/mL) S.E.M. Sig. To Non OB Sig to Non OB C. 
OB + 6 C. 658.26 312.88 n/a 0.0074
OB + 6 105.71 46.01 0.0575 n/a
OB + 3 C. 837.98 463.87 n/a 0.0065
OB + 3 126.23 67.84 0.0503 n/a
OB 0 C. 1831.87 1008.89 n/a 0.0003
OB 0 368.73 208.94 0.0012 n/a
OB - 3 C. 4941.33 3118.07 n/a 0.0025
OB - 3 729.77 459.15 0.0019 n/a
OB - 6 C. 1853.76 1294.58 n/a 0.0316
OB - 6 294.52 212.07 0.0326 n/a
OB C. 483.85 177.14 n/a 0.0004
OB 84.04 23.60 0.0012 n/a
Non OB C. 63.36 14.66  
Non OB 14.95 2.87  
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Appendix Figure 9 - siRNA knockdown, effect on phosphorylation 
a) PBECs were pre-treated with 5nM SMAD1si 24 hours before stimulation with TGF-β1 (10ng/mL) or TNFα 
(20ng/mL) for 30 minutes. Approximately 90% knockdown of SMAD3 was achieved by SMAD3 targeting siRNA. 
Neither a sequence scramble control nor the lipid vector had any effect on SMAD3 knockdown, cell viability or 
morphology. This reduction in total SMAD3 also led to a complete loss of detected phospho-SMAD3 with no 
effect on SMAD3 phosphorylation seen with either the lipid vector or sequence scramble control. Total TAK1 or 
phospho-TAK1 were not affected by SMADsi. 
b) PBECs were pre-treated with 0.1nM IKKsi 24 hours before stimulation with TGF-β1 or TNFα for 30 minutes. 
Approximately 90% knockdown of IKKβ was achieved by IKKβ targeting siRNA. Neither a sequence scramble 
control nor the lipid vector had any effect on IKKβ knockdown, cell viability or morphology. This reduction in total 
IKKβ also led to a strong reduction in detected phospho-IKKβ with no effect on IKKβ phosphorylation seen with 
either the lipid vector or sequence scramble control. Total TAK1 and SMAD3 or phospho-TAK1 and SMAD3 were 
not affected by IKKsi. 
c) PBECs were pre-treated with 3nM TAKsi 24 hours before stimulation with TGF-β1 or TNFα for 30 minutes. 
Approximately 80% knockdown of TAK1 was achieved by TAK1 targeting siRNA. Neither a sequence scramble 
control nor the lipid vector had any effect on TAK1 knockdown, cell viability or morphology. This reduction in total 
TAK1 also led to a reduction in the detected levels of phospho-TAK1 with no effect on TAK1 phosphorylation seen 
with either the lipid vector or sequence scramble control. Total SMAD3, JNK-1/2 and IKKβ and phospho-SMAD3 
were not affected by TAKsi. The phosphorylation of IKKβ was inhibited by knockdown of TAK1. 
d) PBECs were pre-treated with 5nM JNK1si or 10nM JNK2si 24 hours before stimulation with TGF-β1 or TNFα for 
30 minutes. Approximately 100% knockdown of JNK-1 was achieved by JNK-1 targeting siRNA, with JNK-2 
targeting siRNA (10nM) mediating a similar knockdown of JNK-2, neither siRNA demonstrated non-specific 
knockdown. Neither a sequence scramble control nor the lipid vector had any effect on JNK-1/2 knockdown, cell 
viability or morphology. This reduction in total JNK-1 or JNK-2 also led to a reduction in the respective levels of 
phospho-JNK-1/2 with no effect on JNK-1/2 phosphorylation seen with either the lipid vector or sequence 
scramble control. JNK2si but not JNK1si reduced the detected amount of c-Jun for all stimulations. 
pSMAD3 (20µg), pIKKβ and pp38 (40µg), pTAK1, pJNK-1/2 and JNK-1/2 (50µg). 
 
Interestingly production of c-Jun was only inhibited by JNK2si and not JNK1si suggesting that as with the 
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8.7 TNF Receptor Work 
As described in 1.3.2 TNFα signals through two distinct trans-membrane receptors, TNFR1 and TNFR2 
(Locksley et al., 2001). TNFR1 is ubiquitously expressed and can respond to both membrane-bound and 
soluble forms of TNFα whereas TNFR2 is highly regulated in its expression, mainly on immune cells and 
responds, efficiently, only to membrane bound TNFα (Grell et al., 1995). Whilst the receptors do provide 
some form of redundancy they are capable of playing independent roles in cell signalling (16, 26).  
It has also been demonstrated that TNFR2 expression over TNFR1 may mediate collagen deposition in 
response to TNFα (Theiss et al., 2005) and its expression is up-regulated on colonic epithelial cells of patients 
with Crohn's disease and ulcerative colitis (Mizoguchi et al., 2002). We therefore hypothesized that PBECs 
from OB patients may express elevated levels of TNFR2 which may mediate the accentuation of TGF-β1 by 
TNFα by the usage of alternative signalling mechanisms. The below work was carried out in conjunction with 
Dr Lee Borthwick who contributed the data and analysis to the first figure shown below. 
n=6 PBEC cultures from distinct patients were stimulated with TGF-β1 or with soluble TNFα (TNFsol), 
membrane bound TNFα (TNFcys), TNFR1 specific mutant (Cys-TNF32W/86T) membrane bound TNF 
(TNFcysR1) or TNFR2 specific mutant (Cys-TNF143N/145R) membrane bound TNF (TNFcysR2) for 72 hours. 
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8.8 Personal Development 
8.8.1 Presentations 
 November 2009 - Oral Presentation – North East Post-Graduate Research Conference, 
Newcastle University, Newcastle-Upon-Tyne, United Kingdom. “Inflammatory Accentuation of 
EMT in Fibrotic Lung Epithelium via IKK-NF-κB” 
 
 June 2010 - Poster Presentation - Institute of Cellular Medicine Research Day, Newcastle 
University, Newcastle-Upon-Tyne, United Kingdom. “Inflammatory Accentuation of EMT in 
Fibrotic Lung Epithelium” 
 
 March 2010 - Poster Presentation – European Respiratory Society Lung Science Conference, 
Estoril, Portugal. “TNFα accentuates TGF-β1 driven epithelial to mesenchymal transition (EMT) in 
lung epithelium via TNFαReceptor1/TAK-1 dependent signalling” 
* Awarded European Respiratory Society Lung Science Conference Bursary. €550 travel grant. 
 
 December 2010 - Oral Presentation – British Thoracic Society Winter Meeting, London, United 
Kingdom. “The role of Transforming Growth Factor Associated Beta Kinase 1 (TAK1) in the 
development of airway fibrosis” 
 
 January 2011 - Poster Presentation – Keystone Symposia on Epithelial Plasticity and Epithelial to 
Mesenchymal Transition, Vancouver, Canada. “TNFα accentuates TGF-β1 driven Epithelial to 
Mesenchymal Transition in lung epithelium via TGF-β activated kinase-1 (TAK1) dependent 
signalling” 
* Awarded Newcastle University, Graduate Student Travel Award. £600 travel grant. 
 
 March 2011 - Poster Presentation - European Respiratory Society Lung Science Conference, 
Estoril, Portugal. “TNFα accentuates TGF-ß1 driven Epithelial to Mesenchymal Transition (EMT) in 
lung epithelium via TAK1 dependent signalling” 
 
 June 2011 - Oral Presentation – Institute of Cellular Medicine Research Day, Newcastle University, 
Newcastle-Upon-Tyne, United Kingdom. “TNFα accentuates TGF-ß1 driven Epithelial to 
Mesenchymal Transition (EMT) in lung epithelium via TAK1, JNK-1/2 dependent signalling” 
 
 July 2011 – Oral Presentation, Young Investigator Session - British Association of Lung Research 
Summer Meeting, Newcastle-Upon-Tyne, United Kingdom. “TNFα accentuates TGF-β1 driven 
Epithelial to Mesenchymal Transition in lung epithelium via Transforming growth factor β–
activated kinase-1 (TAK1) dependent signalling” 
* Awarded British Association of Lung Research, Best Oral Presentation by a Young Investigator 
2011. £750 travel grant. 
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 November 2011 – Oral Presentation - Newcastle, Edinburgh, Cambridge & Sheffield Lung 
Research Meeting, Cambridge, United Kingdom. “Transforming Growth Factor Beta Activated 
Kinase 1 (TAK1) as a mediator of the fibrogenic synergy between Transforming Growth Factor 
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